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ZUSAMMENFASSUNG 
Das erhöhte Auftreten des kutanen Plattenepithelkarzinoms in Patienten mit Organtransplantat wird 
häufig mit dem Immunsuppressivum Cyclosporin A (CsA) assoziiert. Zusätzlich zu seinem 
therapeutischen Einfluss auf die Immunüberwachung, werden immer mehr Hinweise auf einen 
immun-unabhängigen Mechanismus von CsA auf nicht-Immunzellen publiziert. Jedoch sind diese 
beschriebenen Effekte zum Teil höchst unterschiedlich und die Langzeiteffekte von CsA auf humane 
Keratinozyten innerhalb eines Gewebekontext sind weitestgehend unbekannt. 
Mit Hilfe von 3D organotypischen Hautkulturen (OTKs), die eine Langzeitbehandlung mit CsA in einer 
physiologisch relevanten Umgebung erlauben, konnten wir zeigen, dass CsA die Stratifizierung und 
die Differenzierung von moderat differenzierenden HaCaT Zellen, so wie die von schlecht 
differenzierenden HaCaT-RAS A-5 Zellen, verbessert hat. Dies wurde durch die Histologie, durch 
Immunfluoreszenz-Färbungen von Differenzierungsmarkern, so wie an Hand von differentiell 
regulierter Gene, die Teil des GO-terms ‚epidermal development‘ sind, gezeigt. Verbesserte 
Differenzierung konnte auch durch einen erhöhten transepithelialen elektrischen Widerstand 
nachgewiesen werden. Dieser steht im direkten Zusammenhang mit der epidermalen 
Barrierefunktion. Wir konnten jedoch weder erhöhte Proliferation noch invasives Wachstum nach 
CsA-Behandlung feststellen. Um zu überprüfen ob UV-Bestrahlung als Co-Karzinogen invasives 
Wachstum von CsA-behandelten HaCaT oder HaCaT-RAS A-5 Zellen zulässt, wurden OTKs parallel zu 
der kontinuierlichen CsA-Behandlung kontinuierlich mit UV bestrahlt. Auch diese Kombination aus 
UV+CsA konnte die Zellen nicht tumorigen transformieren. Stattdessen haben wir festgestellt, dass 
die UV-Bestrahlung und die Kombination UV+CsA ein ähnliches Regulationsmuster der ‚epidermal 
development‘ Gene hervorruft, wie das der alleinigen CsA-Behandlung. Daher lässt es sich 
mutmaßen, dass die CsA-Behandlung und die UV-Bestrahlung einen gemeinsamen regulatorischen 
Mechanismus induziert haben. 
Generell überleben HaCaT Zellen in OTKs nur für einen begrenzten Zeitraum. Nach 4 bis 5 Wochen 
werden die Epithelien atrophisch. CsA hat jedoch in reproduzierbaren Experimenten die Lebensdauer 
dieser HaCaT Epithelien verlängert, in dem es mehr vitale basale und suprabasale Keratinozyten 
erhalten hat. Wie durch eine Genexpressionsanalyse und anschließender Ingenuity® Pathway 
Analysis indiziert wurde, hat CsA den Zelltod reduziert, möglicherweise durch den HGF oder Integrin 
Signalweg. 
Da es notwendig war verschiedene Seren für unsere Experimente zu benutzen, haben wir 
festgestellt, dass in einem bestimmten Serum HaCaT Zellen, zusätzlichen zu den oben beschriebenen 
Charakteristika, invasiv gewachsen sind wenn diese mit CsA behandelt wurden. Dies wurde durch die 
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Unterbrechung der Basalmembran und die Infiltration von HaCaT Zellen in die darunter liegende 
Dermis gezeigt. Darüber hinaus wurden mehr Gene differentiell reguliert, im Vergleich zum anderen 
Serum, das keine CsA-induzierte Invasion zugelassen hat. 
Zusammengefasst zeigen unsere Daten, dass CsA grundsätzlich nicht unter allen Bedingungen 
Keratinozyten zu Krebszellen transformiert. Stattdessen haben unsere Daten demonstriert, dass CsA 
die Differenzierung von Keratinozyten verbessert, vor allem in Zellen mit aberranter epidermaler 
Differenzierung, sowie deren Langlebigkeit fördert. Durch Zufall haben wir jedoch festgestellt, dass 
abhängig von bestimmten Serumfaktoren, CsA auch Invasion/Tumorigenität induzieren kann. Dies 
spiegelt auch die Situation einiger Patienten mit Organtransplantat wider, die innerhalb kürzester 
Zeit etliche Plattenepithelkarzinome, auch ‚cutaneous carcinomatous catastrophe‘ genannt, 
bekommen. Mit Hilfe unserer Daten ist unsere Studie nun für tiefergehende Analysen bereit, um 
Signalwege zu identifizieren die HaCaT Zellen für die Invasion sensibilisieren. Mit diesem Wissen 
könnten schlussendlich biologische Targets entdeckt werden, die diesem verheerenden Nebeneffekt 
von CsA entgegenwirken könnten. 
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SUMMARY 
Increased incidence of cutaneous squamous cell carcinomas (cSCCs) in organ transplant recipients is 
frequently associated with the immunosuppressive drug Cyclosporine A (CsA). Besides its therapeutic 
effect on the immune surveillance, evidence is accumulating for an immunity-independent 
mechanism of CsA on non-immune cells. However, the effects described so far are highly diverse and 
its long-term influence on human keratinocytes within a tissue context is largely unknown. 
Using a 3D organotypic skin culture model (OTC), for long-term treatment of keratinocytes within a 
physiologically relevant environment, we showed that CsA improved the stratification and 
differentiation of moderately differentiating HaCaT cells and of poorly differentiating HaCaT-RAS A-5 
cells. This was demonstrated by histology and immunofluorescent stainings for differentiation 
markers, as well as differential RNA expression of several genes associated with the GO-term 
‘epidermal development’. Improved differentiation was also demonstrated by an enhanced 
transepithelial electrical resistance, a trait directly correlated with the epidermal barrier function. 
However, CsA did not induce enhanced proliferation or invasion of neither HaCaT nor HaCaT-RAS A-5 
cells grown in OTCs. In order to determine, whether UV irradiation as a co-carcinogen would enable 
invasive growth of CsA-treated HaCaT or HaCaT-RAS A-5 cells, OTCs were continuously irradiated 
with UV in combination with continuous CsA treatment. However, this did not induce tumorigenic 
transformation. Instead we found that UV irradiation and the combination of UV+CsA induced a 
similar regulation pattern of ‘epidermal development’ genes as did CsA alone, suggesting a common 
regulatory mechanism induced by CsA treatment and UV irradiation. 
In general, HaCaT epithelia only survive for a restricted time span in OTCs. After 4 to 5 weeks the 
epithelia become atrophic. Importantly, CsA reproducibly extended the life span of the HaCaT 
epithelia, by retaining more vital basal and suprabasal keratinocytes. As indicated from an expression 
array and Ingenuity® Pathway Analysis, CsA reduced cell death in these OTCs, possibly through HGF 
or Integrin signaling. 
Having to use different serum batches for our experiments, we finally discovered that by the addition 
of a specific fetal calf serum HaCaT cells, in addition to the above described characteristics, became 
invasive when treated with CsA. Invasion was demonstrated by disruption of the basement 
membrane and penetration of HaCaT cells into the underlying dermal equivalent. This was associated 
with a tremendous increase in differentially expressed genes as compared to the serum conditions 
that did not allow for CsA-induced HaCaT invasion. 
Together, our data confirm that in general CsA is not directly transforming keratinocytes into cancer 
cells under every condition. Instead our data suggest that CsA improves keratinocyte differentiation, 
 XV 
 
in particular in cells with aberrant epidermal differentiation and promotes their longevity. By chance, 
however, we experienced that, depending on certain serum factors, CsA could also rapidly induce 
invasion/tumorigenicity – thus simulating a situation typical for a subgroup of transplant recipients, 
who rapidly develop multiple cSCCs, also termed cutaneous carcinomatous catastrophe. With these 
findings our study is now suited for an in depth analysis to unravel the pathways sensitizing HaCaT 
cells for invasive growth. This knowledge may finally help to identify targets to counteract this 
devastating CsA-dependent side effect. 
 
INTRODUCTION AND AIM 
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1. INTRODUCTION AND AIM 
1.1. Introduction 
1.1.1. Cutaneous squamous cell carcinomas 
Cutaneous squamous cell carcinomas (cSCCs) are epithelial tumors arising from the squamous 
epithelium of the skin. Next to basal cell carcinomas (BCC), which also originate from epidermal cells, 
cSCCs are the second most frequent cancer type. In the United States it was estimated that up to 
400,000 new cases of cSCCs were diagnosed in 2012, of which up to 12,572 patients developed nodal 
metastasis and up to 8791 died of cSCCs (Karia et al. 2013). Taking into account that cSCCs are not 
obliged to be registered and that misunderstanding may occur with patient records stating death by 
skin cancer, without further clarification of the type of skin cancer, numbers might even be 
underestimated for cSCCs (Garrett et al. 2016). Moreover, cSCCs cases are increasing in the 
population. National incidence estimates from the United States demonstrated a steady increase in 
the number of nonmelanoma skin cancers, which include BCCs and cSCCs as the major tumor types. 
Taking data from databases from Medicare and Medicaid Services, cases of cSCCs in the United 
States were estimated based on skin cancer treatments: From 2006 to 2012 procedures for skin 
cancers increased by 14% (Rogers et al. 2015). A similar trend was also reported by the Spanish 
cancer register in Girona. Moreover, the Spanish register showed a higher risk for men to develop 
cSCCs in comparison to women (Rubio-Casadevall et al. 2016). The general metastasize rate of cSCCs 
is about 3.7% and the mortality rate is up to 2.1% (Chrysalyne D. Schmults 2013). Given the high 
number of cases of cSCCs the total number of deaths by cSCCs is comparable to that of melanoma 
deaths in areas like the southern states of the United States (LeBoeuf & Schmults 2011; Karia et al. 
2013). In line with the increase in cSCCs and the associated risk of metastasis it is also discussed to 
rename the commonly used term nonmelanoma skin cancer by keratinocyte carcinomas, thereby 
naming the disease by their cellular origin and not by excluding them from melanoma (Karimkhani et 
al. 2015). 
Surgical excision is the primary care of cSCCs and up to 90% of the cases proceed without further 
complications afterwards (Bahner & Bordeaux 2013). However, cases of high risk cSCCs, also called 
cutaneous catastrophic carcinomas, and patients with metastasis are in the need of other treatment 
options (Berg & Otley 2002; Carucci 2004; Abikhair et al. 2016). Adequate systemic therapies or even 
targeted systemic medications, which could improve the survival rate of these patients, are currently 
not available (Sapijaszko et al. 2015). This is partly due to the lack of corresponding studies with high 
risk cSCCs patients, but is especially true due to a lack of appropriate targets for targeted therapy 
(Sapijaszko et al. 2015; Harwood et al. 2016). One factor which hampers the development of a 
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systemic targeted drug is the fact that cSCCs are genetically very heterogeneous and have the highest 
number of mutations compared to other malignancies (Durinck et al. 2011). cSCC development is 
said to occur in a multistep process (Boukamp 2005a) and precursor stages of cSCCs comprise actinic 
keratosis, SCC in situs and keratoacanthomas. Though the latter is still controversially discussed 
(Burnworth et al. 2006; Burnworth et al. 2007; Leufke et al. 2014). However, more than 80% of 
precursors do not progress into invasive cSCCs (Ratushny et al. 2012). Cumulative exposure of UV 
irradiation, including accumulation of UV dependent DNA changes, is one of the major risk factors of 
cSCC development. Accordingly, most cSCCs arise in sun-exposed areas, such as the face or scalp 
(Boukamp 2005b). The mean age of cSCC appearance is about 76 years, being indicative for a 
multistep development of cSCCs and the necessity of accumulation of genomic changes (Smith et al. 
2004). One very common mutation in cSCCs is the mutational inactivation of the p53 tumor 
suppressor gene, being found in about half of all cSCCs (Brash et al. 1991; Boukamp 2005b; Benjamin 
et al. 2008). However, also in non-lesional skin 25% of skin samples show p53 immunoreactivity, 
arguing that p53 mutations on their own are not the sole driver of cSCCs, although they might 
facilitate the development (Stark et al. 1994; Khorshid et al. 1996). Moreover, p53 mutant mice 
develop spontaneous tumors within the first 6 months; however they do not develop skin tumors in 
that period (Donehower et al. 1992). In contrast mice with an epidermal p53 knockout, who in 
contrast to the p53 mutant mice survive beyond the first 6 months, develop spontaneous tumors 
from hair follicle (Martinez-Cruz et al. 2008). Even more frequently than p53 mutations, mutations 
either in the NOTCH1 or in the NOTCH2 gene are found, namely in up to 75% of cSCCs (Wang et al. 
2011). However, like for p53 mutations, NOTCH mutations were also found in 20% of normal sun-
exposed skin samples, showing that cSCCs emergence needs more than one driver mutation 
(Martincorena et al. 2015). Other mutations in cSCCs, include mutations in HRAS, cyclin D1, MYC, 
FAT1 and CDKN2A (Pierceall et al. 1991; Boukamp 2005a; Burnworth et al. 2007; Martincorena et al. 
2015). 
1.1.2. cSCCs in organ transplant recipients 
In 1954 the first successful allogeneic kidney transplantation among monozygotic twins was 
performed. In the late 1950’s and 1960’s the implementation of immunosuppressive medications 
enabled the first syngeneic transplantations with kidney (1958), liver (1963) and heart (1967) from 
genetically different donors (Katsanos & Donickier 2009). With advances in transplantation medicine 
and the resulting extended organ transplant recipient life expectancy, long-term complications of 
immunosuppression therapy became manifested. Due to the suppressed immune system organ 
transplant recipients have a 2-4-fold increased risk of developing malignancies (Adami et al. 2003; 
Krynitz et al. 2013). Noteworthy, the risk for cSCCs is even increased 56-100-fold (Lindelof et al. 2000; 
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Berg & Otley 2002; Adami et al. 2003). However, not all skin cancers are equally affected. The 
incidence of melanoma is only increased by 2.1-8-fold (Kubica & Brewer 2012) and the risk for BCC 
development in organ transplant recipients is estimated to be 6-fold compared to the normal 
population (Krynitz et al. 2016). Consequently organ transplant recipients, in contrast to the 
immunocompetent population, have more cSCCs than BCCs (Euvrard et al. 2003). This switch in ratio 
might be due to the fact that cSCCs could be under stricter immunosurveillance than BCCs (Walter et 
al. 2010). 
Probably due to different intensities of drug regimens, risk estimations for cSCCs vary depending on 
the type of transplant. For example, in a Swedish cohort with 10,746 organ transplant recipients 
transplanted from 1970-2008, the risk for cSCCs in kidney recipients was 120-fold, 32-fold in liver 
recipients and 198-fold in heart or lung recipients (Krynitz et al. 2013). On average, organ transplant 
recipients are up to 10-12 years younger (54-58.2 years) in comparison to the immunocompetent 
population (64-70.4 years) when diagnosed with the first cSCC (Ong et al. 1999; Smith et al. 2004; 
Lott et al. 2010). The mean time for the first cSCCs after transplantation is about 6.2 ± 2.5 years, as 
calculated for an Australian cohort (Ong et al. 1999). Moreover, the cumulative incidence rate is 
increasing with time after transplantation, reaching as high as up to 73% after 20 years (Bouwes 
Bavinck et al. 1996). In more detail, the incidence rates, which are varying for different cohorts and 
locations, are as follows: After 10 years the cumulative incidence is at 10% in Europe, 35% in the 
United States and up to 45% in Australia (Berg & Otley 2002). After 20 years the risk rises to 20% in 
Sweden, 40% in the Netherlands (Bouwes Bavinck et al. 1996), 54-61% in the UK (Bordea et al. 2004; 
Harwood et al. 2013), 54% in New Zealand (Mackenzie et al. 2010) and 70-73% in Australia (Bouwes 
Bavinck et al. 1996; Ramsay et al. 2002). Noteworthy, those organ transplant recipients who develop 
a primary cSCC after transplantation are much more likely to develop multiple cSCCs in comparison 
to the normal population. While in the normal population the cumulative incidence of a subsequent 
cSCC is about 18% after 3 years, in organ transplant recipients the risk is much higher (Wisgerhof et 
al. 2010): After the first diagnosis of cSCC, 25% of organ transplant recipients develop a second cSCC 
after 13 month (Lindelof et al. 2000) and after 3 years the cumulative incidence is at 34-60%, 
depending on the cohort and type of transplant (Lindelof et al. 2000; Marcil & Stern 2000; Mackenzie 
et al. 2010). 5 years after the first cSCC up to 64-80% of organ transplant recipients will develop 
further cSCCs (Marcil & Stern 2000; Mackenzie et al. 2010). Furthermore, in patients who will 
develop multiple SCC, the occurrence of the first SCC is earlier than in patients which only develop a 
single SCCs (Bordea et al. 2004). 
The occurrence of more than 10 cSCCs and BCC per patient within one year is also called cutaneous 
catastrophic carcinomas and is more frequent in organ transplant recipients than in the normal 
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population. In some cases organ transplant recipients develop more than 100 cSCCs per year (Berg & 
Otley 2002). For example in a Dutch kidney transplant cohort 25% of the organ transplant recipients 
developed more than 10 nonmelanoma skin cancers (Wisgerhof et al. 2010). These numbers also 
illustrate why organ transplant recipients need a tight dermatologic follow-up examination. 
Especially those which were already diagnosed with actinic keratosis or cSCCs before transplantation 
and organ transplant recipients, who already developed multiple cSCCs after transplantation, should 
have a follow up interval of 6 or 2-4 months, respectively (Berg & Otley 2002). While not only the 
number of cSCCs in organ transplant recipients increases, the risk of metastasis also rises from 3.7% 
in the general population to 8% in organ transplant recipients (Berg & Otley 2002; Chrysalyne D. 
Schmults 2013). Next to a higher metastasis rate, the danger of cSCCs in organ transplant recipients 
is also highlighted by the number of deaths from cSCCs after transplantation. For example in the case 
of an Australian heart transplant cohort 15% of deaths 4 years after the transplantation were due to 
advanced cSCCs, while in comparison 10% were due to malignant melanoma (Ong et al. 1999). 
Similarly, in an Canadian renal transplant cohort, 12% of the transplant patients, who developed 
cancer after transplantation, died of cSCCs, while only 2% died of malignant melanoma at the time 
point of the retrospective study (Tremblay et al. 2002). The high occurrence of cSCCs in organ 
transplant recipients not only is a massive psychological burden for these patients, but also very 
costly for the national health insurance (Ruegg et al. 2012). Many risk factors for cSCCs and multiple 
cSCCs in organ transplant recipients, like UV exposure and fair skin type, are common with the 
immunocompetent population. However, some are also specific for organ transplant recipients and 
might explain the higher number of cSCCs in this population (Table 1.1). One such example is the 
length and type of immunosuppression. 
Table 1.1 Known risk factors for cSCC development in organ transplant recipients  
Factors specific for organ 
transplant recipients s 
Environmental Factors Genetic Factors 
Immunosuppression (length, 
level, type)
1, 2
 
Older age
1, 2, 3
 Fair skin type
1, 2, 3
 
cSCCs history before 
transplantation
1
 
Latitude
1
 Light eye color
1, 2, 3
 
Year of transplantation (<1984)
3
 UV exposure
1, 2, 3
 Hair color
1, 2, 3
 
Multiple transplantations
3
   
Transplant type
3, 4
   
1
 (Fortina et al. 2009), 
2
 (Ponticelli et al. 2014), 
3
 (Euvrard et al. 2006), 
4
 (Krynitz et al. 2013) 
1.1.3. Immunosuppression therapy in organ transplant recipients 
Moving from genetically identically donors to genetically diverse donors in the 1960’s was enabled by 
the use of steroids and azathioprine which led to a 50% graft survival after one year (Watson & Dark 
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2012). However, a breakthrough was accomplished with the introduction of new immunosuppressive 
drugs, like the discovery of the calcineurin inhibitor CsA in the mid 1970’s, and its release in the 
beginning of the 1980’s. This caused an increase in kidney graft survival of up to 90-95% after one 
year (Watson & Dark 2012) and consequently also caused an increased survival of renal organ 
transplant recipients in comparison to the standard treatment with azathioprine (Group 1986). With 
time other immunosuppressive medications were established and included in the regimens. In the 
mid 1990’s another calcineurin inhibitor named tacrolimus was released (Johansson & Moller 1990). 
It showed an even stronger positive outcome on graft survival than CsA (Fung et al. 1991). However, 
it also had some more intense side effects like neurotoxicity (Mueller et al. 1994). A bit later 
mycophenolates were available for immunosuppressive therapy. These were well tolerated and 
more potent than azathioprine (Ensley et al. 1993; Sollinger 1995). However, they were not as strong 
as calcineurin inhibitors and they were only approved as a combination therapy with calcineurin 
inhibitors, substituting azathioprine and/or steroids (Stegall et al. 1997). At the end of the 1990’s 
mTOR inhibitors were developed. While mTOR inhibitors are less nephrotoxic than both calcineurin 
inhibitors, they still can induce life-threatening pneumonitis (Cravedi et al. 2010; Errasti et al. 2010). 
Generally, a combination of medications is needed and the regimen has to be adapted to the 
individual patient. Drugs might get decreased or substituted with other drugs to avoid or minimize 
side effects, but it always has to be balanced with the risk of organ rejection. Predictive markers for 
organ rejection may also help to minimize and adapt immunosuppression, but are not identified yet 
(Hanlon et al. 2013). Figure 1.1 shows the trend in immunosuppression therapy after 1992 
demonstrating the response of azathioprine, steroid and CsA, in comparison to newer, more potent 
or more tolerable drugs like tacrolimus, mTOR inhibitors and mycophenolates. As the graph starts 
with 1995 it does not show, that in the 1980’s azathioprine and steroids were the standard regimens, 
with up to 80-90% in case of kidney organ transplant recipients (Durando & Reichel 2005). While 
early graft survival tremendously increased in the last decades due to the above mentioned drugs, 
side effects and lower long-term graft survival still cause a demand for new drugs. Newer 
developments include antibodies or new calcineurin inhibitors, which might have less side effects 
(Hardinger & Brennan 2013). Additionally, new alternatives to the classic immune therapy are as well 
explored at the moment. One new field of research is the administration of donor-derived 
mesenchymal stem cells, which in-vitro and in the rat model can be used as an immunomodulatory 
and potentially pro-tolerogenic tool (Popp et al. 2008). 
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Figure 1.1 Trend in immunosuppressive medication in organ transplant recipients from 1995 to 2008. 
Adapted from (Coghill et al. 2016). 
1.1.4. cSCCs in organ transplant recipients treated with Cyclosporine A 
As mentioned before immunosuppression is a risk factor for cSCCs development in organ transplant 
recipients (Fortina et al. 2009; Ponticelli et al. 2014). Noteworthy, not all immunosuppressive drugs 
have the same impact on cSCC occurrence and some like mTOR-inhibitors even show a decrease in 
cSCC incidence in organ transplant recipients (Feldmeyer et al. 2012). Generally, the effort is made to 
decrease immunosuppressive drugs and, if possible, to substitute for immunosuppressive drugs 
which are not in suspicion of causing or enhancing cancer. One drug which is associated with 
increased cSCCs numbers, however, is Cyclosporine A (CsA) (Hiesse et al. 1995; Petter Jensen 1999; 
Herman et al. 2001). Moreover, CsA usage was linked to the development of cutaneous catastrophic 
carcinomas (Abikhair et al. 2016). These patients develop up to 100 new cSCCs per year (Berg & Otley 
2002) and in 80% of these patients cSCCs appear within 10 month after transplantation in 80% 
(Abikhair et al. 2016). Consequently, several studies were performed to compare different regimens 
and it was demonstrated that withdrawal from CsA caused a reduction of cSCCs (Campistol et al. 
2006; Hofbauer 2010; Caroti et al. 2012). Moreover, the conversion from CsA did reduce the 
vascularization and thickness of cSCCs in organ transplant recipients (Rival-Tringali AL1 2009). 
Alternatively, lowering of the CsA dose also reduced the numbers of cSCCs, but also increased the 
frequency of cellular rejection (Dantal et al. 1998). In comparison to the previous mentioned 
publications, some newer studies could not determine an association with cSCCs development when 
looking at CsA usage vs. no CsA usage in organ transplant recipients (Ingvar et al. 2010; Coghill et al. 
2016). However, a correlation of CsA with cSCCs was also found for other disorders, as for example 
psoriasis. Patients with severe psoriasis are also partly treated with CsA and in these cases an 
increased risk in cSCCs development was shown as well (Paul et al. 2003). 
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1.1.5. CsA – Mode of action 
The fungal (Tolypocladium Inflatum) metabolite CsA was discovered in the 1970’s and was shown to 
inhibit lymphocyte proliferation and thereby allowing murine skin transplantation (Borel et al. 1976). 
After the approval of CsA by the FDA in the early 1980’s, it replaced azathioprine and steroids as a 
standard regimen in kidney transplantation by nearly doubling the graft survival rate. Subsequently 
CsA allowed for subsequent milestone in transplantation of other organs like heart and liver (Watson 
& Dark 2012). CsA is a calcineurin inhibitor, which forms a complex with cyclophilin A within the cell. 
This complex binds and inhibits the calcium- and calmodulin-dependent phosphatase calcineurin. In 
the steady state calcineurin is dephosphorylating cytosolic nuclear factor of activated T-cells (NFAT). 
Dephosphorylated NFAT, which on its own has weak DNA binding capacities, is translocated into the 
nucleus where it, depending on the cell type and cell context, connects with one or more binding 
partners. These binding partners, collectively named NFATn, are dependent on other signaling 
pathways, like for example the MAP kinase pathway. Upon interaction and binding of the DNA, NFAT 
and NFATn initiate cell type specific gene transcription (Figure 1.2) (Medyouf & Ghysdael 2008; 
Crabtree & Schreiber 2009). The immunosuppressive action of CsA is mainly accredited to the 
prevention of a T-cell mediated immune response. Upon donor-derived antigen recognition by T-
cells, Ca2+ is released into the cytoplasm, which leads to calcineurin activation and subsequent NFAT 
dephosphorization. In the nucleus, activated NFAT binds to the transcription factors AP-1 and NF-kB 
amongst others and induces the production of IL-2, which is needed for the T-cell mediated immune 
response. The absence of IL-2, in case of CsA treatment, then leads to reduction of naïve T-cell 
maturation and proliferation, as well as reduction of memory T-cell activation (Hermann-Kleiter & 
Baier 2010; Espinosa et al. 2016). 
In addition to its impact on the calcineurin/NFAT pathway, CsA has also other, calcineurin-
independent, implications. Through binding to cyclophilin D CsA can inhibit the mitochondrial 
permeability transition pore formation and thereby is able to prevent cell death in neural precursor 
cells (Sachewsky et al. 2014). The calcineurin-independent mechanisms are not shared by other 
calcineurin inhibitors like for example tacrolimus, which acts by binding to another immunophilin, 
namely to FK506 binding protein (Chang & Johnson 2002). 
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Figure 1.2 The calcineurin/NFAT signaling pathway. 
CaM: calmodulin, CyA: cyclophilin A, CsA: Cyclosporine A, NFAT: nuclear factor of activated T-cells, NFATn: 
NFAT binding partners. 
1.1.6. Experimental implications of CsA’s role in cSCCs development 
With the achievements in transplantation medicine and long-term survival in the beginning of the 
mid 1970’s, other aspects of the long-term medication were revealed with time (Watson & Dark 
2012). Quite early it was shown that CsA administration in mouse models facilitated growth and 
metastasis of transplanted tumors (Eccles et al. 1980; Servilla et al. 1987). While in the beginning this 
was mainly attributed to the immunosuppressive properties of CsA, in 1999 Hojo et al. showed that 
CsA has as well a cell-autonomous impact on A-549 cells, inducing TGF-β-dependent cell 
transformation favoring invasion. Moreover, the use of immunodeficient mice, lacking T-cells, B-cells 
and natural killer cells, strengthened the conclusion for an immune-independent and TGF-β-
dependent impact of CsA on tumor development. On the one hand Hojo et al. demonstrated a CsA-
induced increase in pulmonary metastasis growth of different tail vein-injected cancer cell lines, on 
the other hand a decrease of pulmonary metastasis growth by the combinatorial treatment with CsA 
and an anti-TGF-β antibody (Hojo et al. 1999). While that specific study did not focus on skin cells, 
others specifically looked for CsA-dependent cSCCs development. While CsA on its own seems not to 
cause any skin tumor development (Han et al. 2012), its impact on UV-induced tumors is differently 
described in different publications. A very early study on UV-induced skin tumors in albino HRA/Skh-1 
mice demonstrated an earlier on set of skin tumors in CsA-treated mice, but not an increase in 
numbers or size of these tumors (Kelly et al. 1987). In contrast, Duncan et al. showed that CsA is 
decreasing the number of UV-induced skin tumors, while it increases the tumor size and 
aggressiveness in SKH-1 hairless mice (Duncan et al. 2007; Wulff et al. 2008). Later Han et al. showed 
that CsA causes an earlier onset of UV-induced skin tumors and higher numbers of tumors in 
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immunocompromised nude mice (Han et al. 2012). The latest study by Voskamp et al. showed that 
CsA decreases UV-induced skin tumors, as well as decreases the tumor size in SKH-1 hairless mice 
(Voskamp et al. 2013). Probably due to different treatment regimens these studies had different 
outcomes concerning the impact of CsA on UV-induced cSCCs. The UV treatment scheme, the applied 
CsA doses, as well as differences in mice models, might play an important role in the outcome of 
those different experiments. However, Voskamp et al. as well emphasized the differences between 
CsA injection, gavage and dietary CsA administration, which as well might have an impact on the 
experimental outcome (Voskamp et al. 2013). 
Additional hints for an immuno-independent impact of CsA on keratinocytes came from studies on 
the calcineurin pathway. It was shown that mice with a keratinocyte specific deletion in calcineurin 
were more prone to chemically-induced carcinogenesis (Wu et al. 2010). Notwithstanding NFATc1 
deletion in follicular stem cells caused a decreased rate of chemically-induced skin malignancies 
(Goldstein et al. 2015). One proposed molecular mechanisms by which CsA is promoting cSCC 
formation was ATF3-dependent inhibition of p53 and subsequent inhibition of senescence (Wu et al. 
2010). Moreover, it was shown that UVA irradiation independently potentiated ATF3 expression in 
keratinocytes (Dziunycz et al. 2014). Hints for other cell autonomous mechanisms, including 
inhibition of DNA repair and inhibition of apoptosis (Yarosh et al. 2005), enhanced survival (Ji et al. 
2012) and enhanced migration (Kashyap & Rabinovitz 2012), were found in cultured keratinocytes. 
Concerning the impact of CsA on proliferation of keratinocytes, published studies showed 
contradictory results. While a positive proliferative impact of prolonged CsA treatment is claimed by 
Han et al. (Han et al. 2010), others showed an anti-proliferative effect of CsA (Fisher et al. 1988; 
Voskamp et al. 2013). 
In addition to a cell autonomous impact on the keratinocytes, other cell types in the skin might be 
involved in cSCC development. While CsA is suppressing the immune system to prevent organ 
rejection, CsA is not completely eliminating all immune cells. Accordingly, all types of immune cells 
including T-cells can be found in cSCCs from organ transplant recipients (Krynitz et al. 2010). In line 
CsA was shown to enhance UV dependent inflammation and facilitated cSCC development via 
enhancement of angiogenesis (Duncan et al. 2007; Yajima et al. 2008; Zhou & Ryeom 2014). 
Moreover, recently Abikhair et al. reported that CsA induces IL-22 expression in T-cells and 
expression of the corresponding receptor in cSCC cells. Together this increased the proliferation and 
invasion of SCC cells. Thus Abikhair et al. presented a mechanism in which close dependence and 
distinct responses of different cell types to CsA favored cSCC development (Abikhair et al. 2016). 
INTRODUCTION AND AIM 
 
10 
 
1.2. Aim and rational of the study design 
CsA is associated with the enhanced occurrence of cSCCs in organ transplant recipients. Since its 
discovery in the 1970’s, many clinical and experimental studies addressed the impact of CsA on 
tumorigenesis. However, despite all those studies, the consequences of CsA on human skin 
keratinocytes are still poorly understood. Effects of CsA were investigated primarily on cultured (2D 
conventional culture) cells or in mouse models. Utilizing human three-dimensional (3D) organotypic 
skin cultures (Berning et al. 2015), which provide a more in-vivo-like situation with all its 
consequences on tissue-dependent gene regulation, might thus provide more physiologically 
relevant information about the role of CsA on human skin keratinocytes, while it also avoids species-
specific differences. 
As cSCCs development commonly requires a latency period of 5 to 10 years, a direct transformation 
of normal keratinocytes by CsA appears unlikely. Therefore, keratinocytes were used which already 
have gained genetic alteration that made them more similar to pre-stages in the multistep process of 
cSCCs. These included the HaCaT cells, spontaneously immortalized human keratinocytes, which 
exhibit UV signature mutations in the p53 gene, as well as chromosomal aberrations, which are 
similarly found in cSCCs (Boukamp et al. 1988). While these cells are non-tumorigenic, we also 
included the HaCaT-RAS A-5 cells, which because of transfection with the H-RasG12V oncogene gained 
the ability to form benign cysts in nude mice, thus representing a benign-tumorigenic variant of the 
HaCaT cells (Boukamp et al. 1990). Investigating these cells in the in-vivo-like organotypic cultures, 
the following questions were addressed:  
1. What are the consequences of continuous CsA treatment on epithelial morphology of the 
non-tumorigenic HaCaT and the benign-tumorigenic HaCaT-RAS A-5 keratinocytes? 
2. What are the consequences of CsA on epithelial tumorigenesis (proliferation, invasion)? 
3. How is the epithelial gene expression changed upon continuous CsA treatment? 
As for immunocompetent patients, cSCCs in organ transplant recipients primarily appear in sun 
exposed areas (Smith et al. 2004). Thus, UV irradiation might be an important co-factor for CsA-
enhanced cSCCs development: 
4. Does a combination of UV and CsA further change the epithelial morphology and/or the gene 
expression and is this combination necessary for tumorigenic conversion? 
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2. RESULTS 
2.1. Determination of a CsA dose for further experiments 
For a first impression of the impact of CsA on keratinocytes several experiments with different doses 
of CsA were performed with cultured cells. Moreover, experiments were performed to determine an 
in-vitro CsA dose for OTCs, which is comparable to the in-vivo blood concentration in organ 
transplant recipients. 
2.1.1. CsA impact proliferation and apoptosis of cultured cells 
HaCaT keratinocytes were treated with CsA in conventional cultures (2D) and analyzed using the 
CellTiter-Blue® assay, which measures the amount of fluorescent resorufin metabolized from added 
resazurin. HaCaT keratinocytes were treated with increasing amounts of CsA (50 ng ml-1 - 100 µg ml-1) 
or the corresponding amount of its solvent DMSO for 72h. Fluorescent signals of doses up to 0.5 µg 
ml-1 CsA and the corresponding amount of 0.002% DMSO were not deviating from each other. 
Starting with 1 µg ml-1 CsA had a reducing impact on signal intensity when compared with lower CsA 
concentrations or the corresponding DMSO concentration. Signal intensity of 2.5 -7.5 µg ml-1 CsA 
were similar to each other and further reduced the signal when compared to 1 µg ml-1 CsA. A drastic 
decrease in signal intensity was determined for doses starting at 15 µg ml-1 CsA. Signal intensities of 
DMSO-treated HaCaT keratinocytes were not impacted up to the amount of 0.03% DMSO, which 
corresponds to 7.5 µg ml-1 CsA. Signal intensities of 0.06% and 0.1% DMSO, corresponding to 15 and 
25 µg ml-1 CsA, were similar to each other, but lower in comparison to lower DMSO doses. 0.2% and 
0.4%, corresponding to 50 and 100 µg ml-1 CsA, drastically decreased the signal intensity (Figure 
2.1A). Additionally, a SYBR Green incorporation assay was performed to assess cell numbers after 
CsA treatment. CsA treatment did not have an immediate impact on cell numbers of HaCaT or 
HaCaT-RAS A-5 cells after 24h or 48h. However, after 72h CsA a non-significant decrease in cell 
numbers was observed (Figure 2.1B). A FACS-assisted apoptosis assay was performed in order to test 
whether the decrease in cell numbers might result from apoptosis. In HaCaT cells treated with DMSO 
around 18% apoptotic cells were detected. A dose of 1 µg ml-1 decreased the rate to 16%. 2.5 µg ml-1 
CsA and 10 µg ml-1 CsA slightly increased the rate to 20-21%. HaCaT-RAS A-5 cells treated with DMSO 
had a slightly smaller rate of apoptosis in comparison to HaCaT cells: 15%. 0.25 µg ml-1 CsA and 10 µg 
ml-1 CsA decreased the rate to about 10-12%. However, 2.5 µg ml-1 CsA had no impact in comparison 
to the DMSO-treated cells. In contrast, a concentration of 100 µg ml-1 CsA clearly elevated the 
apoptosis rate in HaCaT-RAS A-5 keratinocytes to 32%. Due to technical issues the measurement for 
100 µg ml-1 CsA in HaCaT cells is not available (Figure 2.1C). 
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Summarized, the CellTiter-Blue® and the SYBR Green assay suggested that CsA is decreasing the 
proliferation rate of keratinocytes. Moreover, measurement of apoptotic cells excluded the 
possibility that cell numbers decreased due to induction of apoptosis. 
 
Figure 2.1 CsA impact on proliferation and apoptosis of cultured cells. 
(A) CellTiter-Blue® assay. Monolayer HaCaT keratinocytes were treated with different doses of CsA or the 
solvent DMSO alone for 72h. The relative fluorescence of metabolized resazurin (additive) was measured. The 
graph shows the mean (n=8) and the standard error of the mean. Data points of DMSO or CsA were normalized 
to the mean of the lowest DMSO or CsA concentration, respectively. The orange bar marks the range of CsA 
within the epithelium of OTCs treated with 10 µg ml
-1
 CsA via growth medium supplementation, which was 
taken as standard concentration in subsequent experiments. (B) SYBR Green incorporation. Relative cell 
numbers (fluorescence intensity) of cultured HaCaT and HaCaT-RAS A-5 keratinocytes after CsA or DMSO 
(0.04%) treatment. Data points represent the mean and the standard error of the mean (n=8). Values from 
each CsA concentration or DMSO were normalized to the mean of the 24h value of DMSO or the corresponding 
CsA concentration, respectively. (C) FACS-assisted apoptosis assay. Cultured HaCaT and HaCaT-RAS A-5 cells 
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were treated with CsA or DMSO (0.04%) for 24h. The graph shows single cell analysis for AnnexinV (early 
apoptosis marker) and PI (late apoptosis marker). The plot shows the mean percentage of positive cells per 
total cell number. Per sample 3800 – 6000 single cells were analysed. 
2.1.2. Continuous long-term treatment of cultured HaCaT cells 
CsA might have a genotoxic impact, as described for lymphocytes (Oliveira et al. 2004; Ozturk et al. 
2008). To assess a genotoxic impact of CsA on HaCaT cells, cultured cells were treated for 9 weeks. 
Maintenance and splitting of HaCaT cells was done according to standard cell culture procedures. 
CsA was added together with fresh medium three times a week. 
After 9 weeks of continuous CsA treatment multiplex fluorescence in situ hybridization (M-FISH) was 
performed to assess chromosomal changes. New chromosomal aberrations, which were not present 
within the control (DMSO) treated HaCaT keratinocytes, were counted. Two different doses of CsA 
were applied: 0.25 and 2.5 µg ml-1 CsA. This long-term treatment of HaCaT keratinocytes was 
performed twice. Due to a change of serum within the laboratory, both experiments were done in 
individual sera, serum A and serum B. Serum B was also used for the previous described short-term 
assays (Figure 2.1). In serum A about 9 new chromosomal aberrations per metaphase appeared in 
the DMSO-treated HaCaT cells. This number increased to 19 and 21 new aberrations per metaphase 
for 0.25 µg ml-1 CsA and 2.5 µg ml-1 CsA, respectively. In serum B the number of new aberrations per 
metaphase in DMSO HaCaT cells was higher than for serum A, namely 19. New aberrations for 0.25 
µg ml-1 CsA increased to 31 per metaphase, but decreased to 9 for 2.5 µg ml-1 CsA (Figure 2.2A). The 
increase in new chromosomal aberrations in serum A, neither had an impact on the morphology of 
HaCaT keratinocytes (Figure 2.2B), nor was the impact on proliferation changed upon CsA treatment 
(Figure 2.2C) when compared to short-term treatment with CsA as described in Figure 2.1B. 
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Figure 2.2 Long-term CsA treatment of cultured HaCaT keratinocytes. 
Cultured HaCaT cells were treated for 9 weeks with 0.25 or 2.5 µg ml
-1
 CsA or DMSO (0.04%). (A) Multiplex 
fluorescence in situ hybridization. The graph shows the mean of new chromosomal aberrations per metaphase 
spread. In total 30 metaphase spreads were analysed per treatment. (B) Light microscopy images from cultured 
HaCaT cells after 9 weeks of continuous treatment with DMSO as control (HaCaT-LT DMSO) or 2.5 µg ml
-1
 CsA 
(HaCaT-LT CsA) in serum A. (C) SYBR Green incorporation. Relative cell number of HaCaT-LT after CsA or DMSO 
(0.04%) treatment in serum A after 24h, 48h and 72h. Data points represent the mean and the standard error 
of the mean of one experiment with four biological replicates each. Values from CsA or DMSO were normalized 
to the mean of the corresponding CsA or DMSO 24h value, respectively. 
2.1.3. CsA is reaching the epithelium in HaCaT- and HaCaT-RAS A-5-OTCs – MassSpec 
measurements 
OTCs lack perfusion by blood vessels and drug distribution is merely possible by diffusion. In order to 
treat OTCs with CsA, CsA was supplemented to the growth medium, feeding the cells from below by 
diffusion. In order to determine whether and how much CsA is reaching the dermis and the 
epidermis via diffusion, mass spectrometry measurements were performed in the dermal, as well as 
in the epidermal part of OTCs after 3 weeks of continuous CsA treatment. No CsA could be detected 
for the dermal or epidermal samples treated with DMSO in HaCaT-OTCs. Supplementation of 0.25 µg 
ml-1 CsA in HaCaT-OTCs, led to 0.04 µg ml-1 CsA and 0.07 µg ml-1 CsA within the dermal and epidermal 
samples, respectively. The supplementation of 2.5 µg ml-1 CsA, led to 0.57 µg ml-1 CsA and 0.44 µg ml-
1 CsA in the dermal and epidermal samples, respectively. The highest amount of CsA within the 
epithelium was measured after the supplementation of 10 µg ml-1 CsA, namely 0.937 µg ml-1 CsA. In 
the dermal sample, the same supplementations led to an amount of 0.23 µg ml-1 CsA. Similar to 
HaCaT-OTCs, no CsA was detected in HaCaT-RAS A-5-OTCs treated with DMSO. Supplementation of 
0.25 µg ml-1 CsA and 2.5 µg ml-1 CsA led in both cases to around 0.017 µg ml-1 CsA in the dermal and 
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0.047 µg ml-1 CsA in the epidermal samples. The amount of CsA after 10 µg ml-1 CsA supplementation 
in HaCaT-RAS A-5-OTCs was similar to HaCaT-OTCs, namely 0.214 µg ml-1 CsA in the dermal and 1.1 
µg ml-1 CsA in the epidermal sample (Figure 2.3). These measurements were comparable to the 
HaCaT samples, except for the amount of CsA in the epidermis after 2.5 µg ml-1 CsA supplementation, 
which was higher in HaCaT epithelia. Measurements after 2.5 µg ml-1 CsA supplementation were only 
done once, in contrast to 10 µg ml-1 CsA supplementation, which was measured in 3 independent 
samples. Therefore it is not explicitly evidenced whether HaCaT epithelia manifested more CsA than 
HaCaT-RAS A-5 cells after 2.5 µg ml-1 CsA supplementation. 
 
Figure 2.3 Mass spectrometry measurements of CsA concentration within HaCaT- and HaCaT-RAS A-5-OTCs. 
Measurements were done separately with dermal or epidermal compartments of corresponding OTCs. The 
graphs represent the mean and the standard error of the mean from two experiments (DMSO: n=2, 10 µg ml
-1
 
CsA: n=6) or from one experiment (0.25 and 1x 2.5 µg ml
-1
 CsA: n=1, 2.5 µg ml
-1
 CsA in HaCaT-RAS A-5: n=2). 
2.1.4. Impact of 10 µg ml-1 CsA and higher doses on HaCaT- and HaCaT-RAS A-5-OTCs 
The blood CsA concentration in organ transplant recipients is about 25 ng ml-1 – 1.25 µg ml-1, 
depending on type of graft and time point of blood measurements (Saigal et al. 2002; Sommerer et 
al. 2006), whereas it was shown that CsA can accumulate within the skin reaching levels of about 2.8 
µg ml-1 (Fisher et al. 1988). Mass spectrometry measurements showed that at least a dose of 10 µg 
ml-1 CsA (in cell culture medium) is needed to reach a level within the in-vivo blood range (25 ng ml-1 
– 2.8 µg ml-1) in the epithelial cells. Accordingly OTCs were prepared and treated with 10 µg ml-1 CsA 
and higher doses (25-100 µg ml-1 CsA) to analyze the overall morphology of these cultures. H&E 
histological stainings revealed that increased DMSO (0.04%-0.4%) had no morphologic impact on 
HaCaT- and HaCaT-RAS A-5-OTCs. HaCaT-OTCs treated with 10 µg ml-1 CsA and 25 µg ml-1 CsA had a 
more structured morphology when compared to the corresponding DMSO-treated HaCaT-OTC, but 
did not show any obvious sign of atrophy. Treatment with 50 µg ml-1 CsA and 100 µg ml-1 CsA led to 
atrophic epithelia and to an acantholytic morphology. HaCaT-RAS A-5-OTCs treated with 10 µg ml-1 
CsA had, similar to HaCaT-OTCs a more structured and as well a more differentiated epithelium when 
compared to the DMSO-treated HaCaT-RAS A-5-OTC. In contrast to HaCaT-OTCs, in HaCaT-RAS A-5-
OTCs an atrophic and acantholytic epithelium was already triggered by 25 µg ml-1 CsA (Figure 2.4).  
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Figure 2.4 Impact of high CsA doses on HaCaT- and HaCaT-RAS A-5-OTCs. 
HaCaT- and HaCaT-RAS A-5-OTCs were treated with the indicated concentrations of CsA or the corresponding 
amount of the solvent DMSO via growth medium supplementation. OTCs were harvested after 2 weeks 
(HaCaT-OTCs) or 3 weeks (HaCaT-RAS A-5 OTCs) and processed for H&E histological staining. Scale bars: 100 
µm. 
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2.2. Continuous CsA treatment of HaCaT- and HaCaT-RAS A-5-OTCs 
As a minimum dose of 10 µg ml-1 CsA is needed to reach a CsA level (Figure 2.3) comparable to in-vivo 
blood levels (Saigal et al. 2002; Sommerer et al. 2006) and doses starting with 25 µg ml-1 CsA led to 
atrophic growth in HaCaT-RAS A-5-OTCs (Figure 2.4), 10 µg ml-1 CsA was taken as standard 
supplementation to the growth medium for all further experiments with OTCs. 
In order to get an impression on the impact of continuous CsA on keratinocytes over time and to 
assess the impact in a realistic physiologic environment time series of CsA-treated HaCaT- and 
HaCaT-RAS A-5-OTCs were prepared. HaCaT or HaCaT-RAS A-5 keratinocytes were allowed to build 
an epithelium in the OTCs without CsA treatment for one week. CsA was then added to the OTCs and 
continuously treated for 1, 2 and 3 weeks. 
2.2.1. Continuous CsA improved epithelial organization of HaCaT- and HaCaT-RAS A-5-OTCs and 
decreased the proliferation of keratinocytes 
Morphology and overall appearance from continuously CsA-treated HaCaT- and HaCaT-RAS A-5-OTCs 
were assessed by H&E histological staining. From earlier studies it is known that HaCaT-OTCs form a 
multi-layered parakeratotic epithelium (Berning et al. 2015). Moreover, in comparison to OTCs built 
with normal human keratinocytes, the organization of the stratified epithelium of HaCaT-OTCs is 
rather disorganized (Berning et al. 2015). In accordance, control HaCaT-OTCs treated with DMSO 
showed this typical HaCaT organization at all time points (before treatment start and after 1, 2 and 3 
weeks of treatment). Treatment with CsA had a rather minor impact on the HaCaT growth pattern. 
Histology of early OTCs revealed that CsA did not alter the diameter of the epithelium, nor could 
invasion be detected. However, after 2 and 3 weeks of CsA treatment the epithelial stratification 
seemed more organized with all strata being more separated from each other. Moreover, after 3 
weeks of treatment the vital cell layers, stratum basale and spinosum, as identified by intense nuclei 
staining, appeared thicker and better organized in CsA-treated HaCaT-OTCs (Figure 2.5). 
HaCaT-RAS A-5 cells form a hyper-proliferative multi-layered, parakeratotic epithelium, with invading 
buds penetrating into the underlying dermal equivalent when grown in OTCs. In addition, in 
comparison to HaCaT epithelia, HaCaT-RAS A-5 epithelia are less differentiated (Berning et al. 2015). 
Also for these cells, DMSO treatment did not alter the expected morphological appearance of HaCaT-
RAS A-5 epithelia. Furthermore, and similar to CsA-treated HaCaT cells, CsA treatment enhanced the 
tissue organization and increased differentiation (Figure 2.5). 
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Figure 2.5 H&E histological staining of HaCaT- and HaCaT-RAS A-5-OTCs after 1-3 weeks of continuous CsA 
treatment. 
HaCaT- and HaCaT-RAS A-5-OTCs were harvested and processed for H&E histological staining one week after 
epithelia seeding and after 1, 2 and 3 weeks of treatment. OTCs were treated with 10 µg ml
-1
 CsA or the solvent 
DMSO (0.04%). Scale bars: 100 µm. 
H&E histological stainings revealed no thickening of the epithelia upon CsA treatment. In order to 
further exclude an impact on proliferation, cryosections of HaCaT- and HaCaT-RAS A-5-OTCs were 
stained for the proliferation marker Ki67. Immunofluorescent stainings showed that especially 
suprabasal proliferation was diminished after CsA treatment (Figure 2.6A). The Proliferation index 
(Ki67+ per length of basement membrane) demonstrated a decrease in proliferation of HaCaT and 
HaCaT-RAS A-5 cells after 2 and 3 weeks of continuous CsA treatment (Figure 2.6B). 
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Summarized, CsA led to an improvement of tissue organization and differentiation of HaCaT and 
HaCaT-RAS A-5 epithelia, while it reduced cell proliferation of both cell types, especially in suprabasal 
cell layers. 
 
Figure 2.6 Proliferation of HaCaT and HaCaT-RAS A-5 keratinocytes within OTCs upon continuous CsA. 
Cryosections from HaCaT- and HaCaT-RAS A-5-OTCs, treated with 10 µg ml
-1
 CsA or DMSO (0.04%) for 2 (HaCaT) 
or 3 (HaCaT-RAS A-5) weeks, were stained for Ki67 (green). (A) Immunoflourescent staining. Pictures show 
representing sections stained for Ki67 (green) and nuclei (blue). The dotted line marks the basement 
membrane. Scale bars: 100 µm. (B) Proliferation index (Ki67
+
 cells). Each data point represents the number of 
Ki67
+
 cells per length of basement membrane. n=9 (from 3 OTCs). The orange bar marks the mean and the 
error bars represent the standard error of the mean. *: p-value of 0.03, **: p-value of 0.002 (two-sided, 
unpaired t-test). 
2.2.2. Genome wide RNA expression analysis from continuously CsA-treated HaCaT and HaCaT-
RAS A-5 epithelia 
In order to reveal changes on a transcriptional level, genome wide RNA expression profiles were 
performed from epithelia of HaCaT and HaCaT-RAS A-5 cells, which were treated with CsA for 2 or 3 
weeks, respectively. As HaCaT-OTCs have a shorter lifespan than HaCaT-RAS A-5-OTCs, RNA was 
extracted already after 2 weeks in order to get a view at a time point of maximal vitality of the 
control OTCs. 
2.2.2.1. RNA expression profiles from CsA-treated HaCaT and HaCaT-RAS A-5 epithelia were 
distinct from their corresponding control samples 
Expression profiling was done from three biological replicates per condition. Evaluation of the raw 
data from RNA from HaCaT and HaCaT-RAS A-5 epithelia was done as follows: Raw data from both 
treatment groups (DMSO and CsA) were normalized together and non-metric multidimensional 
scaling (NMDS) and hierarchical clustering were applied to assess the quality of the data. For both 
experiments (HaCaT epithelia and HaCaT-RAS A-5 epithelia) all triplicates from one treatment groups 
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(DMSO and CsA) separated along the first dimension using NMDS (Figure 2.7A). In agreement, 
hierarchical clustering split all samples into DMSO or CsA as depicted in the dendrogram (Figure 
2.7B). Both analyses showed that biological replicates clustered well, implying a similar expression 
pattern. Furthermore, differential gene expression was determined and filtered by p-value ≤ 0.01. 
The 20 highest and lowest differentially expressed genes are listed in the appendix (Tables 7.1 and 
7.2). 
 
Figure 2.7 Visualizations of biological replicates from RNA expression profiles from CsA-treated HaCaT and 
HaCaT-RAS A-5 epithelia by NMDS and hierarchical clustering. 
(A) Non-metric multidimensional scaling (NMDS) and (B) hierarchical clustering were applied to assess the 
discriminability of the 3 biological replicates from both treatment groups (DMSO and CsA). Clustering and 
visualization was performed with Chipster from normalized data. 
In total 507 genes were differentially regulated in case of the RNA from CsA-treated HaCaT epithelia. 
Of these genes 25% (128/507) were regulated above 1.5-fold. A bit above half of these genes were 
down-regulated (58%, 75/128). This was as well the case for the total number of differentially 
expressed genes, from which 55% (278/507) were down-regulated. The total number of differentially 
expressed genes in epithelia from CsA-treated HaCaT-RAS A-5 was comparable to HaCaT epithelia, 
namely 521. However, fold changes of differentially expressed genes was stronger affected in HaCaT-
RAS A-5 epithelia, in which 63% (327/521) of all differentially expressed genes were above 1.5-fold 
regulated (Figure 2.8A). The higher magnitude of fold changes in HaCaT-RAS A-5 epithelia can also be 
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seen in the scatterplot (Figure 2.8B). 44% (HaCaT: 156/507) or 43% (HaCaT-RAS A-5: 156/521) of all 
differentially expressed genes were regulated in both data sets (Figure 2.8C). 
 
Figure 2.8 Number and magnitude of differentially expressed genes (DMSO vs. CsA) from HaCaT and HaCaT-
RAS A-5 epithelia. 
(A) Differentially expressed genes (DMSO vs. CsA). Whole genome RNA expression profiles from HaCaT and 
HaCaT-RAS A-5 epithelia treated with DMSO or CsA. The table shows the total number of differentially 
expressed genes and the number of differentially expressed genes with a fold change ≥ 1.5. Differentially 
expressed genes were calculated with Chipster (filtered by p-value ≤ 0.01). (B) Scatterplot of relative gene 
expression. Each dot shows the mean of the relative expression value (log2) from 3 biological replicates for one 
gene. Y-axis (DMSO), x-axis (CsA). Dots on line of origin = no differential gene expression. Data for the 
scatterplot were neither normalized nor filtered. (C) Overlap of differential gene expression from both data sets 
(HaCaT and HaCaT-RAS A-5 epithelia). 
2.2.2.2. CsA treatment affected many genes from the GO-term: ‘epidermal development’ 
From the 20 highest up- and down- regulated genes from CsA-treated HaCaT and HaCaT-RAS A-5 
epithelia expression profiles, 10/40 genes (HaCaT) and 12/40 genes (HaCaT-RAS A-5) were part of the 
GO-term (GO-0008544) ‘epidermal development’ (underlined in Tables 7.1 and 7.2). Accordingly, the 
complete gene expression profile sets HaCaT and HaCaT-RAS A-5 epithelia were filtered by this GO-
term. Both resulting lists were combined and a heat map was created (Figure 2.9). In total 38 genes 
were part of the term ‘epidermal development’ from the CsA-treated HaCaT RNA expression profile 
and 47 genes in case of the CsA-treated HaCaT-RAS A-5 RNA expression profile. The heat map 
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revealed that genes, which were regulated in both gene sets, were either both up- or both down-
regulated, suggesting a common regulation pattern. Most genes were up-regulated. However, some, 
as for example keratin 15 (KRT15) and E74 like ETS transcription factor 3 (ELF3), were down-
regulated in both cell types. In addition, especially one specific gene group seemed to be responding 
to CsA, namely late cornified envelope (LCE) genes. 
 
Figure 2.9 Heat map of differentially expressed genes from genome wide RNA expression profiles from 
HaCaT and HaCaT-RAS A-5 epithelia (DMSO vs. CsA) sorted by the GO-term ‘epidermal development’. 
Differentially expressed genes (DMSO vs. CsA) from CsA-treated HaCaT and HaCaT-RAS A-5 RNA expression 
profiles were filtered by p-value (≤0.01) and the GO-term ‘epidermal development’ (GO-0008544). Fold 
changes (log2) are depicted by the indicated color. The rows are sorted alphabetically. 
2.2.3. Differentially expressed genes could be validated by qRT-PCR and IF staining 
From the list of differentially expressed genes involved in ‘epidermal development’ 7 genes were 
selected for validation by qRT-PCR with RNA from 2-4 independent experiments as well as 
immunofluorescent stainings from one representing experiment. It is suggested that calcineurin 
inhibition by CsA is causing down-regulation of certain differentiation genes, like for example 
filaggrin (FLG) in keratinocytes (Santini et al. 2001). Therefore, OTCs built with normal human 
keratinocytes were prepared and treated with CsA for 3 weeks. RNA and cryosections from these 
NHEK-OTCs were included in the validation experiments. 
LCE proteins comprise 3 groups LCE1, LCE2 and LCE3. From groups LCE2 and LCE3 one gene each was 
chosen for validation by qRT-PCR, namely LCE2A and LCE3A. Additionally localization of LCE2 and 
LCE3 (Niehues et al. 2015) was highlighted by immunofluorescent staining. According to the RNA 
expression profile data HaCaT cells showed no increase in LCE2A and a 2.9-fold increase for LCE3A. 
For HaCaT-RAS A-5 cells the profile revealed an increase in LCE2A (5.6-fold) and no regulation for 
LCE3. Using qRT-PCR, LCE2A was down-regulated (0.7-fold) and LCE3A was up-regulated (1.7-fold) in 
NHEK epithelium. As expected from the gene expression array data, fold changes measured by qRT-
PCR for LCE2A and LCE3A were higher in HaCaT-RAS A-5 cells (LCE2A: 32-fold regulation; LCE3A: 4-
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fold regulation) than in HaCaT cells (LCE2A: 1.3-fold regulation; LCE3A: 2.1-fold regulation) (Figure 
2.10A). Immunofluorescent staining of control (DMSO) NHEK epithelia nicely revealed LCE2 
deposition in the stratum corneum and granulosum and LCE3 within early differentiating cells in the 
stratum spinosum as well as stratum granulosum. This correlated to previous published stainings in 
human skin (Niehues et al. 2015). Due to the fact that LCE2 and LCE3 were strongly deposited in 
NHEK control epithelia, potential minor changes could not be detected in CsA-treated NHEK epithelia 
by immunofluorescent staining. In case of HaCaT epithelia the control OTCs showed a similar 
distribution of LCE proteins to the NHEK epithelia; LCE2 were only in the outermost layers and LCE3 
in differentiating cells excluding the outermost layers. However, the amount of deposited LCE2 and 
LCE3 was much less and LCE3 appeared later in comparison to NHEK epithelia with several 
suprabasal cells very weakly or not stained for LCE3. In control HaCaT-RAS A-5 epithelia, LCE2 was 
nearly absent; nevertheless those proteins present were also deposited in the outermost layers of 
the epithelium. LCE3 proteins were also deposited in the suprabasal cells underneath the outermost 
layer; however it even appeared later than in HaCaT epithelia. Interestingly, and in line with the 
increased RNA expression in CsA-treated HaCaT and HaCaT-RAS A-5 epithelia, the 
immunofluorescent staining detected more LCE proteins deposited in differentiating cells in HaCaT 
and HaCaT-RAS A-5 epithelia. Noteworthy, the distribution, with LCE2 in the outermost and LCE3 in 
suprabasal cells, but underneath LCE2, was maintained (Figure 2.10B). 
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Figure 2.10 Relative gene expression and protein localization of LCE2A/LCE2 and LCE3A/LCE3 in NHEK, HaCaT 
and HaCaT-RAS A-5 epithelia treated with CsA. 
(A) Relative RNA expression. RNA isolated from indicated epithelia treated with DMSO (0.04%) or CsA (10 µg ml
-
1
) for 3 weeks was quantified by qRT-PCR. The graphs show the mean and standard error of the mean. NHEK: 
n=9 (from 3 independent experiments), HaCaT and HaCaT-RAS A-5: n=11 (from 4 independent experiments). 
(B) Immunofluorescent staining for LCE2 (green) and LCE3 (red) on cryosections from the indicated OTCs 
treated with DMSO (0.04%) or CsA (10 µg ml
-1
) for 2 (HaCaT) or 3 (NHEK and HaCaT-RAS A-5) weeks. Sections 
were counterstained by DAPI to stain nuclei (blue). The dotted line marks the basement membrane. Scale bar: 
50 µm.  
Another example was the keratin 10 (KRT10) gene, a commonly used marker for early epidermal 
differentiation. KRT10 was not differentially expressed in HaCaT cells based on the genome wide RNA 
expression array data set, while a 1.7-fold up-regulation was seen for HaCaT-RAS A-5 cells. 
Measurements by qRT-PCR revealed no changes in RNA regulation for NHEK epithelia. In HaCaT 
epithelia KRT10 RNA expression slightly increased (1.3-fold) and in HaCaT-RAS A-5 epithelia exhibited 
4-fold up-regulation of KRT10 RNA (Figure 2.11A) upon CsA treatment. In control (DMSO) NHEK and 
HaCaT epithelia KRT10 was deposited in all suprabasal cell layers. In contrast in control HaCaT-RAS A-
5 epithelia KRT10 deposition was limited to the upper part of the epithelium, while many suprabasal 
keratinocytes were not stained for KRT10. No major difference in KRT10 protein deposition could be 
detected for CsA-treated NHEK and HaCaT epithelia by immunofluorescent staining in comparison to 
the control. Noteworthy, in CsA-treated HaCaT-RAS A-5-OTCs KRT10 deposition was increased; after 
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CsA treatment most suprabasal layers could be stained for KRT10, while the basal cell layer and 
several cells from the first and second suprabasal cell layer remained KRT0 negative (Figure 2.11B). 
 
Figure 2.11 Relative gene expression and protein localization of KRT10 in NHEK, HaCaT and HaCaT-RAS A-5 
epithelia treated with CsA. 
(A) Relative KRT10 RNA expression. RNA isolated from indicated epithelia treated with DMSO (0.04%) or CsA 
(10 µg ml
-1
) for 3 weeks was quantified by qRT-PCR. The graphs show the mean and the standard error of the 
mean. NHEK: n=9 (from 3 independent experiments), HaCaT: n=6 (from 2 independent experiments), HaCaT-
RAS A-5: n=3 (1 experiment). (B) Immunofluorescent staining for KRT10 (red) on cryosections from the 
indicated OTCs treated with DMSO (0.04%) or CsA (10 µg ml
-1
) for 2 (HaCaT) or 3 (NHEK and HaCaT-RAS A-5) 
weeks. Sections were counterstained by DAPI to stain nuclei (blue). The dotted line marks the basement 
membrane. Scale bars: 50 µm. 
FLG is a typically used epidermal marker to demonstrate late/terminal differentiation. FLG was not 
detected by the array in HaCaT epithelia, but 3.7-fold up-regulated in HaCaT-RAS A-5 epithelia. qRT-
PCR measurements revealed a similar pattern as for KRT10 expression: RNA levels were not critically 
changed (mean 1.1-fold up-regulated) by CsA in NHEK epithelia, were 2.5-fold up-regulated in HaCaT 
epithelia and 4.6-fold up-regulated in HaCaT-RAS A-5 epithelia (Figure 2.12A). By immunofluorescent 
staining FLG was detected in the stratum granulosum and the stratum corneum of control (DMSO) 
NHEK epithelia. As the strata granulosum and corneum are less developed in HaCaT-OTCs and HaCaT-
RAS A-5 -OTCs the staining for FLG was accordingly less strong. However, in HaCaT- and HaCaT-RAS 
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A-5-OTCs, CsA treatment increased the amount of deposited FLG in the outermost strata; while no 
change could be detected in CsA-treated NHEK epithelia (Figure 2.12B). 
 
Figure 2.12 Relative gene expression and protein localization of FLG in NHEK, HaCaT and HaCaT-RAS A-5 
epithelia treated with CsA. 
(A) Relative FLG RNA expression. RNA isolated from indicated epithelia treated with DMSO (0.04%) or CsA (10 
µg ml
-1
) for 3 weeks was quantified by qRT-PCR. The graphs show the mean and the standard error of the 
mean. NHEK: n=9 (from 3 independent experiments), HaCaT: n=8 (from 3 independent experiments), HaCaT-
RAS A-5: n=6 (2 independent experiments). (B) Immunofluorescent staining for FLG (red) on cryosections from 
the indicated OTCs treated with DMSO (0.04%) or CsA (10 µg ml
-1
) for 3 weeks. Sections were counterstained 
by DAPI to stain nuclei (blue). The dotted line marks the basement membrane. Scale bar: 50 µm. 
Small proline rich (SPRR) proteins function as cross-linking proteins within the cornified envelope. 
Expression of SPRR2B was slightly up-regulated in the HaCaT genome wide RNA expression array data 
set (1.9-fold) and strongly up-regulated in the HaCaT-RAS A-5 data set (5.9-fold). qRT-PCR 
measurements showed that SPRR2B was 0.7-fold down-regulated in NHEK epithelia. In contrast to 
the profile data no mayor SPRR2B RNA regulation was seen for HaCaT epithelia (1.1-fold up-
regulation) upon CsA treatment. In CsA-treated HaCaT-RAS A-5 cells SPRR2B RNA levels were 8-fold 
up-regulated by qRT-PCR (Figure 2.13A). SPRR2 proteins were widely distributed in the stratum 
corneum and differentiating cells of control NHEK epithelia, less concentrated in HaCaT epithelia and 
nearly absent from control HaCaT-RAS A-5 epithelia. Concurrent to the RNA results from SPRR2B, the 
antibody recognized more SPRR2 within the CsA-treated HaCaT-RAS A-5 epithelium. No major 
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differences could be detected for SPRR2 deposition in CsA-treated NHEK and HaCaT epithelia (Figure 
2.13B). 
 
Figure 2.13 Relative gene expression and protein localization of SPRR2B/SPRR2 in NHEK, HaCaT and HaCaT-
RAS A-5 epithelia treated with CsA. 
(A) Relative SPRR2B RNA expression. RNA isolated from indicated epithelia treated with DMSO (0.04%) or CsA 
(10 µg ml
-1
) for 3 weeks was quantified by qRT-PCR. The graphs show the mean and the standard error of the 
mean. n=9 (3 independent experiments). (B) Immunofluorescent staining for SPRR2 (red) on cryosections from 
the indicated OTCs treated with DMSO (0.04%) or CsA (10 µg ml-1) for 3 weeks. Sections were counterstained 
by DAPI to stain nuclei (blue). The dotted line marks the basement membrane. Scale bar: 100 µm. 
Several genes from the GO-term ‘epidermal development’ were up-regulated upon CsA treatment, 
while some were down-regulated. Cornulin (CRNN) was 0.2-fold down-regulated in HaCaT epithelia 
and 0.49-fold down-regulated in HaCaT-RAS A-5 epithelia according to the expression profiles. 
Validation by qRT-PCR confirmed down-regulation of CRNN in HaCaT epithelia (0.2-fold) and HaCaT-
RAS A-5 (0.62-fold). Different from HaCaT and HaCaT-RAS A-5 epithelia, CRNN was slightly up-
regulated (1.5-fold) in NHEK-OTCs (Figure 2.14). 
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Figure 2.14 Relative CRNN gene expression in CsA-treated NHEK, HaCaT and HaCaT-RAS A-5 epithelia. 
RNA isolated from indicated epithelia treated with DMSO (0.04%) or CsA (10 µg ml
-1
) for 3 weeks was 
quantified by qRT-PCR. The graphs show the mean and standard error of the mean. NHEK: n=9 (from 3 
independent experiments), HaCaT and HaCaT-RAS A-5: n=6 (from 2 independent experiments). 
To summarize, most of the results from the RNA expression profile could be replicated by qRT-PCR. 
Noteworthy, fold changes were generally higher according to qRT-PCR than to the RNA expression 
profile. Moreover, in case of LCE3A (HaCaT-RAS A-5), KRT10 (HaCaT) and FLG (HaCaT) qRT-PCR 
revealed RNA up-regulation, which was not detected by expression profiling. Only in the case of 
SPRR2B HaCaT epithelia, which was 1.9-fold up-regulated according to the RNA expression profile, 
qRT-PCR did not validate the finding and qRT-PCR only detected a very weak 1.1-fold up-regulation. 
Noteworthy, the low mean expression value resulted from 3 different independent experiments, 
which individually revealed a 0.6-fold down-regulation and 1.1-fold or 1.64-fold up-regulation, 
respectively. These inter-experimental variations, which can be identified by the quite high standard 
errors of the mean, were also observed from other measurements, like for example KRT10 in HaCaT 
epithelia. In principal inter-experimental variations in morphology and grade of differentiation 
typically occur in OTCs with HaCaT and HaCaT-RAS A-5 keratinocytes. These inter-experimental 
different grades of differentiation could be reflected in the magnitude of fold change of CsA-induced 
differentially expressed genes. A general observation was: the more differentiated the control OTCs 
were, the less strongly was the fold change in differentiation-associated genes induced by continuous 
CsA treatment. In accordance to that observation, gene expression of differentiation-associated 
genes in NHEK epithelia, which is fully differentiated, was only very weakly affected and fold changes 
were in all cases below the fold changes of the less differentiated HaCaT or HaCaT-RAS A-5 epithelia. 
Moreover, and in line with that observation, fold changes of CsA-induced gene expression in HaCaT-
RAS A-5 epithelia, which inherently are less differentiated than HaCaT epithelia, usually was affected 
strongest. In case of HaCaT-RAS A-5 epithelia increased RNA expression could as well nicely be 
demonstrated by immunofluorescent staining of LCE2, LCE3, KRT10, FLG and SPRR2. In case of HaCaT 
epithelia immunofluorescent staining only could reveal more deposition for LCE3 and FLG. For all 
other stainings a quantitative statement was impaired due to the inherent high deposition of the 
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corresponding proteins. Nevertheless, all immunofluorescent stainings of CsA-treated HaCaT and 
HaCaT-RAS A-5 epithelia revealed an improved stratification. 
2.2.4. Continuous CsA treatment led to an increase in transepithelial electrical resistance in 
HaCaT- and HaCaT-RAS A5-OTCs 
Interestingly, many of the CsA-induced regulated genes were involved in ‘epidermal development’ 
and differentiation. The epidermis has a protective function, preventing pathogens or chemicals 
entering the human body as well as being a barrier against UV irradiation. Epithelia with reduced 
differentiation most often also exhibit defects in barrier function, as it is for example the case for 
atopic dermatitis (Palmer et al. 2006; Mildner et al. 2010). Measurements of transepithelial electrical 
resistance (TEER) (Koria et al. 2003) was used in order to determine a potential difference in the skin 
barrier of OTCs treated with CsA. 
Compared to NHEK epithelia, HaCaT and HaCaT-RAS A-5 epithelia, which are characterized by a 
parakeratotic epithelium, differentiate less (Berning et al. 2015). Accordingly NHEK-OTCs showed the 
highest TEER of about 10,000 Ω. This reflected a fully developed skin barrier, which impeded the 
current flow of applied voltage. In contrast, the measured resistance from HaCaT- and HaCaT-RAS A-
5-OTCs displayed multi-fold lower values of 180 Ω and 50 Ω, respectively. This clearly revealed the 
reduced differentiation and demonstrated a non-functional skin barrier (Figure 2.15A). Next TEER 
was measured to quantify changes in barrier function of HaCaT- and HaCaT-RAS A-5-OTCs treated 
with CsA. Interestingly, resistance increased in CsA-treated HaCaT- and HaCaT-RAS A-5-OTCs to 280 Ω 
and 70 Ω, respectively, correlating to the increase in differentiation-associated genes (Figure 2.15B). 
 
Figure 2.15 Transepithelial electrical resistance of NHEK-, HaCaT- and HaCaT-RAS A-5-OTCs and HaCaT- and 
HaCaT-RAS A-5-OTCs treated with CsA. 
The transepithelial electrical resistance (TEER) was measured with a Volt-Ohm meter. (A) TEER of control OTCs. 
(B) TEER of DMSO- and CsA-treated OTCs. OTCs were treated with DMSO (0.04%) or CsA (10 µg ml
-1
) for 3 
weeks. n=6 (from two independent experiments). The line indicates the mean. p-value (two-sided unpaired t-
test). *≤0.05, **≤0.01. 
2.2.5. Did CXCL14, DEFB4A or IGFL1 increase differentiation in HaCaT- and HaCaT-RAS A-5-OTCs? 
CsA specifically up-regulated differentiation-associated genes like LCEs and thereby improved the 
barrier function of HaCaT- and HaCaT-RAS A-5-OTCs. In order to identify potential factors inducing 
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these differentiation-associated genes, a gene list was put together which contained genes 
differentially expressed in HaCaT and HaCaT-RAS A-5 epithelia (Table 7.3). 
Three candidates from this list were chosen for validation by qRT-PCR in independent experiments. 
The first factor was defensin beta 4A (DEFB4A) which was the second highest up-regulated gene in 
HaCaT epithelia and also was regulated in HaCaT-RAS A-5 epithelia. Defensins play an important role 
in bacterial defense (Ganz 2005) and are regulated during keratinocyte differentiation. Moreover, 
DEFB1 was also shown to induce differentiation in HaCaT keratinocytes (Frye et al. 2001; Abiko et al. 
2003). The second factor was the cytokine CXCL14, whose expression is strongly increased in dense 
epithelial cells in parallel to differentiation markers like IVL (Ikoma et al. 2012). Third, the rather 
undescribed factor IGFL1 was chosen, which was found to be expressed in embryonic growing and 
differentiating epithelial tissue (Emtage et al. 2006) and being up-regulated in skin upon wounding 
and inflammation (Lobito et al. 2011; Nuutila et al. 2012). Up-regulation of all three factors could be 
validated by qRT-PCR in HaCaT and HaCaT-RAS A-5 epithelia (Figure 2.16). 
 
Figure 2.16 Relative gene expression of CXCL14, DEFB4A and IGFL1 in HaCaT and HaCaT-RAS A-5 epithelia 
treated with CsA. 
RNA isolated from indicated epithelia treated with DMSO (0.04%) or CsA (10 µg ml
-1
) for 3 weeks was 
quantified by qRT-PCR. The graphs show the mean and the standard error of the mean. CXCL14 (HaCaT): n=11 
(from 4 independent experiments), DEFB4A and IGFL1 (HaCaT): n=8 (from 3 independent experiments), CXCL14 
(HaCaT-RAS A-5): n=9 (3 independent experiments), DEFB4A and IGFL1 (HaCaT-RAS A-5): n=3 (1 experiment). 
In order to determine whether one of these 3 factors could induce differentiation in HaCaT or HaCaT-
RAS A-5 cells, OTCs were treated with DEFB4A (100 ng ml-1), CXCL14 (100 ng ml-1) or IGFL-1 (10nM). 
OTCs treated with CsA were run in parallel for comparison. Treatment was performed for 3 weeks 
before OTCs were harvested and the RNA from the epithelia was sampled. 4 genes, FLG, LCE1B, 
LCE2A and LCE3A were chosen to assess the state of differentiation. In case of HaCaT-RAS A-5-OTC 
RNA extraction was done from the whole OTC as separation of epithelia and dermal equivalent was 
not possible. 
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In CsA-treated HaCaT epithelia FLG, LCE1B, LCE2A and LCE3A were upregulated 5.9-fold, 1.6-fold, 3.1-
fold and 2.6-fold, respectively (Figure 2.17A), which confirmed previous experiments. In contrast, 
DEFB4A treatment led to 0.9-fold, 0.7-fold and 0.95-fold down-regulation of FLG, LCE1B and LCE2A 
RNA, respectively, and 1.4-fold up-regulation of LCE3A. Accordingly H&E histological sections did not 
reveal an increase in differentiation (Figure 2.17B). A similar result was obtained with CXCL14 
treatment. Histology of PBS-treated HaCaT-OTCs and CXCL14-treated HaCaT-OTCs were very similar. 
Moreover, FLG, LCE1B, LCE2A and LCE3A RNA expression were hardly regulated: 0.8-fold, 0.9-fold, 
0.95-fold down-regulated and 1.1-fold up-regulated, respectively (Figure 2.17C). H&E histological 
stainings of IGFL1-treated HaCaT-OTCs did not reveal an induction of differentiation. While LCE1B 
and LCE2A RNA expression was hardly changed upon IGFL1 (both 0.8-fold down-regulated), FLG was 
0.4-fold down-regulated and LCE3A 1.5-fold up-regulated (Figure 2.17D). 
As previous experiments showed the strongest effect on HaCaT-RAS A-5 upon continuous CsA 
treatment, they might be more susceptible for differentiation triggers. Therefore HaCaT-RAS A-5 cells 
were as well treated with DEFB4A, CXCL14 and IGFL1. RNA levels of FLG, LCE1B, LCE2A and LCE3A 
revealed a considerable increase in CsA-treated HaCaT-RAS A-5-OTCs: 4.2-fold, 8.9-fold, 14.7-fold and 
2.7-fold up-regulation, respectively. Moreover, the H&E histological staining showed improved 
stratification (Figure 2.18A). On the contrary, DEFB4A treatment led to a decrease in FLG, LCE1B, 
LCE2A and LCE3A RNA levels (0.4-fold, 0.5-fold, 0.3-fold and 0.9-fold, respectively). Consequently, 
stratification or differentiation did not change significantly in H&E histological stainings (Figure 
2.18B). Similarly, CXCL14 did not induce obvious differentiation in HaCaT-RAS A-5-OTCs. FLG, LCE1B 
and LCE2A RNA levels were decreased upon CXCL14 treatment (0.6-fold, 0.9-fold and 0.5-fold, 
respectively), while LCE3A was 1.1-fold up-regulated (Figure 2.18C). IGFL1 treatment did not majorly 
influence gene expression of FLG, LCE1B and LCE3A (0.95-fold, 0.95-fold and 0.99-fold down-
regulated), while LCE2A was 1.4-fold up-regulated. Accordingly, H&E histology revealed a comparable 
undifferentiated epithelium for control- and IGFL1-treated HaCaT-RAS A-5-OTCs (Figure 2.18D). 
Summarized these factors (DEFB4A, CXCL14 and IGFL1) did not consistently enhance the expression 
of the tested differentiation genes and accordingly they did not change the histology appearance of 
the epithelia. These results suggested that these factors were not responsible for a better structured 
and differentiated epithelium induced by CsA treatment of HaCaT and HaCaT-RAS A-5 epithelia, but 
rather were up-regulated concurrent to up-regulation of differentiation-associated genes. 
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Figure 2.17 H&E histology of HaCaT-OTCs stimulated with CsA, DEFB4A, CXCL14 or IGFL1 and corresponding 
RNA levels of differentiation markers (FLG, LCE1B, LCE2A, LCE3A). 
HaCaT-OTCs were either stimulated with (A) CsA (10 µg ml
-1
), (B) DEFB4A (100 ng ml
-1
), (C) CXCL14 (100 ng ml
-1
) 
or (D) IGFL1 (10 nM) or the corresponding indicated solvent for 3 weeks and then processed for H&E 
histological stainings and RNA isolation from the epithelium. Relative RNA expression was quantified by qRT-
PCR. Scale bars: 100 µm. The graphs show the mean and the standard error of the mean. n=2. 
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Figure 2.18 H&E histology of HaCaT-RAS A-5-OTCs stimulated with CsA, DEFB4A, CXCL14 or IGFL1 and 
corresponding RNA levels of differentiation markers (FLG, LCE1B, LCE2A, LCE3A). 
HaCaT-RAS A-5-OTCs were either stimulated with (A) CsA (10 µg ml
-1
), (B) DEFB4A (100 ng ml
-1
), (C) CXCL14 
(100 ng ml
-1
) or (D) IGFL1 (10 nM) or the corresponding indicated solvent for 3 weeks and then processed for 
H&E histological stainings and RNA isolation from the epithelium. Relative RNA expression was quantified by 
qRT-PCR. Scale bars: 100 µm. The graphs show the mean and the standard error of the mean. n=3. 
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2.3. CsA treatment of HaCaT-OTCs cultivated for over 4 weeks 
NHEK-OTCs can be cultivated for several months. In contrast, it is a general trait of HaCaT cells that 
when grown in OTCs they lose vitality after about 4-6 weeks and the epithelium renders atrophic. As 
the organization of the HaCaT epithelium normalized under CsA treatment we asked whether the 
improved organization would also favor a longer life span of the epithelium. Therefore, the previous 
long-term experiment was extended to 6 weeks of CsA treatment. 
As expected, the control HaCaT-OTCs treated with DMSO showed the typical growth pattern with the 
vital cell layers, marked by intense nuclei staining, diminishing after 4 weeks. After 5 weeks the vital 
epithelium was reduced to 1 cell layer and after 6 weeks only few basal cells remained vital. In 
contrast, in the CsA-treated cultures more vital cells were present and the epithelium was nicely 
organized also after 4-6 weeks. Astonishingly, after cultivation for 6 weeks, CsA-treated HaCaT-OTCs 
still had a multi-layered vital epithelium, strongly resembling normal human epidermis. Additionally, 
CellTiter-Blue® assays were performed in order to measure the cell metabolism and thus vitality of 
the HaCaT-OTCs. These measurements validated that, while after 3 weeks of CsA or DMSO treatment 
the vitality of the OTCs was comparable, after 4-6 weeks of treatment the vitality of HaCaT-OTCs 
treated with CsA was higher than that of the DMSO-treated HaCaT-OTCs, describing the difference 
vital cells (Figure 2.19B). 
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Figure 2.19 H&E histology of CsA-treated (3-6 weeks) HaCaT-OTCs and relative cell metabolism. 
HaCaT-OTCs were treated with CsA (10 µg ml
-1
) or the solvent DMSO (0.04%) for 3 – 6 weeks. (A) H&E 
histological staining. Scale bar: 100 µm. (B) CellTiter-Blue® assay (relative metabolism). Relative fluorescence of 
metabolized resazurin (additive) was measured within the culture medium. The graph shows the mean (n=3) 
and the standard error of the mean. Values from one time point were normalized to the mean of all DMSO 
replicates from that time point. p-value (two-sided, unpaired t-test). *≤0.05; ns: not significant = p-value ˃ 0.05. 
2.3.1. Genome wide RNA expression profile from HaCaT-OTCs treated with DMSO or CsA for 4 
weeks 
In order to get further insights into the regulation of the HaCaT epithelium with and without CsA, a 
genome wide RNA expression profile was done from RNA isolated from the epithelium of HaCaT-
OTCs treated for 4 weeks with DMSO or CSA, respectively. Here the 4 weeks’ time point was chosen 
in order to still evaluate vital cells in both treatment conditions. Atrophy in control HaCaT-OTCS 
treated with DMSO already was too much advanced in older HaCaT-OTCs. Raw data from three 
biological replicates, from HaCaT-OTC epithelia treated with DMSO or CsA, respectively, were 
normalized. Clustering according to NMDS (Figure 2.20A) and hierarchical clustering (Figure 2.20B) 
demonstrated that biological replicates clustered according to their treatment group, showing a 
similar expression pattern. Differentially expressed genes were calculated and filtered by p-value (≤ 
0.01). The 20 highest and lowest differentially expressed genes are listed in the appendix (Table 7.3). 
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In total 508 genes were differentially expressed. 23% (117/508) of these genes were regulated above 
1.5-fold. 51% (258/508) of all differentially expressed genes and 63% (74/117) of differentially 
expressed genes above 1.5-fold regulation were down-regulated (Figure 2.20C). 
 
Figure 2.20 RNA expression profile from CsA-treated (4 weeks) HaCaT epithelia. 
(A) Non-metric multidimensional scaling (NMDS) and (B) hierarchical clustering were applied to assess the 
discriminability of the 3 biological replicates from both treatment groups (DMSO and CsA). Clustering and 
visualization was performed with Chipster from normalized data. (C) Numbers of differentially expressed genes 
(DMSO vs. CsA). Left column: total number of differentially expressed genes. Right column: Number of 
differentially expressed genes with a fold change ≥ 1.5. Differentially expressed genes were calculated with 
Chipster (filtered by p-value ≤ 0.01). 
Differentially expressed genes were used for Ingenuity® Pathway Analysis to find molecular/cellular 
functions and pathways which are affected by CsA in these old HaCaT-OTCs. The TOP 3 molecular and 
cellular functions from this analysis were: ‘cellular movement’, ‘cellular growth & proliferation’ and 
‘cell death & survival’ (Figure 2.21A). The activation z-scores, which describe the potential up- or 
down-regulation of annotated function, are depicted in Figure 2.21B. Z-scores for the function 
‘cellular movement’ predicted a mixture of activation and inactivation for most terms, except for the 
terms invasion and recruitment, for which the z-scores predicted exclusively an activation in CsA-
treated HaCaT epithelia. Z-scores for the function ‘cellular growth & proliferation’ mainly predicted 
activation for all terms in CsA-treated HaCaT epithelia, while for the function ‘cell death & survival’ 
predominantly an inactivation was predicted in CsA-treated HaCaT epithelia (Figure 2.21B). When 
looking at the most probably affected pathways, these included: HGF signaling, Integrin signaling and 
Oncostatin M signaling. All three were predicted to be activated in CsA-treated HaCaT epithelia 
(Figure 2.21C). 
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Figure 2.21 Prediction of molecular/cellular functions and canonical pathways impacted by CsA in HaCaT-OLD 
epithelia using Ingenuity® Pathway Analysis. 
Differentially expressed genes (filtered by p-value: 0.01) from HaCaT epithelia treated with DMSO or CsA for 4 
weeks were used for Ingenuity® Pathway Analysis. (A) Top 3 predicted cellular functions. List is sorted by p-
value (Benjamini-Hochberg procedure). (B) Z-Score visualization of top molecular/cellular functions. One square 
corresponds to one annotated molecular/cellular function within the indicated topic. The square size is 
calculated based on the magnitude of z-score. The activation z-score expresses the predicted positive or 
negative activation of a specific function. (C) Top 3 canonical pathways. List is sorted by p-value (Benjamini-
Hochberg procedure). Pathways without a z-score or a z-score of 0 were neglected. 
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2.3.2. Comparison of RNA expression profiles from CsA-treated HaCaT epithelia (2 and 4 weeks 
treatment) 
When comparing the complete gene set (HaCaT-OLD, DMSO vs. CsA, 4 weeks treatment) with the 
RNA expression profile from HaCaT epithelia, described in 2.2.2 (DMSO vs. CsA, 2 weeks treatment), 
the numbers of differential gene expression were comparable (Figure 2.8 and Figure 2.20). However, 
only 26% of both gene sets were overlapping (130/507 and 130/508) (Figure 2.22). Moreover, when 
looking at canonical pathways predicted by Ingenuity® Pathway Analysis in CsA-treated HaCaT-OLD 
epithelia (Figure 2.21), less of these genes were differentially regulated in HaCaT epithelia treated 
with CsA for 2 weeks in comparison to HaCaT-OLD epithelia treated with CsA for 4 weeks. In case of 
HGF signaling 16 genes were part of the gene set ‘HGF signaling’ (Ingenuity® Pathway Analysis) from 
HaCaT-OLD epithelia, while only 5 were present in the HaCaT epithelia (2 weeks treatment) data set. 
16 genes from the HaCaT-OLD data set were part of the Ingenuity® Pathway Analysis gene set 
‘Integrin signaling’, while it were 6 genes in the HaCaT (2 weeks treatment) data set. None of the 
genes of the HaCaT data set were part of the gene set ‘Oncostatin M signaling’ (Ingenuity® Pathway 
Analysis), while there were 6 from the HaCaT-OLD data set (Figure 2.22.). The higher number of 
genes from Ingenuity® Pathway Analysis canonical pathway gene sets (HGF, Integrin and Oncostatin 
M) in the HaCaT-OLD data set could indicate that these pathways were not activated after 2 weeks of 
CsA treatment, but might be activated after 4 weeks of continuous treatment. 
 
Figure 2.22 Comparison of RNA expression profiles from CsA-treated HaCaT epithelia (2 and 4 weeks of 
treatment). 
Overlap of differential gene expression from data sets HaCaT (2 weeks CsA treatment, chapter 2.2.2) and 
HaCaT-OLD (4 weeks treatment) with Ingenuity® Pathway Analysis canonical pathway gene sets. 
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2.4. Impact of UV irradiation on CsA-treated HaCaT and HaCaT-RAS A-5 epithelia 
Organ transplant patients are strongly advised to avoid extensive sun exposure (Perez et al. 2016) 
and it was shown that rigorous sunscreen use has a beneficial impact on invasive cSCCs occurrence in 
those patients (Ulrich et al. 2009). Moreover, like in immunocompetent patients, renal transplant 
patients have a high number of UV-specific mutations in their skin lesions (Queille et al. 2007) and 
cSCCs in organ transplant recipients appear as well primarily in sun exposed areas (Smith et al. 2004). 
Thus, additional UV irradiation may be an important co-factor for the development of cSCCs in organ 
transplant recipients. Therefore, an experiment was performed, which combines UV irradiation and 
continuous CsA treatment. HaCaT- and HaCaT-RAS A-5-OTCs were used and treated with CsA for 2 or 
for 3 weeks, respectively. In addition, OTCs were irradiated with UVA and UVB (5 J/cm2 UVA, 10 
mJ/cm2 UVB) three times per week. This single dose is below the minimal erythema dose, which, 
depending on the skin type, lies between 23 and 51 mJ/cm2 UVB (Perez Ferriols et al. 2014). For UVA 
no abnormal skin reaction could be determined by Perez et al. for doses as high as 20 J/cm2. 
2.4.1. Assessment by H&E histology and Ki67 staining of CsA-treated HaCaT and HaCaT-RAS A-5 
epithelia irradiated with UV 
Histological H&E stainings were assessed to potentiate morphological changes of HaCaT- and HaCaT-
RAS A-5-OTCs after CsA or UV or UV+CsA treatment. Similar to the previous experiments CsA 
enhanced the tissue organization and also increased differentiation, as indicated by more intense 
eosin staining in the upper parts HaCaT-RAS A-5 epithelia. HaCaT epithelia were not so much 
improved by CsA, based on H&E histological staining, as seen in previous experiments. Interestingly, 
UV irradiation resulted in a similar phenotype as CsA treatment, enhancing tissue organization and 
differentiation in HaCaT- and HaCaT-RAS A-5-OTCs. The combination of UV+CsA did not further 
change that phenotype. Also in combination tissue organization and differentiation was improved. 
Importantly, neither for HaCaT nor for HaCaT-RAS A-5 cells did a combinatory treatment induce 
invasion (Figure 2.23A). 
Cryosections from treated HaCaT- and HaCaT-RAS A-5-OTCs were stained for Ki67 to measure the 
proliferation index. As also shown in Figure 2.6, CsA decreased the proliferation index of HaCaT and 
HaCaT-RAS A-5 keratinocytes grown in OTCs. UV irradiation and the combination of UV irradiation 
with CsA caused as well a reduction in mean proliferation. However, in contrast to CsA treatment this 
trend was not significant (Figure 2.23B). In detail the proliferation indices of HaCaT epithelia were as 
follows: the CsA proliferation index being the lowest (19.5), UV a bit higher (20.7) and the 
combination of UV +CsA a bit higher than CsA or UV alone (23.5), but still less than the control (26.2). 
In HaCaT-RAS A-5 epithelia the mean proliferation indices had a similar trend to the results from the 
HaCaT epithelia: the index was lowest for CsA treatment (27.3), higher in UV irradiated samples 
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(42.5), and even higher in the combination of UV+CsA (48.2), which was similar to the control 
samples (50.9) (Figure 2.23B). 
 
Figure 2.23 Impact of UV irradiation on CsA-treated HaCaT and HaCaT-RAS A-5 epithelia. 
(A) H&E histological staining of HaCaT- and HaCaT-RAS A-5-OTCs after 2 weeks (HaCaT) or 3 weeks (HaCaT-RAS 
A-5) of treatment. Treatment conditions (three time per week): DMSO (0.04%), CsA (10 µg ml
-1
), UV (5 J/cm
2
 
UVA + 10 mJ cm
2
 UVB; OTCs were as well treated with 0.04% DMSO) or UV+CsA. Scale bar: 100 µm. (B) 
Proliferation index (Ki67
+
 cells). Each data point represents the number of Ki67
+
 cells per length of basement 
membrane. Data from OTCs treated with DMSO or CsA alone were also shown in Figure 2.6. The orange bar 
marks the mean. DMSO, CsA: n=9 (from 3 biological replicates), UV (HaCaT): n=6 (from 3 biological replicates), 
UV+CsA (HaCaT): n=8 (from 3 biological replicates), UV, UV+CsA (HaCaT-RAS A-5): n=6 (from 2 biological 
replicates). The error bars are the standard error of the mean. *: p-value of 0.03, **: p-value of 0.002, ns: not 
significant = p-value ˃ 0.05 (two-sided, unpaired t-test). 
2.4.2. Genome wide RNA expression profiles of HaCaT and HaCaT-RAS A-5 epithelia treated with 
UV or UV+CsA 
In order to reveal changes on a transcriptional level, genome wide expression profiles were made. 
Raw data from all treatment groups (DMSO, CsA, UV, UV+CsA) were normalized together. Raw data 
from DMSO and CsA were already used for the analysis described in section 2.2.2. Replicates from 
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HaCaT epithelia separated by NMDS into four groups (Figure 2.24A) and hierarchical clustering 
divided both UV groups from non-UV, as depicted in the dendrogram (Figure 2.24B). In contrast, 
biological replicates from HaCaT-RAS A-5 epithelia were not as strictly separated by NMDS (Figure 
2.24C). Accordingly, hierarchical clustering could not separate UV groups from non-UV groups and 
also located 1 UV replicate within the UV+CsA group, as depicted in the dendrogram (Figure 2.24D). 
However, histology did not reveal any abnormalities for this one sample (data not shown), which did 
cluster to the wrong treatment group. Moreover, the histology of both treatment groups, UV and 
UV+CsA very much resembled, which might be reflected in the expression profile. Thus, all replicates 
were included in the differential gene expression analysis. The lists of the 20 highest and lowest 
differentially expressed genes (p-value ≤ 0.01) for DMSO vs. UV and DMSO vs. UV+CsA can be found 
in the appendix (Tables 7.5 - 7.8). Moreover, a list with differentially expressed genes, which are 
regulated in both cell types, HaCaT and HaCaT-RAS A-5, as well as in all treatment options (CsA, UV 
and UV+CsA) can be found in the appendix (Table 7.9). 
 
Figure 2.24 Visualizations of biological replicates from genome wide RNA expression profiles from HaCaT and 
HaCaT-RAS A-5 epithelia treated with DMSO, CsA, UV or UV+CsA by NMDS and hierarchical clustering. 
(A) Non-metric multidimensional scaling (NMDS) and (B) hierarchical clustering were applied to assess the 
discriminability of the 3 biological replicates from 4 treatment groups (DMSO, CsA, UV and UV+CsA). Clustering 
and visualization was performed with Chipster from normalized data. 
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2.4.2.1. Overlap of RNA expression profiles from epithelia treated with CsA, UV or UV+CsA 
904 genes were differentially expressed in HaCaT epithelia treated with the combination UV+CsA. 
More than half of these genes (67%) were regulated below 1.5-fold and only 218 were regulated 
above 1.5-fold. From these 218 differentially expressed genes 63% (138/218) were down-regulated, 
while from the total number of differentially expressed genes 53% were down-regulated (475/904). 
In HaCaT epithelia, which were irradiated with UV without CsA treatment, much less genes were 
differentially expressed. In total 346 genes were differentially expressed, with 31% of these genes 
being regulated above 1.5-fold. 62% (222/346) of total differentially expressed genes and 76% 
(82/108) of differentially expressed genes above 1.5-fold regulation were down-regulated (Figure 
2.25A). H&E histology revealed that phenotypes of CsA, UV and UV+CsA resembled. When comparing 
the expression profiles with each other, 25% (125/509) of the CsA expression profile, 36% (125/346) 
of the UV expression profile and 14% (125/904) of the UV+CsA expression profile overlapped with all 
three gene sets (CsA, UV and UV+CsA) (Figure 2.25B). When filtering the expression profiles 
according to the GO-term ‘epidermal development’, these percentages of overlap increased to 37% 
(14/38, CsA), 54% (14/26, UV) and 24% (14/58, UV+CsA) (Figure 2.25B). The heat map, visualizing 
differentially expressed genes filtered by the GO-term ‘epidermal development’, revealed that those 
genes, which were regulated in all three gene sets, were either all up- or all down-regulated (Figure 
2.25C). 
RESULTS 
 
43 
 
 
Figure 2.25 Numbers and overlap of differentially expressed genes (DMSO vs. CsA, DMSO vs. UV or DMSO vs. 
UV+CsA) from HaCaT epithelia. 
(A) Numbers of differentially expressed genes (DMSO vs. CsA, DMSO vs. UV and DMSO vs. UV+CsA). Whole 
genome RNA expression profiles from HaCaT epithelia treated with DMSO, CsA, UV or UV+CsA. The table shows 
the total number of differentially expressed genes and the number of differentially expressed genes with a fold 
change ≥ 1.5. Differentially expressed genes were calculated with Chipster (filtered by p-value ≤ 0.01). (B) 
Overlap of differential gene expression from complete data sets (DMSO vs. CsA, DMSO vs. UV and DMSO vs. 
UV+CsA) or those data sets filtered for the GO-term ‘epidermal development’ (GO-0008544). (C) Heatmap of 
differentially expressed genes (DMSO vs. CsA, DMSO vs. UV and DMSO vs. UV+CsA) filtered by the GO-term 
‘epidermal development’ (GO-0008544) from HaCaT epithelia. Fold changes (log2) are depicted by the 
indicated color. The rows are sorted alphabetically. Data from DMSO vs. CsA was also shown in Figure 2.9. 
2594 genes were differentially expressed in HaCaT-RAS A-5 epithelia after the combinatorial 
treatment of UV+CsA. 46% (1188/2594) were regulated above 1.5-fold, of which 61% (724/1188) 
were down-regulated. From the total number of differentially expressed genes 48% (1239/2594) 
were down-regulated. UV irradiation without CsA treatment resulted in 962 differentially expressed 
genes, which is less than half of that regulated in the combination of UV+CsA. Of these 962 genes 
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62% (597/962) were above 1.5-fold regulated. 55% (331/597) of these genes were down-regulated 
and from the total number of differentially expressed genes 58% (557/962) were down-regulated 
(Figure 2.26A). As for HaCaT-OTCs, the histology of HaCaT-RAS A-5-OTCs of all treatment groups (CsA, 
UV and UV+CsA) resembled. When comparing the expression profiles, 70% (365/521) of all genes 
from the CsA expression profile, 38% (365/962) from the UV expression profile and 14% (365/2594) 
from the UV+CsA expression profile were overlapping with all three gene sets (CsA, UV, UV+CsA). 
When comparing expression profiles filtered according to the GO-term ‘epidermal development’, 
these percentages increased to 78% (36/46, CsA), 47% (36/76, UV) and 37% (36/97, UV+CsA) (Figure 
2.26B). The heat map, visualizing differentially expressed genes filtered by the GO-term ‘epidermal 
development’, revealed those genes, which were regulated in all three gene sets, were either all up- 
or all down-regulated (Figure 2.26C). 
In summary the comparison of the data sets showed that there was quite a high overlap of gene 
expression altered by CsA, UV and UV+CsA treatment in HaCaT epithelia and even more in HaCaT-
RAS A-5 epithelia. Moreover, as for CsA treatment, UV irradiation led to increased regulation of 
‘epidermal development’ genes, which was as well true for the combination treatment UV+CsA. 
Especially in the case of HaCaT-RAS A-5 epithelia, which in general were more affected by CsA, UV or 
UV+CsA treatment than HaCaT epithelia, a similar regulation pattern for the ‘epidermal 
development’ genes for all three treatments (CsA, UV and UV+CsA) was detected, suggesting a 
common regulation pattern of the differentiation program for CsA treatment and UV irradiation. 
RESULTS 
 
45 
 
 
Figure 2.26 Numbers and overlap of differentially expressed genes (DMSO vs. CsA, DMSO vs. UV or DMSO vs. 
UV+CsA) from HaCaT-RAS A-5 epithelia. 
(A) Numbers of differentially expressed genes (DMSO vs. CsA, DMSO vs. UV and DMSO vs. UV+CsA). Whole 
genome RNA expression profiles from HaCaT-RAS A-5 epithelia treated with DMSO, CsA, UV or UV+CsA. The 
table shows the total number of differentially expressed genes and the number of differentially expressed 
genes with a fold change ≥ 1.5. Differentially expressed genes were calculated with Chipster (filtered by p-value 
≤ 0.01). (B) Overlap of differential gene expression from complete data sets (DMSO vs. CsA, DMSO vs. UV and 
DMSO vs. UV+CsA) or those data sets filtered for the GO-term ‘epidermal development’ (GO-0008544). (C) 
Heatmap of differentially expressed genes (DMSO vs. CsA, DMSO vs. UV and DMSO vs. UV+CsA) filtered by the 
GO-term ‘epidermal development’ (GO-0008544) from HaCaT-RAS A-5 epithelia. Fold changes (log2) are 
depicted by the indicated color. The rows are sorted alphabetically. Data from DMSO vs. CsA was also shown in 
Figure 2.9. 
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2.4.3. Comparison analysis of RNA expression data sets from CsA and UV+CsA treatment by 
Ingenuity® Pathway Analysis 
Most of the genes regulated by CsA treatment were also regulated by UV and or UV+CsA, 65% 
(328/507) in the case of HaCaT and 87% (452/521) in the case of HaCaT-RAS A-5. However, 49% 
(441/904) in the case of HaCaT and 65% (1694/2594) in the case of HaCaT-RAS A-5 of the genes 
regulated by the combination UV+CsA were unique to that combination treatment and were not 
regulated by CsA or UV (Figure 2.25B and Figure 2.26B). In order to get an idea of different molecular 
regulation in CsA and UV+CsA samples, the data sets were used for a comparison analysis with 
Ingenuity® Pathway Analysis. While some canonical pathways, like interferon signaling and G2/M 
DNA damage checkpoint regulation, were regulated likewise in CsA- and UV+CsA-treated epithelia, 
others like thrombin and Rho family GTPases signaling, were down-regulated in CsA-treated 
epithelia, but up-regulated in UV+CsA-treated epithelia. 
 
Figure 2.27 Prediction of canonical pathways impacted by CsA and UV+CsA in HaCaT and HaCaT-RAS A-5 
epithelia using Ingenuity® Pathway Analysis. 
Differentially expressed genes (filtered by p-value: 0.01) from HaCaT and HaCaT-RAS A-5 epithelia (DMSO vs. 
CsA and DMSO vs. UV+CsA) were used for a comparison analysis with Ingenuity® Pathway Analysis. The list is 
sorted by z-scores from all 4 data sets. The activation z-score expresses the predicted positive or negative 
activation of the specific pathway. 
2.4.4. Validation of differential gene expression by qRT-PCR 
Several genes from the RNA expression profile were chosen for validation by qRT-PCR. In case of 
HaCaT, ELF3, FLG, LCE1B and LCE2A were analyzed. ELF3 is a transcription factor, which was down-
regulated in CsA, UV and UV+CsA-treated HaCaT epithelia (0.64-fold, 0.39-fold and 0.41-fold, 
respectively). In all three cases down-regulation could be validated by qRT-PCR (CsA: 0.45-fold, UV: 
0.37-fold and UV+CsA: 0.25-fold). FLG was not regulated in the CsA RNA expression profile, while it 
was 1.76-fold and 1.34-fold up-regulated in the UV and UV+CsA RNA expression profile. Validation by 
qRT-PCR from one experiment could not detect regulation of FLG in CsA and UV+CsA-treated HaCaT 
epithelia, while it revealed a 1.75-fold up-regulation in UV irradiated HaCaT epithelia. Next, two LCE 
genes, which stood out at previous experiments, were examined by qRT-PCR. LCE1B was not 
detected in the CsA, UV or UV+CsA RNA expression profile, while LCE2A was 1.43-fold up-regulated in 
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the CsA RNA expression profile, while it was not detected in the UV or UV+CsA expression profile. In 
contrast to the expression profile, LCE1B RNA up-regulation could be measured in CsA-, UV- and 
UV+CsA-treated HaCaT epithelia by qRT-PCR (2.54-fold, 3.34-fold and 2.46-fold, respectively). LCE2A 
RNA expression was 1.94-fold up-regulated in case of CsA-treatment, not regulated in case of UV 
irradiation and 1.51-fold up-regulated in the combinatorial treatment UV+CsA (Figure 2.28). 
For validation with HaCaT-RAS A-5 epithelia following genes were chosen: ELF3, FLG, KRT10, KRT15, 
LCE1b and LCE2A. ELF3 was down-regulated in the RNA expression profile from HaCaT-RAS A-5 
epithelia treated with CsA (0.28-fold), UV (0.12-fold) or UV+CsA (0.09-fold). All three results could be 
replicated by qRT-PCR (CsA: 0.26-fold, UV: 0.08-fold and UV+CsA: 0.06-fold). FLG was up-regulated in 
HaCaT-RAS A-5 epithelia treated with CsA (3.78-fold), UV (5.94-fold) or UV+CsA (5.59-fold), according 
to the RNA expression profile. Using qRT-PCR these findings were replicated (CsA: 5.07-fold, UV: 4.8-
fold, UV+CsA: 3.55-fold). KRT10 was as well up-regulated in CsA- (1.74-fold), UV- (2-fold) and 
UV+CsA- (2.2-fold) treated HaCaT-RAS A-5 epithelia according to the RNA expression profiles. 
Validation was successful by qRT-PCR: CsA (4.12-fold), UV (4.33-fold) and UV+CsA (4.59-fold). In 
contrast to KRT10, KRT15 was down-regulated in all three treatment conditions in HaCaT-RAS A-5 
epithelia according to the RNA expression profile (CsA: 0.38-fold, UV: 0.12-fold and UV+CsA 0.11-
fold). These down-regulations could be validated by qRT-PCR: CsA (0.36-fold), UV (0.06-fold) and 
UV+CsA (0.06-fold). Last, LCE1B and LCE2A were up-regulated in all treatment options in the RNA 
expression profiles in HaCaT-RAS A-5 epithelia. LCE1B: CsA (4.08-fold), UV (4.21-fold) and UV+CsA 
(1.92-fold). LCE2A: CsA (4.41-fold), UV (6.71-fold) and UV+CsA (2.58-fold). Measurements by qRT-PCR 
validated all results. However, the up-regulation was stronger affected than in the RNA expression 
profile. LCE1B: CsA (12.4-fold), UV (14.77-fold) and UV+CsA (10.9-fold). LCE2A: CsA (13.75-fold), UV 
(23.36-fold) and UV+CsA (15.56-fold). 
To summarize, qRT-PCR measurements from HaCaT-RAS A-5 epithelia could be validated in all 
examples, while for HaCaT epithelia some measurements deviated from the RNA expression profile. 
Differential gene expression was in general much stronger in HaCaT-RAS A-5 epithelia than in HaCaT 
epithelia, which might explain why low regulation in some cases (for example 1.34-fold up-regulation 
in UV+CsA-treated HaCaT epithelia) could not be replicated by qRT-PCR. In contrast in case of LCE1B 
and LCE2A gene regulation could be detected by qRT-PCR, which was not evident in the RNA 
expression profile. In general replication of qRT-PCR with RNA from HaCaT epithelia might need 
replication with further experiments, which could strengthen the results in case of weak differential 
gene expression. 
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Figure 2.28 Relative RNA expression of HaCaT and HaCaT-RAS A-5 epithelia treated with CsA, UV or UV+CsA. 
RNA isolated from indicated epithelia treated with DMSO (0.04%), CsA (10 µg ml
-1
), UV (5 J/cm
2
 UVA + 10 
mJ/cm
2
 UVB; OTCs were as well treated with 0.04% DMSO) or the combination UV+CsA, was quantified by qRT-
PCR. The graphs show the mean and the standard error of the mean. n=3. 
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2.5. Continuous CsA treatment of HaCaT-OTCs in GOLD serum 
Experiments described so far were replicated several times in order to exclude experimental 
variation. Results, like morphology and regulation of differentiation-associated gene expression could 
be replicated in several independent experiments. Due to logistical reasons the serum had to be 
replaced making it necessary to perform further experiments with a different serum (GOLD serum). 
OTCs will be stated HaCaT-GOLD-OTCs in contrast to the previous experiment in another serum. 
Experiments in GOLD serum comprised continuous treatment of HaCaT-GOLD-OTCs with CsA for 1, 2 
and 3 weeks. 
2.5.1. Morphology of CsA-treated HaCaT-GOLD-OTCs 
Histology examination of control HaCaT-GOLD-OTCs treated with DMSO demonstrated that HaCaT 
cells established a multi-layered well organized epidermis with a parakeratotic stratum corneum 
increasing over time. These results were comparable to previous experiments. Upon CsA treatment 
tissue organization was disturbed and already after 1 week of treatment the HaCaT cells invaded the 
dermal equivalent. Moreover, an increase in differentiated cell layers when compared with the 
corresponding control OTC was shown (Figure 2.29A). Staining for the proliferation marker Ki67 
revealed that the invasion was not associated with increased proliferation (Figure 2.29B). Moreover, 
the metabolic activity of HaCaT-GOLD-OTCs remained unchanged by CsA treatment for the first two 
weeks and after 3 weeks it even slightly decreased (Figure 2.29C). In order to visualize the invasion 
and the disruption of the basement membrane, two components from the basement membrane 
were stained: Collagen IV (ColIV) and Collagen VII (ColVII). The epidermal dermal junction in control 
HaCaT-GOLD-OTCs treated with DMSO showed strong reactivity with the ColIV antibody, 
demonstrating the presence of a continuous basement membrane. In CsA-treated HaCaT-GOLD-OTCs 
ColIV staining at the dermal-epidermal junction was distinct to the control HaCaT-GOLD-OTCs. While 
it was clustered underneath non-invading epithelial cells, intense staining was absent at sites of 
invasion in CsA-treated HaCaT-GOLD-OTCs (Figure 2.29D). In contrast to the ColIV staining ColVII 
deposition was not demonstrating a continuous basement membrane staining in the control HaCaT-
GOLD-OTCs treated with DMSO. Different to the normal skin distribution of ColVII, ColVII in HaCaT-
GOLD-OTCs was only scattered in some areas of the epidermal dermal junction. This distribution of 
ColVII was not further changed by CsA treatment and ColVII disposition at the epidermal dermal 
junction could be detected only very sparsely (Figure 2.29E). Summarized, histology revealed that the 
experiment using the GOLD serum validated the differentiation phenotype, but in addition resulted 
in invasion of the HaCaT keratinocytes. 
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Figure 2.29 HaCaT-GOLD-OTCs after 1-3 weeks of continuous CsA treatment. 
(A) Histology H&E staining of HaCaT-GOLD-OTCs 1 week after epithelia seeding and after 1, 2 or 3 weeks of 
treatment with CsA (10 µg ml
-1
) or the solvent DMSO (0.04%). Scale bar: 100 µm. (B) Immunofluorescent 
staining for Ki67 (green) and KRT1O (red). Cryosections of HaCaT-GOLD-OTCs, treated with CsA (10 µg ml
-1
) or 
DMSO (0.04%) for 3 weeks were counterstained with DAPI to visualize nuclei (blue). Arrows indicate Ki67
+
 cells. 
Scale bar: 100 µm. (C) CellTiter-Blue® assay (relative metabolism). Relative fluorescence of metabolized 
resazurin (additive) was measured within the culture medium. The graph shows the mean (n=3) and the 
standard error of the mean. Values from one time point were normalized to the mean of all DMSO replicates 
from that time point. ns: not significant = p-value ˃ 0.05 (two-sided unpaired t-test). Immunofluorescence 
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staining for (D) ColIV (red) and PanKRT (green) or (E) ColVII (red) and PanKRT (green) on cryosections from 
HaCaT-GOLD-OTCs treated with DMSO (0.04%) or CsA (10 µg ml
-1
) for 3 weeks. Sections were counterstained 
by DAPI to stain nuclei (blue). Scale bars: 50 µm. 
2.5.2. Proteolytic activity was increased in HaCaT-GOLD-OTCs treated with CsA 
In order to reveal enzymatic activity enabling this penetration an in situ gelatinase assay was 
performed. The assay could demonstrate the presence of gelatinase activity within the basal 
keratinocyte cell layer and the dermis from CsA-treated HaCaT-GOLD-OTCs (Figure 2.30A). A general 
gelatinase activity was also measured within the differentiated cell layers of DMSO and CsA-treated 
epithelia. This activity occurs because of the assembly and crosslinking of the cornified envelope 
(Candi et al. 2005). Genome wide RNA expression profiles showed up-regulation of MMP10, MMP3 
and MMP1 in the epithelium of CsA-treated HaCaT-GOLD-OTCs. This could be validated by qRT-PCR 
(Figure 2.30A). Interestingly, expression of these genes in the fibroblast in the dermal equivalent was 
down-regulated after CsA treatment (Figure 2.30B). Protein levels of pro-MMP1, total MMP3 and 
pro-MMP10 were measured by ELISA in the culture medium. Interestingly and despite the RNA 
regulation, only MMP10 was slightly upregulated and pro-MMP1 and total MMP3 were clearly down-
regulated after continuous CsA treatment (Figure 2.30C). 
 
Figure 2.30 Proteolytic activity and MMP1, MMP3 and MMP10 protein and RNA levels in HaCaT-GOLD-OTCs 
treated with CsA. 
(A) Gelatin in situ zymography with unfixed cryosections from HaCaT-GOLD-OTCs treated with DMSO (0.04%) 
or CsA (10 µg ml
-1
) for 3 weeks. The dotted line marks the basement membrane. Scale bar: 50 µm. (B) Relative 
RNA expression. RNA isolated from HaCaT-GOLD epithelia treated with DMSO (0.04%) or CsA (10 µg ml
-1
) was 
quantified by qRT-PCR. The graphs show the mean and the standard error of the mean. n=6 (from 2 and 3 
weeks of treatment). (C) Protein levels of pro-MMP1, MMP3 and pro-MM10 within the culture medium were 
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measured by ELISA. The graph shows the mean and the standard error of the mean. n=6 (from 2 and 3 weeks of 
treatment). **: p-value ≤0.01, ns: not significant = p-value ˃ 0.05 (two-sided, unpaired t-test). 
2.5.3. Genome-wide RNA expression profile from HaCaT-GOLD epithelia treated with CsA 
For a deeper insight into the regulation induced by CsA in the GOLD serum a genome-wide RNA 
expression profile was conducted. RNA from control (DMSO) and CsA-treated HaCaT-GOLD-OTCs 
were analyzed in biological triplicates. These triplicates clearly separated along the first dimension 
using NMDS (Figure 2.31A) and also could be divided in two different groups by hierarchical 
clustering as depicted by a dendrogram (Figure 2.31B). The 20 highest and lowest differentially 
expressed genes (p-value ≤ 0.01) are listed in the appendix (Table 7.10). In total 1915 genes were 
differentially regulated, of which 26% (490/1915) were regulated above 1.5-fold. Of these 
differentially expressed genes 40% (194/490) were down-regulated; while from the total number of 
differentially expressed genes 49% (929/1915) were down-regulated (Figure 2.31C). Histology of the 
GOLD experiment suggested an induction of differentiation. Moreover, differentiation-associated 
genes, like LCE3E and LCE3D were within the TOP 20 regulated genes from HaCaT-GOLD epithelia 
treated with CsA. To get a complete list of all genes involved in differentiation, the gene set was 
filtered for the GO-term ‘epidermal development’ (GO-0008544). In total 81 genes were involved in 
‘epidermal development’ (Figure 2.31D). 
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Figure 2.31 RNA expression profile from CsA-treated HaCaT-GOLD epithelia. 
(A) Non-metric multidimensional scaling (NMDS) and (B) hierarchical clustering were applied to assess the 
discriminability of the 3 biological replicates from 2 treatment groups (DMSO and CsA). Clustering and 
visualization was performed with Chipster from normalized data. (C) Numbers of differentially expressed genes 
(DMSO vs. CsA). The table shows the total number of differentially expressed genes and the number of 
differentially expressed genes with a fold change ≥ 1.5. Differentially expressed genes were calculated with 
Chipster (filtered by p-value ≤ 0.01). (D) Heatmap of differentially expressed genes (DMSO vs. CsA) filtered by 
the GO-term ‘epidermal development’ (GO-0008544) from the CsA-treated HaCaT-GOLD RNA expression 
profile. Fold changes (log2) are depicted by the indicated color. The rows are sorted alphabetically. 
2.5.4. Validation of RNA expression profile by qRT-PCR and immunofluorescent staining 
Following genes were chosen for validation by qRT-PCR: LCE3A, SPRR2B, KRT10, FLG, GRHL3 and 
HRNR. Except for GRHL3 and HRNR protein immunofluorescent staining for these proteins was 
performed on cryosections from DMSO- and CsA-treated HaCaT-GOLD-OTCs. LCE3A was up-regulated 
1.8-fold according to the RNA expression array, while LCE2A was not within the differentially 
expressed genes. qRT-PCR measurements of LCE3A RNA revealed a clear increase of about 3.9-fold, 
while RNA levels of LCE2A were only slightly up-regulated (1.3-fold) (Figure 2.32A). Localization of 
LCE2 and LCE3 proteins was not changed by CsA treatment. Moreover, regulation of LCE2 or LCE3 
could not be detected by immunofluorescent staining (Figure 2.32B). SPRR2B RNA was 1.7-fold up-
regulated according to the RNA expression array. Using qRT-PCR it was revealed that it was 0.7-fold 
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down-regulated (Figure 2.32A). Signal intensity of the corresponding IF staining was similar between 
DMSO- and CsA-treated HaCaT-GOLD-OTC. However, basal cells in CsA-treated HaCaT-GOLD-OTCs 
were less stained by the anti-SPRR2B antibody (Figure 2.32B). The RNA expression profile showed 
that KRT10 is down-regulated (0.39-fold), which was validated by qRT-PCR (0.1-fold down-regulated) 
(Figure 2.32A). Immunofluorescence hardly showed a difference in the amount of KRT10 deposition 
in HaCaT-GOLD-OTCs treated with DMSO or CsA. In both epithelia KRT10 was present in the 
differentiated cell layers. However, while in DMSO-treated epithelia KRT10 deposition started quite 
early and some basal cells were as well KRT10 positive, in CsA-treated HaCaT-GOLD epithelia KRT10 
occurred later, in the second suprabasal cell layer. Moreover, KRT10 was absent from keratinocytes 
which invaded into the dermal equivalent (Figure 2.32B). FLG expression was down-regulated (0.2-
fold) by CsA in GOLD serum according to the expression array. qRT-PCR could validate this finding 
and demonstrated a downregulation of 0.29-fold (Figure 2.32A). Despite the clear down-regulation in 
RNA, immunofluorescence showed no clear difference in the amount of FLG protein in DMSO- and 
CsA-treated HaCaT-GOLD epithelia. FLG was deposited in the late differentiated cell layers of HaCaT-
GOLD-OTCs treated with DMSO. In CsA-treated HaCaT-GOLD epithelia FLG was also deposited in the 
late differentiating cells (Figure 2.32B). GRHL3 RNA expression was hardly up-regulated in the 
expression array (1.4-fold), in qRT-PCR the up-regulation even diminished to 1.1-fold. Like FLG, HRNR 
was downregulated (0.14-fold) in the expression profile. This finding could as well be validated by 
qRT-PCR, which even showed a stronger down-regulation (0.015-fold) (Figure 2.32A). 
To summarize, the results from the RNA expression array for LCE3A, KRT10, FLG and HRNR could be 
replicated by qRT-PCR, while for SPRR2B RNA contrary results  were revealed with qRT-PCR (1.7-fold 
up-regulation according to the array and 0.7-fold down-regulation according to qRT-PCR). For GRHL3 
regulation was only very weakly measureable according to qRT-PCR (1.1-fold up-regulation), in 
contrast to 1.4-fold up-regulation in the array. Moreover, qRT-PCR revealed weak up-regulation (1.3-
fold) of LCE2A, which was not detected by the RNA expression profile. Finally, immunofluorescent 
stainings nicely demonstrated the improved structure of the HaCaT-GOLD epithelium induced by CsA 
treatment. 
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Figure 2.32 Relative RNA expression/protein localization of selected genes in CsA-treated HaCaT-GOLD 
epithelia. 
(A) Relative RNA expression of indicated genes. RNA isolated from HaCaT-GOLD epithelia treated with DMSO 
(0.04%) or CsA (10 µg ml
-1
) was quantified by qRT-PCR. The graphs show the mean and standard error of the 
mean. n=6 (from 2 and 3 weeks of treatment). (B) Immunofluorescent staining for indicated proteins on 
cryosections from HaCaT-GOLD-OTCs treated with DMSO (0.04%) or CsA (10 µg ml
-1
) for 2 weeks (LCE2, LCE3, 
and KRT10) or 3 weeks (SPRR2B, FLG). Sections were counterstained by DAPI to stain nuclei (blue). The dotted 
line marks the basement membrane. Arrows indicate KRT10 negative keratinocytes within the dermal 
equivalent. Scale bars: 50 µm. 
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2.5.5. IL-1α and CSF2 are up-regulated in CsA-treated HaCaT-GOLD-OTCs 
One of the TOP 20 up-regulated genes of the expression profile of CsA-treated HaCaT-GOLD epithelia 
was interleukin-1α (IL-1α), which were 5.4-fold up-regulated. Using ELISA, it was demonstrated that 
secreted Il-1α protein was up-regulated in CsA-treated HaCaT-GOLD-OTCs (58 pg ml-1) in comparison 
to the DMSO-treated control OTCs (10 pg ml-1) (Figure 2.33A). IL-1α, secreted by keratinocytes, 
contributes to proper growth and differentiation of keratinocytes by inducing granulocyte-
macrophage colony-stimulating factor (GM-CSF; gene: CSF2) and fibroblast growth factor 7 (FGF7) 
expression in fibroblasts (Maas-Szabowski et al. 2000). Accordingly RNA levels of CSF2 and FGF7 were 
measured in fibroblasts from CsA-treated HaCaT-GOLD-OTCs and also in the epithelial part. In 
addition, RNA levels of two other known growth factors, epidermal growth factor (EGF) and 
hepatocyte growth factor (HGF) were analyzed. HGF expression in fibroblast was also shown to be 
regulated by IL-1α (Maas-Szabowski & Fusenig 1996), while EGF is known to improve epithelization 
(Bhora et al. 1995; El Ghalbzouri et al. 2004). Mean CSF2 RNA expression was very slightly up-
regulated (1.35-fold) in fibroblasts, while FGF7 did not appear to be regulated. Interestingly CSF2 
expression in keratinocytes was strongly up-regulated (4.89-fold). However, this was not the case for 
FGF7, which was down-regulated (0.6-fold) in keratinocytes. Levels of RNA of EGF and HGF were 
down-regulated in both samples; from CsA-treated dermis and epithelium (Figure 2.33B). In order to 
demonstrate whether the increase in CSF2 RNA expression in keratinocytes is leading to an increase 
in GM-CSF an ELISA was performed. However, despite the high increase in CSF2 RNA, the protein 
level was only increased very slightly from about 4 pg ml-1 to about 5.3 pg ml-1. This increase was not 
significant and the standard error of the mean was quite high. This could be correlated to the general 
low abundance of GM-CSF in the culture medium and hence measurements of the protein around 
the detection minimum of the ELISA kit (Figure 2.33C). 
 
Figure 2.33 IL-1α and GM-CSF protein levels and CSF2, FGF7, EGF and HGF RNA expression levels in CsA-
treated HaCaT-GOLD-OTCs. 
(A) Protein levels of IL-1α within the culture medium from HaCaT-GOLD-OTCs treated with DMSO (0.04%) or 
CsA (10 µg ml
-1
) was measured by ELISA. The graphs show the mean and the standard error of the mean. n=6 
(from 2 and 3 weeks of treatment). ***: p-value ˂ 0.0001 (two-sided, unpaired t-test). (B) Relative RNA 
expression in the dermis or the epithelia from HaCaT-GOLD-OTCs treated with DMSO (0.04%) or CsA (10 µg ml
-1
) 
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quantified by qRT-PCR. The graph shows the mean and the standard error of the mean. n=6 (from 2 and 3 
weeks of treatment). (C) Protein levels of GM-CSF within the culture medium of HaCaT-GOLD-OTCs treated with 
DMSO (0.04%) or CsA (10 µg ml
-1
) measured by ELISA. The graph shows the mean and the standard error of the 
mean. n=6 (from 2 and 3 weeks of treatment). ns: not significant = p-value ˃ 0.05 (two-sided, unpaired t-test). 
2.5.6. Ingenuity® Pathway Analysis of CsA-treated HaCaT-GOLD epithelia expression profile 
In order to further analyze the RNA expression profile from CsA-treated HaCaT-GOLD epithelia the 
data was used for Ingenuity® Pathway Analysis. The analysis for molecular and cellular functions 
revealed the following three functions most likely affected by CsA treatment: ‘cellular movement’, 
‘cell death & survival’ and ‘cellular growth & proliferation’ (Figure 2.34A). In accordance with the 
invasive phenotype, nearly all functions from the top term ‘cellular movement’ were predicted to be 
activated; amongst others these are invasion and migration. The only function within the term 
‘cellular movement’, which was predicted to be down-regulated, is related to cellular infiltration of 
inflammatory cells. In contrast, most functions from the term ‘cell death & survival’ were predicted 
to be down-regulated. Interestingly, and despite our finding that CsA is not increasing proliferation of 
HaCaT cells, the functions from the term ‘cellular growth and proliferation’ were all predicted to be 
up-regulated. 
Next the pathway mostly likely affected by CsA was determined by Ingenuity® Pathway Analysis. It 
was revealed that this was Integrin signaling. Interestingly, none of the genes related to Integrin 
signaling (Figure 2.35A) were among the top regulated genes. Upon this finding two Integrins, 
namely Integrin α-6 (ITGA6) and Integrin β-1 (ITGB1) were visualized by immunofluorescent staining 
in DMSO- and CsA-treated HaCaT-GOLD epithelia (Figure 2.35B). Both, ITGA6 and ITGB1, were 
deposited at the epidermal dermal junction in DMSO-treated HaCaT-GOLD-OTCs. Interestingly, in 
CsA-treated HaCaT-GOLD-OTCs, ITGA6 and ITGB1 clustered below non-invading basal cells, while only 
little ITGA6 or ITGB1 was present at the invasive front. 
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Figure 2.34 Prediction of molecular/cellular functions impacted by CsA in GOLD serum using Ingenuity® 
Pathway Analysis. 
Differentially expressed genes (filtered by p-value ≤ 0.01) from HaCaT-GOLD epithelia (DMSO vs. CsA, 2 weeks 
treatment) were used for Ingenuity® Pathway Analysis. (A) Top 3 predicted cellular functions. List is sorted by p-
value (Benjamini-Hochberg procedure). (B) Z-Score visualization of top molecular/cellular functions. One square 
corresponds to one annotated molecular/cellular function within the indicated topic. The square size is 
calculated based on the magnitude of z-score. The activation z-score expresses the predicted positive or 
negative activation of a specific function. 
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Figure 2.35 ‘Integrin signaling’ genes and ITGA6 and ITGB1 localization in CsA-treated HaCaT-GOLD epithelia. 
(A) Differentially expressed genes ‘Integrin Signaling’ from CsA-treated HaCaT-GOLD epithelia. Genes were 
taken from the expression profile and sorted for association with ‘Integrin Signaling’ according to Ingenuity® 
Pathway Analysis. Fold changes were recalculated from log2. Values below 1 (negative fold changes) were 
converted by the following formula: fold change= –(1/x). (B) Immunofluorescent staining for (left) ITGA6 (red) 
and PanKRT (green) or (right) ITGB1 (red) and ColIV (green) on cryosections from HaCaT-GOLD-OTCs treated 
with DMSO (0.04%) or CsA (10 µg ml
-1
) for 3 weeks. Sections were counterstained by DAPI to stain nuclei (blue). 
Scale bars: 50 µm. 
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2.6. ColVII deposition, MMP levels, IL-1α and CSF2/GM-CSF in CsA-treated HaCaT epithelia 
The results described in previous passages showed that in some parts the results from CsA-treated 
HaCaT and HaCaT-GOLD epithelia differed. While in both experiments the epithelial structure was 
improved, only in GOLD serum the HaCaT keratinocytes invaded into the dermal equivalent. 
Accordingly, different aspects were analyzed in the HaCaT-GOLD experiment in comparison to the 
HaCaT experiment. In the next paragraph aspects which emerged during the analysis of the HaCaT-
GOLD experiment were analyzed as well in the HaCaT experiment: ColVII deposition, MMP 
expression and secretion and IL-1α/GM-CSF expression and secretion. 
ColVII staining of HaCaT-OTCs revealed a deposition at the epidermal/dermal junction indicating for a 
continuous basement membrane. Moreover, the deposition resembled human skin (Martins et al. 
2009). Deposition of ColVII was not affected by CsA treatment in HaCaT-OTCs, which as well showed 
a continuous basement membrane staining (Figure 2.36).  
Secretion of pro-MMP1, MMP3 and pro-MMP10 were measured by ELISA. Culture medium from CsA-
treated HaCaT-OTCs had in average a lower amount of pro-MMP1 (8.9 ng ml-1) and MMP3 (3.3 ng ml-
1) in comparison to the DMSO-treated control OTCs, which had 30.3 ng ml-1 pro-MMP1 and 13.3 ng 
ml-1 MMP3. Secreted pro-MMP10 deviated only very slightly in CsA-treated HaCaT-OTCs (5.6 ng ml-1) 
from DMSO-treated HaCaT-OTCs (6.4 ng ml-1) (Figure 2.37A). While all RNAs from MMP1, MMP3 and 
MMP10 were downregulated (0.6-fold, 0.6-fold and 0.7-fold, respectively) in CsA-treated HaCaT 
epithelia, RNA expression of MMP1 and MMP10 were slightly up-regulated (1.2-fold and 1.5-fold, 
respectively) and MMP3 down-regulated (0.6-fold) in the dermal part (Figure 2.37B). 
The expression profile from CsA-treated HaCaT epithelia did not reveal a change in IL-1α. In line with 
the expression profile no significant difference in IL-1α protein was detected in the culture medium 
of CsA-treated (32.6 pg ml-1) or control HaCaT-OTCs (22.6 pg ml-1) (Figure 2.38A). Moreover, CSF2 
RNA measured by qRT-PCR was down-regulated in the dermis and the epithelium (0.52-fold and 0.4-
fold, respectively) (Figure 2.38B). Moreover, the GM-CSF protein level in CsA-treated HaCaT-OTCs 
(6.2 pg ml-1) was slightly lower than in the control HaCaT-OTCs (10.6 pg ml-1) (Figure 2.38C). 
To summarize, the findings concerning ColVII deposition in DMSO-treated HaCaT-GOLD epithelia and 
MMP, IL-1α and CSF2/GM-CSF expression or secretion in CsA-treated HaCaT-GOLD epithelia, could 
not be replicated in CsA-treated HaCaT epithelia. This could indicate that some of these findings 
might play a role in the additional invasive phenotype in CsA-treated HaCaT-GOLD epithelia. 
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Figure 2.36 ColVII deposition in HaCaT-OTCs treated with DMSO or CsA. 
Immunofluorescent staining for ColVII (red) and PanKRT (green) on cryosections from HaCaT-OTCs treated with 
DMSO (0.04%) or CsA (10 µg ml
-1
) for 3 weeks. Sections were counterstained by DAPI to stain nuclei (blue). 
Scale bar: 50 µm. 
 
Figure 2.37 Protein and RNA levels of MMP1, MMP3 and MMP10 in CsA-treated HaCaT-OTCs. 
(A) Protein levels of pro-MMP1, MMP3 and pro-MM10 within the culture medium of HaCaT-OTCs treated with 
DMSO (0.04%) or CsA (10 µg ml-1) were measured by ELISA. The graph shows the mean and the standard error 
of the mean. n=6 (from 2 and 3 weeks of treatment). ns: not significant = p-value ˃ 0.05 (two-sided, unpaired t-
test). (B) Relative RNA expression. RNA isolated from HaCaT-GOLD epithelia treated with DMSO (0.04%) or CsA 
(10 µg ml
-1
) was quantified by qRT-PCR. The graphs show the mean and the standard error of the mean. n=6 
(from 2 and 3 weeks of treatment). 
 
Figure 2.38 IL-1α and GM-CSF protein levels and CSF2 RNA expression levels in CsA-treated HaCaT-OTCs. 
(A) Protein levels of IL-1α within the culture medium of HaCaT-OTCs treated with DMSO (0.04%) or CsA (10 µg 
ml
-1
) were measured by ELISA. n=6 (from 2 and 3 weeks of treatment). ns: not significant = p-value ˃ 0.05 (two-
sided, unpaired t-test). (B) Relative CSF2 RNA expression in the dermis or in the epithelium from HaCaT-OTCs 
treated with DMSO (0.04%) or CsA (10 µg ml
-1
) quantified by qRT-PCR. The graph shows the mean and the 
standard error of the mean. n=6 (from 2 and 3 weeks of treatment). (C) Protein levels of GM-CSF within the 
culture medium of HaCaT-OTCs treated with DMSO (0.04%) or CsA (10 µg ml
-1
) were measured by ELISA. The 
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graph shows the mean and the standard error of the mean. n=6 (from 2 and 3 weeks of treatment). ns: not 
significant = p-value ˃ 0.05 (two-sided, unpaired t-test). 
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2.7. Comparison of the HaCaT and HaCaT-GOLD epithelial RNA expression profiles (DMSO vs. 
CsA) 
In order to get an idea of the molecular differences between the CsA-treated HaCaT and the CsA-
treated HaCaT-GOLD experiment, both RNA expression profiles (each DMSO vs. CsA) were compared 
with each other. 
The number of differentially expressed genes (DMSO vs. CsA) in HaCaT-GOLD epithelia (invasive) was 
nearly 4-fold higher in comparison to the HaCaT epithelia (non-invasive). Interestingly, the number of 
down-regulated genes was lower in GOLD than in the other experiment (48% vs. 55%). For genes 
differentially expressed above 1.5-fold, this difference even increased, with 39% of down-regulated 
genes in CsA-treated HaCaT-GOLD epithelia in comparison to 59% in CsA-treated HaCaT epithelia 
(Figure 2.8A and Figure 2.31C). The higher number of differentially expressed genes could also be 
seen in the scatterplot, which as well showed the higher magnitude of fold changes in CsA-treated 
HaCaT-GOLD epithelia in comparison to the CsA-treated HaCaT epithelia (Figure 2.39A). Looking at 
the overlap of differential gene expression from both data sets it was revealed, that 54% (272/507) 
of the HaCaT data set were overlapping with HaCaT-GOLD, while only 14% (272/1915) of the HaCaT-
GOLD data set were overlapping with the HaCaT data set. When filtering the data sets for the GO-
term ‘epidermal development’ the percentages of overlap increased for both data sets; 63% (24/38) 
in the case of HaCaT and 29% (24/81) in the case of HaCaT-GOLD (Figure 2.39B). In total 38 (HaCaT) 
and 81 (HaCaT-GOLD) differentially expressed genes belonged to the GO-term ‘epidermal 
development. The heatmap of these genes showed that the majority (21) of the 24 overlapping 
genes, regulated in HaCaT and HaCaT-GOLD, were both likewise either up- or down-regulated (Figure 
2.39C). 
Making a comparison analysis with HaCaT and HaCaT-GOLD epithelial RNA expression profiles using 
Ingenuity® Pathway Analysis, it became apparent that functions related to cell migration, movement 
and invasion had a positive z-score, meaning a predicted activation of that function, for CsA-treated 
HaCaT-GOLD (invasive phenotype). These results were in line with the Ingenuity® Pathway Analysis of 
the individual CsA-treated HaCaT-GOLD analysis in Figure 2.34. However, the same functions had a 
negative z-score and with that a predicted inactivation in CsA-treated HaCaT epithelia (non-invasive 
phenotype). One function which was likewise activated in both data sets was ‘synthesis of lipids’ 
(Figure 2.40A). The comparison also revealed that while 49 genes of the HaCaT-GOLD data set were 
part of the Ingenuity® Pathway Analysis ‘Integrin signaling’ gene set, only 6 genes of the HaCaT data 
set were part of that gene set (Figure 2.40B). 
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Summarized, the high number of genes uniquely differentially expressed (DMSO vs. CsA) in the 
HaCaT-GOLD experiment might play a role in the additional invasive phenotype of CsA-treated 
HaCaT-GOLD keratinocytes. It was shown that the HaCaT and HaCaT-GOLD data sets both manifested 
regulation of ‘epidermal development’ genes, but differed in respect to Ingenuity® Pathway Analysis 
and prediction of cell functions related to invasion and activation of the integrin pathway. 
 
Figure 2.39 Comparison of whole genome RNA expression profiles (DMSO vs. CsA) from HaCaT and HaCaT-
GOLD epithelia. 
(A) Scatterplots of relative gene expression. Each dot shows the mean of the relative expression value from 3 
biological replicates for one gene (log2). Y-axis (DMSO), x-axis (CsA). Dots on line of origin = no differential gene 
expression. Data for the scatterplot were neither normalized nor filtered. The HaCaT scatterplot was also 
shown in Figure 2.8. (B) Overlap of differential gene expression (DMSO vs. CsA) from both data sets (HaCaT and 
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HaCaT-GOLD epithelia). Left: whole data sets. Right: Data sets filtered by the GO-term ‘epidermal development’ 
(GO-0008544). (C) Heatmap of differentially expressed genes (DMSO vs. CsA) filtered by the GO-term 
‘epidermal development’ (GO-0008544) from HaCaT and HaCaT-GOLD RNA expression profiles. Fold changes 
(log2) are depicted by the indicated color. The rows are sorted alphabetically. Data from HaCaT was also shown 
in Figure 2.9 and Figure 2.25. 
 
Figure 2.40 Ingenuity® Pathway Analysis comparison of RNA expression profiles (DMSO vs. CsA) from HaCaT 
and HaCaT-GOLD epithelia. 
(A) Predicted cellular/molecular functions (Ingenuity® Pathway Analysis) induced by CsA in HaCaT and HaCaT-
GOLD epithelia. Indicated are the activation z-scores, which express the predicted positive or negative 
activation of the function. The list is sorted by the magnitude of z-scores of both data sets. (B) Overlap of 
differentially expressed genes from the expression profiles (DMSO vs. CsA) from HaCaT and HaCaT-GOLD 
epithelia with the Ingenuity® Pathway Analysis gene set ‘Integrin signaling’. 
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2.8. ATF expression in OTCs treated with CsA 
Previously it was suggested that ATF3 is playing a role in CsA-induced tumorigenesis (Wu et al. 2010). 
In our RNA expression profiles ATF3 regulation was not apparent. However, in order to examine a 
possible association of ATF3 expression and CsA treatment in our experiments, RNA expression of 
ATF3 and also of ATF4 and ATF5 was analyzed in CsA-treated NHEK-, HaCaT-, HaCaT-GOLD- and 
HaCaT-RAS A-5-OTCs. 
RNA expression of ATF3 was 1.31-fold up-regulated upon CsA treatment in NHEK epithelia, while the 
expression of ATF4 and ATF5 was not regulated on average. ATF3 RNA expression in CsA-treated 
HaCaT epithelia was 1.35-fold up-regulated and expression of ATF4 (0.64-fold) and ATF5 (0.65-fold) 
were down-regulated. In HaCaT-GOLD epithelia treated with CsA ATF3 expression was minorly up-
regulated (1.06-fold), ATF4 down-regulated (0.84-fold) and ATF5 expression was not changed. Last, in 
CsA-treated HaCaT-RAS A-5 epithelia ATF3 was 1.26-fold up-regulated, ATF4 1.22-fold up-regulated 
and ATF5 minorly (1.06-fold) up-regulated (Figure 2.41). 
Summarized CsA might have an impact on ATF3 expression in NHEK, HaCaT and HaCaT-RAS A-5 
epithelia. Noteworthy, the changes measured in our experiments were very low, below a fold change 
of 2. Nevertheless, further experiments were not performed, due to the reason that the proposed 
CsA-induced and ATF3-driven senescence inhibitory mechanism (Wu et al. 2010) relies on p53wt and 
H-rasV12 cells, which are not present in our HaCaT system, nor common in human cSCCs (Boukamp 
2005a). 
 
Figure 2.41 Relative ATF3, ATF4 and ATF5 RNA expression in NHEK, HaCaT-, HaCaT-GOLD-, and HaCaT-RAS A-
5 epithelia treated with CsA. 
RNA isolated from indicated epithelia treated with DMSO (0.04%) or CsA (10 µg ml
-1
) for 3 weeks was 
quantified by qRT-PCR. The graphs show the mean and the standard error of the mean. NHEK, HaCaT and 
HaCaT-RAS A-5: n=9 (from 3 independent experiments), HaCaT-GOLD: n=3. 
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3. DISCUSSION 
Raising incidence of cSCCs in organ transplant patients are a huge challenge in immunosuppression 
therapy. Yet the direct impact of CsA on human keratinocytes remains elusive. While studies in 
cultured cells can give valuable insight into the biology of CsA, it might not be necessarily relevant for 
keratinocytes, as it was shown that calcineurin/NFAT signaling is in fact ubiquitously present in 
various cell types, but depends on different co-signaling pathways in different cell types (Crabtree 
1999; Aramburu et al. 2004). Besides, effects seen in cultured cells can be tremendously different to 
the effects within a tissue context. In order to prevent species-dependent differences, a human in-
vivo-like 3D organotypic skin culture system was used to unravel the direct impact of CsA on human 
keratinocytes in a homeostatic and physiologically relevant environment. 
3.1. Improvement of differentiation of HaCaT and HaCaT-RAS A-5 cells by CsA 
One constant characteristic of CsA treatment in our experiments was the normalization of epidermal 
differentiation. HaCaT- and HaCaT-RAS A-5-OTCs regenerate an epithelium with reduced 
differentiation. After CsA treatment the epithelial strata were better distinguishable and developed 
much more like skin in-vivo. Importantly, this was consistent also when different sera were used for 
performing the OTCs. While another phenotype, invasion of HaCaT cells into the dermis, was only 
seen in one particular serum (discussed in section 3.2). In line with the better structured epithelium 
seen in H&E histology, improved distribution of differentiation markers, as demonstrated by 
immunofluorescent stainings could be demonstrated. This was also confirmed by gene expression 
analysis: As defined by GO-terms, CsA caused regulation of ‘epidermal development’ genes. 
Moreover, we could show that CsA-treated HaCaT and HaCaT-RAS A-5 epithelia had a higher 
transepithelial electric resistance, reflecting an improved skin barrier. Interestingly regulation of gene 
expression was dependent on the basic differentiation status of the cell type. HaCaT cells, which still 
have maintained a better differentiation potential in comparison to HaCaT-RAS A-5 cells under 
standard conditions, showed less regulation than the poorly differentiating HaCaT-RAS A-5 cells. 
Moreover, in NHEK epithelia, which form a perfect epidermis, i.e. optimally differentiate under 
standard conditions, CsA did not seem to be able to further potentiate differentiation: CsA-
dependent differential gene expression of ‘epidermal development’ genes was not apparent in NHEK 
cells grown in OTCs. We thus hypothesize that CsA is inducing a normalization of epithelia leading to 
an improvement of differentiation (Figure 3.1), by contributing to the regulation of the 
differentiation program. However, it remains open whether normalization is induced in all epithelia 
with reduced differentiation or whether only in p53 mutant epithelia. HaCaT and HaCaT-RAS A-5 cells 
are p53 mutant cells and it was shown that p53 mutant cells are more easily pushed into terminal 
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differentiation (Freije et al. 2014). Additional experiments, with different p53 mutant and wild type 
keratinocytes would be needed to validate whether a p53 mutation is necessary for the phenotype 
we have described. 
 
Figure 3.1 Hypothesis: CsA-induced normalization of differentiation. 
NHEK (normal human epidermal keratinocytes). The more differentiated the epithelium of the corresponding 
cell type in OTCs is, the less are ‘epidermal development’ genes affected by CsA. 
3.1.1. The role of Calcineurin and CsA in epidermal differentiation and improvement of the skin 
barrier 
In-vitro studies with murine keratinocytes suggested that calcineurin inhibition by CsA leads to a 
decrease in the expression of some calcium-induced differentiation markers (KRT1, LOR and FLG) 
(Santini et al. 2001). A closer look into calcineurin and NFAT mice models challenges this assumption. 
Neither a knockdown of calcineurin A nor of calcineurin B reduces epidermal differentiation in mice. 
While knockouts of epidermal calcineurin B1 exhibit a cyclic alopecia phenotype (Mammucari et al. 
2005), mice with a calcineurin A-α knockout had a decreased stratum spinosum and thickened 
stratum corneum. While the authors discussed whether a parallel increase in Tunnel positive cells 
within the suprabasal cells could argue for an increase in apoptosis or argues for an increase in 
premature differentiation (Pena et al. 2010), our results would argue for the latter. Similar to the 
calcineurin B knockout, a knockdown in NFATc1 caused an increase in follicular cell cycling and 
follicular growth (Horsley et al. 2008). However, neither did the knockdown affect the interfollicular 
epidermis, nor did overexpression of NFATc1 impact terminal differentiation. This suggested that 
NFATc1 is primarily playing a role in follicular cells (Horsley et al. 2008). In contrast to the NFATc1 
knockdown, an NFATc2 knockdown did not cause alopecia, nor did the mice show any other obvious 
abnormality (Hodge et al. 1996). Additionally, as discussed by Wu et al., no skin phenotypes were 
described for other NFAT mutants, including NFATc3 and NFATc4 (Wu et al. 2007). 
Taking together, the literature shows that calcineurin signaling plays a role in the epidermis, 
however, little information is available on the mechanism of calcineurin within the epidermal context 
and its exact role in differentiation. Our data clearly demonstrated that continuous CsA treatment led 
to ‘normalization’ of stratification and thus improvement of differentiation of HaCaT and HaCaT-RAS 
A-5 cells when grown in OTCs. However, further experiments would be needed to link this phenotype 
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with a decrease in calcineurin signaling or to exclude calcineurin signaling responsible for this 
phenotype. Evidence could be provided by the usage of different inhibitors, like for example the 
peptide VIVIT, which was shown to inhibit NFAT activity, but not general calcineurin activity 
(Aramburu et al. 1999) or by molecular inhibition, overexpressing the endogenous RCAN1, which 
binds calcineurin and thereby inhibits NFAT activity (Fuentes et al. 2000). 
Calcineurin or NFAT knockout models can provide information about the role of calcineurin signaling 
in epidermal differentiation. However, while we did not see changes in differentiation in the 
epidermis of NHEK, we saw an improvement/normalization of differentiation in HaCaT and HaCaT-
RAS A-5 epithelia. Both epithelia show a reduced state of differentiation under standard culture 
condition. Hence mice models with initial defective skin epithelia would reflect our results better. 
Interestingly, in NC/Nga mice, a model for atopic dermatitis (Suto et al. 1999), in which sodium 
dodecyl sulfate treatment disrupted the skin barrier, CsA improved the clinical phenotype and 
enhanced KRT10 expression (Kim et al. 2013). Moreover, up-regulation of KRT10 after combined CsA 
and Rapamycin treatment was also described in a humanized mouse model of inflamed human skin 
grafts (huPBL-SCID-huSkin) (de Oliveira et al. 2012). In that study, the CsA-induced reduction of 
inflammation was discussed to be the major decisive cause for the improved phenotype. In light of 
our own results, the improvement of skin barrier and the up-regulation of KRT10 might also be due 
to a direct impact of CsA on the keratinocytes. In addition, in-vivo data from atopic dermatitis 
showed that topical treatment with pimecrolimus, another calcineurin inhibitor, led to an 
improvement of barrier function and also restoration (up-regulation) of FLG after three weeks 
(Jensen et al. 2009). CsA treatment has been reported to be also beneficial for severe cases of 
psoriasis (Ho 2004). In psoriasis, an inflammatory disease, which is as well characterized by a 
defective skin barrier (Bergboer et al. 2012), several LCE genes are reduced in lesioned skin as 
compared to uninvolved skin (Bergboer et al. 2011). Interestingly, LCE genes were among the genes, 
which in our results were consistently up-regulated by CsA in HaCaT and HaCaT-RAS A-5 cells. Hence, 
while CsA most certainly has a beneficial impact on psoriatic lesions by reducing the inflammation, 
our results suggest that improvement of psoriatic lesions by CsA is also caused by up-regulation of 
LCE genes in the keratinocytes and thereby improving the skin barrier. 
3.1.2. Similarities between CsA and UV irradiation on epidermal differentiation and improved 
skin barrier 
We found that in HaCaT and HaCaT-RAS A-5 epithelia long-term UV irradiation caused an increase in 
epidermal differentiation. Especially in HaCaT-RAS A-5 epithelia, which only poorly differentiate 
under standard conditions, a strong increase in differentiation could already be seen in histological 
stainings. Interestingly morphology in histological stainings of UV-irradiated OTCs resembled the 
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morphology of CsA-treated OTCs. Moreover, comparison of gene expression profiles revealed a 
considerable overlap of genes regulated by long-term UV irradiation and continuous CsA treatment. 
The combination UV+CsA induced a much higher number of differentially expressed genes than UV-
irradiation and CsA-treatment alone. Nevertheless this did not further strengthen the phenotype of 
improved differentiation based on histological stainings. Noteworthy, comparing the ‘epidermal 
development’ gene expression profiles of CsA, UV and UV+CsA demonstrated that those genes, 
which were regulated in all three conditions, were either all up- or all down-regulated, arguing for a 
common regulatory mechanism induced by UV irradiation and CsA treatment. 
Single UV irradiation was shown to decrease barrier function (Haratake et al. 1997; Biniek et al. 
2012). However, there is also evidence that the epithelia can restore barrier function (Johnson et al. 
2014) and increase the stratum corneum upon continuous UV irradiation in the sense of a protective 
shield against UV (Cabral et al. 2001). Interestingly, the study from Haratake et al. showed that CsA, 
administered directly after the UV irradiation, prevented the short-term UV-induced barrier defects. 
The authors argued that CsA reduced inflammation and T cell infiltration and thereby restored the 
barrier function. However, considering our results, this might have at least in part been a direct 
effect of CsA on gene expression in the keratinocytes. Also in line with our findings that CsA did not 
augment differentiation in NHEK, the authors did not find an impact of CsA on the skin barrier of 
healthy unaffected skin (Haratake et al. 1997). 
Within the ‘epidermal development’ gene sets several genes from two specific gene groups were 
affected by CsA, UV and UV+CsA. These two gene groups were LCE and SPRR. Both were previously 
shown to be induced by UV irradiation and suggested to be part of a long term protective adaption of 
skin towards UV irradiation (Kartasova & van de Putte 1988; Cabral et al. 2001; Jackson et al. 2005). 
Especially SPRR4, which is differentially expressed also in our HaCaT-RAS A-5 epithelia in all 
treatment options (CsA, UV and UV+CsA), seems to play a central role in the adaption to UV 
irradiation (Cabral et al. 2001). As CsA regulated a similar set of ‘epidermal development’ genes as 
UV, it might be hypothesized that a CsA-sensitive signaling pathway is taking a part in the above 
mentioned UV adaption mechanism. While it might be a CsA-sensitive signaling pathway, it might be 
asked, whether this adaption mechanism is a NFAT- or even calcineurin-independent mechanism, as 
it was shown that UV activates NFAT (Huang et al. 2000), which is commonly inhibited by CsA 
(Hermann-Kleiter & Baier 2010). 
3.1.3. Differentiation status of cSCCs and high-risk cSCCs in organ transplant recipients  
We showed that CsA improved differentiation of poorly or moderately differentiated epithelia. In 
agreement, in organ transplant recipients, as it is the case in immunocompetent patients, the 
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majority of cSCCs is well differentiated (Smith et al. 2004; Lindelöf et al. 2006). On the other hand, 
patients treated with CsA are more prone to cutaneous catastrophic carcinomas (Abikhair et al. 
2016) and also CsA enhanced metastasis in mice models (Hojo et al. 1999; Guba et al. 2002). 
Although the probability for poorly differentiated cSCCs is higher to develop into high risk cSCCs 
(Brougham et al. 2012), differentiation status per se does not exclude advanced disease (Cherpelis et 
al. 2002) and some studies even showed that the majority of metastatic cSCCs are well differentiated 
(Dinehart et al. 1997). 
3.2. CsA-induced invasion 
Using GOLD serum in the OTC experiments, continuous CsA treatment caused extensive invasion of 
the HaCaT keratinocytes. Invasion into the dermal equivalent and especially penetration through the 
basement membrane were nicely demonstrated by immunofluorescent staining for the basement 
membrane marker ColIV. In contrast, experiments using a different serum, could not replicate the 
CsA-induced invasive growth of HaCaT keratinocytes. Noteworthy, the improvement of stratification 
and differentiation was consistent in both sera. 
3.2.1. The role of MMPs in CsA-induced invasion 
While enhanced proliferation could be excluded as causative origin for the invasion, we measured 
enhanced gelatinase activity, arguing for an enzymatic assisted invasion. One interesting factor, 
MMP26, was found more often in tumor cells from cSCCs from organ transplant recipients than in 
cSCCs from immunocompetent patients and could be one factor responsible for the more aggressive 
cSCCs in organ transplant recipients (Kuivanen et al. 2009). However, we did not find MMP26 within 
our expression data. In contrast, gene expression analysis showed a massive up-regulation of MMP3 
and MMP10, as well a 2-fold up-regulation of MMP1 within the epithelial cells. MMP expression 
levels were as well measured in the corresponding CsA-treated fibroblast from the dermal 
equivalent. However, in contrast to the epithelial cells, all three MMPs, MMP1, MMP3 and MMP10 
were down-regulated in CsA-treated fibroblasts. Moreover, despite massive RNA expression in the 
epithelial cells, there was only a weak up-regulation of pro-MMP10 proteins, while pro-MMP1 and 
MMP3 proteins were clearly down-regulated by CsA. 
Interestingly, ITGA6, which we showed is reduced at the basement membrane at invasion sites in 
CsA-treated HaCaT-GOLD-OTCs, is a direct substrate of MMP10 (Schlage et al. 2015). Furthermore, 
MMP10 RNA transcripts were shown to be up-regulated in cSCCs in comparison to skin and to actinic 
keratosis (Haider et al. 2006; Lambert et al. 2014). Moreover, Mitsui et al. demonstrated that 
MMP10 is especially up-regulated at the leading edge of cSCCs (Mitsui et al. 2014). In line with our 
expression data, MMP10 proteins were shown to be more expressed by cancer cells than from 
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stroma cells in cSCCs (Boyd et al. 2009). Interestingly, it was previously shown that CsA is inducing 
MMP10 expression in another tissue context. Tiu et al. presented gene expression data of CsA-
treated SCC-15 oral epithelial cells indicating up-regulation of MMP10 (Tiu et al. 2006). In addition 
Dannewitz et al. revealed enhanced MMP10 expression in oral epithelial cells from CsA-induced 
gingival overgrowth, a common side effect of CsA therapy in organ transplant recipients (Dannewitz 
et al. 2006). While we miss the proof that the slight increase in MMP10 by CsA seen in our 
experiments is sufficient for the invasive growth of HaCaT keratinocytes, MMP10 was also shown to 
activate pro-MMP9 (Schlage et al. 2015). MMP9 proteins are as well commonly up-regulated in cSCCs 
(Verdolini et al. 2001; Roh et al. 2012) and activation of pro-MMP9 by MMP10 might explain why we 
did not see enhanced MMP9 RNA expression in the CsA-treated HaCaT-GOLD epithelia. 
3.2.2. The role of integrins in CsA-induced invasion 
Analysis of the RNA expression profile of CsA-treated HaCaT-GOLD epithelia with Ingenuity® Pathway 
Analysis revealed that several genes from the integrin signaling pathway were regulated. Among 
these were ITGA6 and ITGB1, which are expressed in basal keratinocytes (Janes & Watt 2006). In 
agreement with the RNA expression results, Immunofluorescent staining of CsA-treated HaCaT-GOLD 
epithelia demonstrated enhanced ITGA6 and ITGB1 deposition in basal keratinocytes, especially at 
the basement membrane underneath non-invading basal cells, in comparison to the control HaCaT-
OTCs. 
Increased expression of Integrins is associated with head and neck cancer (Bornstein et al. 2016), 
where they participate in the invasion process. However, dysregulation of Integrin are as well found 
in cSCCs (Savoia et al. 1993; Janes & Watt 2006). Moreover, knockdown of ITGB1 in vulvar SCC cells 
diminished their invasive capacity (Brockbank et al. 2005), while overexpression of active ITGB1 in 
basal keratinocytes favored chemical induced malignant skin tumor formation (Ferreira et al. 2009). 
Moreover, gene expression profiling from actinic keratosis and cSCCs revealed a set of genes 
involved in migration, including ITGA5 (Lambert et al. 2014). When comparing cSCCs to normal 
epidermis it was shown that ITGA3, ITGA5, and ITGA6 were up-regulated, especially at the leading 
edge of the invasive cSCCs (Mitsui et al. 2014). Moreover, CsA was shown to up-regulate ITGB3 in 
trophoblast cells (Huang et al. 2014). In contrast, CsA caused downregulation of ITGB1 and ITGA5 in 
oral epithelial cells (Sardarian et al. 2015). In the epithelia of the HaCaT-GOLD cells we found up-
regulation of ITGB1 and ITGA6 upon CsA treatment and this correlated with invasive growth. The 
final proof for their role in the invasive process by e.g. blocking antibodies or knockdown of the 
integrins, however, still needs to be undertaken. 
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3.2.3. The role of IL-1α and GM-CSF 
While CsA induced invasion of HaCaT keratinocytes grown in GOLD serum, CsA did not induce 
invasion in a different serum. Lists of differentially expressed genes from both experiments, CsA-
treated HaCaT epithelia (versus the corresponding DMSO control) and CsA-treated HaCaT-GOLD 
epithelia grown in GOLD serum (versus the corresponding DMSO control grown as well in GOLD 
serum), were both screened and compared. One gene which was strongly up-regulated in the CsA-
treated invasive HaCaT-GOLD cells, which was not regulated in the non-invasive CsA-treated HaCaT 
cells, was IL-1α. Moreover, not only RNA levels were increased, IL-1α proteins were also strongly up-
regulated in CsA-treated HaCaT-GOLD-OTCs. IL-1α is typically expressed in skin and is playing a role in 
keratinocyte growth regulation via a paracrine loop with fibroblasts (Maas-Szabowski et al. 2000). 
While in that regulatory loop IL-1α and IL-1β from keratinocytes stimulate CSF2/GM-CSF expression 
in fibroblasts, we could not find CSF2 up-regulation in CsA-treated fibroblasts. However, it was 
already suggested earlier that IL-1α is also up-regulating CSF2 in keratinocytes (Kupper et al. 1988). In 
agreement with that publication we demonstrated elevated CSF2 levels in CsA-treated HaCaT-GOLD 
epithelia. Concerning the involvement of IL-1α and CSF2/GM-CSF with the invasive phenotype, it was 
previously shown in-vitro that excess IL-1α enhanced migration of keratinocytes (Chen et al. 1995). 
Moreover, forced expression of GM-CSF enhanced infiltration of HaCaT-RAS A-5 keratinocytes into 
the underlying collagen, when grown in collagen-based organotypic cultures (Obermueller et al. 
2004). Moreover the same group showed that stimulation of head and neck SCC cells with GM-CSF 
enhanced migration of these cells and that blocking GM-CSF antibodies reduced invasive growth of 
these head and neck SCC cells grown in organotypic cultures (Gutschalk et al. 2006). In our CsA-
treated HaCaT-GOLD-OTCs the levels of GM-CSF protein was, however, comparably low. Thus 
without further proof, for example using blocking antibodies against GM-CSF, it has to remain open 
whether GM-CSF was at least in part responsible for the invasive phenotype. 
3.2.4. The difference between CsA-treated HaCaT and HaCaT-GOLD epithelia 
While CsA enhanced in-vitro invasion of trophoblast cells (Tang et al. 2012) and A-549 
adenocarcinoma cells (Hojo et al. 1999), it also was found to reduce in-vitro invasion, namely of 
prostate cancer cells (Kawahara et al. 2015), glioblastoma cells (Sliwa et al. 2007) and liver cells 
(Sakai et al. 2004). These different publications nicely demonstrated that CsA is not inducing invasion 
in every cell context, but rather requires the right conditions. Our experiments proved that not only 
different cell types respond differently, but that the same HaCaT keratinocytes when grown in 
different sera responded to CsA with invasion in only one of the sera. Although improved 
differentiation could be seen in all tested sera. Thus the external influence can have profound 
influence and obviously is able to sensitize or desensitize a cell for CsA-induced invasion. One 
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difference between HaCaT- and HaCaT-GOLD-OTCs, which were grown in the standard and the GOLD 
serum, was the deposition of ColVII. ColVII is part of the basement membrane (Leigh et al. 1988). 
While in the standard serum HaCaT-OTCs were stained positive for ColVII at the dermal epidermal 
junction, HaCaT-GOLD OTCs were almost negative for ColVII. ColVII RNA expression could be 
measured in these OTCs (data not shown), suggesting that the GOLD serum is not supporting ColVII 
maturation and deposition at the basement membrane of HaCaT-GOLD-OTCs. Loss of ColVII by a 
mutation in patients with dystrophic epidermolysis bullosa causes severe blistering of the skin 
(Brummer et al. 1993). Moreover, these patients are also much more susceptible to cSCCs. While it is 
still discussed why these patients are more susceptible for cSCCs (Kim & Murrell 2015), it was shown 
that re-expression of ColVII in dystrophic epidermolysis bullosa-derived fibroblasts, prevents invasion 
of dystrophic epidermolysis bullosa-derived SCC cells in organotypic cultures (Ng et al. 2012). 
However, the loss of ColVII in our system was not enough to induce invasive growth of non-
tumorigenic HaCaT-GOLD keratinocytes, but needed additional CsA treatment. The absence of ColVII 
at the basement membrane probably facilitated invasion, but was not the exclusive cause. In 
addition, we saw that differential gene expression induced by CsA was much stronger affected in 
GOLD serum. Those additional regulated genes most likely were necessary for the invasive growth of 
HaCaT keratinocytes in the GOLD serum. Furthermore, more genes were downregulated (59%) in the 
case of the standard serum, in comparison to the GOLD serum (40%). It was shown that in 
splenocytes of CsA-treated rats the RNA synthesis rate was decreased by 63% (Eun et al. 1987). It 
might be that this inhibition of RNA synthesis is overcome in the GOLD serum, leading to a much 
greater differential gene expression. 
While it remains elusive what the exact difference between the sera is, extensive mass spectrometry 
could give a hint. For example Zheng at al. compared the protein composition of three different sera 
by mass spectrometry. These sera promoted different growth properties of cultured retinal epithelial 
pigment cells and they found that in those sera, which did not promote growth as good as the other 
serum, several growth factors, like TGFβ1 or bFGF, were less or not present (Zheng et al. 2006). 
Another promising approach is the comparison of the differential gene expression between the 
epithelia of control HaCaT-OTCs from both sera. This analysis is currently ongoing in cooperation with 
the bioinformatics group by Jörg Galle at the Interdisciplinary Centre for Bioinformatics in Leipzig. 
Results could show which pathways are activated or inactivated in one or the other serum and which 
might sensitize the HaCaT keratinocytes to CsA-induced invasion. 
3.3. CsA-induced maintenance of vital cell layers in HaCaT epithelia 
Control HaCaT-OTCs lose vitality and become atrophic when cultured for more than 4 weeks. 
Interestingly, continuous CsA treatment for 4 weeks decelerated this process. First of all this was 
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demonstrated by histological staining, showing that CsA-treated HaCaT-OTCs maintained more vital 
cell layers after 4 weeks than the control HaCaT-OTCs. Moreover, we could demonstrate that these 
CsA-treated HaCaT-OTCs with more vital cell layers were metabolically more active than the time 
matched control HaCaT-OTCs. Furthermore, Ingenuity® Pathway Analysis predicted that CsA-treated 
OTCs underwent less cell death, apoptosis or necrosis after 4 weeks of treatment than the controls. 
In addition to less cell death, Ingenuity® Pathway Analysis also predicted that HGF and Integrin 
signaling were activated in the HaCaT epithelia treated for 4 weeks with CsA. Interestingly, both 
factors are associated with cell survival. 
HGF in epithelial cells is an important growth factor and mice lacking HGF or its receptor Met, exhibit 
severe defects in liver or placenta development (Schmidt et al. 1995; Uehara et al. 1995). Moreover, 
in conditional skin knockout mice it was shown that HGF is essential for skin regeneration 
(Chmielowiec et al. 2007). Finally, it was demonstrated that HGF protects corneal epithelial cells from 
Staurosporine-induced cell death (Kakazu et al. 2004) and primary keratinocytes from UVB-induced 
apoptosis (Mildner et al. 2002). However, it has also to be mentioned that Mildner et al. showed that 
HGF is not inhibiting apoptosis in cultured HaCaT cells. 
The adhesion proteins Integrins are expressed in basal, vital keratinocytes (Watt 2002). With regard 
to cell survival, it was shown that α3β1 integrin is necessary for keratinocyte survival (Manohar et al. 
2004) and that loss of β4 Integrin protects epithelial cells from apoptosis (Weaver et al. 2002). 
Moreover, it was shown that adhesion of small cell lung cancer cells to extracellular matrix reduced 
cell death induced by chemotherapeutics and that this reduction was dependent on ITGB1 (Sethi et 
al. 1999). 
Altogether, we saw that CsA maintained vital cell layers after long-term cultivation, while control 
OTCs lost their vital cell layers. Ingenuity® Pathway Analysis anticipated that HGF and Integrin 
signaling is activated in 4 weeks CsA-treated HaCaT-OTCs, but is less likely affected in 2 weeks CsA-
treated HaCaT-OTCs. Accordingly, we believe that activation of these pathways is not a general trait 
of CsA treatment, but rather we suppose that they are down-regulated in control HaCaT-OTCs after 
prolonged cultivation and that this down-regulation is prevented by CsA. Hence, by maintenance of 
HGF and Integrin signaling CsA might prevent atrophy and the reduction in vital keratinocytes in 
HaCaT-OTCs older than 4 weeks. 
3.4. Conclusion  
In summary, our results suggest that an overall normalization of epithelia and enhanced endurance 
of vital keratinocytes is induced by CsA. We showed that CsA in all tested conditions restored 
differentiation in HaCaT and HaCaT-RAS A-5 epithelia. Furthermore, while HaCaT keratinocytes after 
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4 weeks cultivation in OTCs became atrophic, we demonstrated that CsA preserved the vitality of 
HaCaT keratinocytes grown in OTCs. This was possibly due to a reduction of cell death, triggered in 
HaCaT-OTCs cultured for over 4 weeks, as predicted by Ingenuity® Pathway Analysis. Our results 
agree with in-vivo data showing that CsA is not directly transforming keratinocytes into cancer cells 
under all conditions. Instead our results suggest that CsA could support cSCCs emergence by a 
potential impact on keratinocyte viability. In-vivo CsA may lead to preservation of basal 
keratinocytes, which upon genomic or external stress might get lost via differentiation or cell death. 
These could remain in place with CsA and may finally develop into ‘defective’ cell clones, further 
developing into cSCCs. We further showed, that under certain conditions, using a specific serum, CsA 
is able to induce invasion of pre-malignant HaCaT keratinocytes. Changed parameters necessary for 
CsA-induced invasion in our experiments might as well correlate to a subgroup of transplant patients, 
who develop cutaneous catastrophic carcinomas. This subgroup of patients rapidly develops, within 
10 month of transplantation, up to 100 cSCCs per year (Abikhair et al. 2016). Our data is now suited 
for in depth analysis to identify pathways, which might sensitize keratinocytes for CsA-induced 
invasion. Finding these targets might as well help identifying patients in danger of developing 
cutaneous catastrophic carcinomas and to counteract this devastating CsA-induced side effect. 
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4. MATERIALS AND METHODS 
4.1. Cell culture methods 
4.1.1. Cells 
Normal human dermal fibroblasts (NHDF) and normal human epidermal keratinocytes (NHEK) used in 
this study were derived from one healthy donor (female, 23 years, abdomen). Isolation was done by 
Iris Martin (DKFZ) according to the guidelines of the Institutional Commission of Ethics of the 
University of Freiburg (42/2005). In short, skin samples were cut into pieces and incubated in 
thermolysin (0.5 mg ml-1) overnight at 4°C. Afterwards dermal and epidermal compartments were 
separated. For NHDF isolation dermal fragments were submersed in D20 medium (Table 4.1) and 
incubated (37°C, 5% CO2, 5% O2, 95% humidity) on standard cell culture plates. NHDF grew out after 
around 3 weeks and dermal fragments were removed. When cells reached confluency, NHDF were 
trypsinized and propagated or frozen in liquid nitrogen for later usage as passage 1. For NHEK 
isolation epidermal fragments were incubated in 0.4% Trypsin/0.05% EDTA for 10 min at 37°C. 
Afterwards keratinocytes were separated by vigorous tapping and filtering (70 µm). 5000 NHEKs per 
cm² were seeded on standard cell culture plates with a feeder layer. For the feeder layer 6000 
irradiated NHDFs (5 Mio NHDF per ml in suspension irradiated with 70 gray) per cm² were seeded in 
FADcomplete medium (Table 4.1) 24h prior to keratinocyte seeding in order to precondition the 
medium. When NHEK reached 80-90% confluency cells were trypsinized and propagated or frozen in 
liquid nitrogen as passage 1. 
HaCaT keratinocytes (Boukamp et al. 1988) were used in passages 32-39 and HaCaT-RAS A-5 
keratinocytes (Boukamp et al. 1990), HaCaT keratinocytes transfected with H-RasG12V, were used in 
passages 25-29. 
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Table 4.1 Cell culture media 
Medium name Application Formula 
D10 NHDF, HaCaT, HaCaT-RAS A-5 
cultivation 
DMEM
1
, 10% (v/v) FBS
2
, 1% (v/v) P/S
3
 
D20 NHDF isolation DMEM
1
, 20% (v/v) FBS
2
, 1% (v/v) P/S
3
 
Freezing  Freezing of all cell types DMEM, 20% (v/v) FBS, 1% (v/v) P/S, 10% DMSO
4
 
rFAD OTC cultivation DMEM and DMEM-F12
5
 (1:1), 10% (v/v) FBS, 1% (v/v) P/S, 
200 µg/ml 2-phospho-L-ascorbic acid, 0.1mM cholera toxin, 
0.4 µg/ml hydrocortisone 
FADcomplete NHEK isolation DMEM and DMEM-F12 (1:1), 5% (v/v) FBS, 1% (v/v) P/S, 24 
ng/ml adenine, 0.1 nM cholera toxin, 2 ng/ml EGF
6
, 0.4 
µg/ml hydrocortisone, 5 µg/ml insulin 
FDM Dermal equivalent cultivation DMEM and DMEM-F12 (1:1), 10% (v/v) FBS, 1% (v/v) P/S, 
200 µg/ml 2-Phospho-L-Ascorbic Acid, 2.5 ng/ml EGF, 5 
ng/ml FGF
7
-basic, 5 µg/ml insulin, 1 ng/ml TGF-β1
8 
DermaLife K
9
 NHEK cultivation As described by manufacturer. 
1
 Dulbecco’s Modiefied Eagle’s Medium (Lonza), 
2
 fetal bovine serum (GOOD, GE Healthcare, Lot.: P132307 or GOLD, PAN-
Biotech, Lot: A15112-1936), 
3
 penicillin/streptomycin (10,000 U/ml), 
4
 dimethyl sulfoxide, 
5
 1:1 mixture DMEM and F12 
(Lonza), 
6
 epidermal growth factor, 
7
 fibroblast growth factor, 
8
 transforming growth factor β1, 
9
 Lifeline Cell Technology 
 
4.1.2. Maintenance of cultured cells 
Frozen cells (stored in cryotubes in liquid N2) were thawed at 37°C and transferred to cell type 
specific culture medium (Table 4.1). Cultivation was done at 37°C, 95% humidity and 5% CO2 for 
NHEK, HaCaT and HaCaT-RAS A-5. NHDF were kept at 37°C, 95% humidity, 5% CO2 and 5% O2. 
Medium was exchanged every 2nd or 3rd day. HaCaT keratinocytes were split every 10th day at a ration 
1:10 or at a density of 0.5 Mio cells per 10 cm dish. HaCaT-RAS A-5 cells were split every 7th day a 
ration of 1:15 or at a density of 0.5 Mio cells per 10 cm dish. NHDF were split after reaching 
confluency and seeded at a density of 1 Mio per 15 cm dish. NHEK were split at 80% confluency and 
seeded at a density of 1.5 Mio cells per 15 cm dish. Splitting procedure was done according to Table 
4.2. In short, cells were washed with PBS, incubated with EDTA, which was removed and cells were 
incubated with Trypsin. The enzymatic reaction was stopped with serum containing culture medium. 
Cell stocks of HaCaT and HaCaT-RAS A-5 cells were tested for cell contaminations (Multiplexion 
GmbH, Heidelberg, Germany). All cells, including NHEK and NHDF and media from OTCs prior to 
harvest, were regularly tested for mycoplasmas (Venor® GeM Classic Mycoplasma PCR Detection Kit, 
Minerva Biolabs; Berlin, Germany). Tests were performed according to manufacturer’s protocol by 
Hermann Stammer. All samples from this thesis were mycoplasma negative. 
For storage, cells were frozen in cryo tubes and stored at liquid N2. 2 Mio cells of the corresponding 
type were centrifuged (1000 rpm) and resuspended in 1ml freezing medium (Table 4.1). For 
controlled and gentle freezing cryo tubes were transferred to cryo-safe freezing boxes (neoLab, 
Germany) and kept at -80°C for 24h before transferring to liquid nitrogen. 
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Table 4.2 Incubation times for cell passaging 
Cell Type 1. Rinse with PBS 2. EDTA Treatment 3. Trypsin Treatment 
NHDF yes no 3-5 min (0.05% in 0.05% EDTA) 
NHEK yes Rinsed (0.05%) 1-3 min (0.4% in 0.05% EDTA) 
HaCaT yes 10 min (0.05%) 3-5 min (0.05% in 0.05% EDTA) 
HaCaT-RAS A-5 yes 10 min (0.05%) 3-5 min (0.05% in 0.05% EDTA) 
4.1.3. Preparation of organotypic skin cultures (OTCs) 
OTCs were prepared as described by Berning et al. except for the number of fibroblasts and time of 
pre-cultivation of the dermal equivalents (Berning et al. 2015). In short, preparation was performed 
as follows: ThinCerts (0.4 µm, translucent, Greiner Bio-One) were kept in deep-well ThinCert 12-well 
cell culture plates (Greiner Bio-One) containing 5 ml FDM medium (Table 4.1). 0.33 Mio NHDFs in 0.5 
ml FDM medium were seeded dropwise into the culture inserts. This seeding step was repeated two 
times together with an overall exchange of FDM medium within the insert and the deep-well plate 
on the 2nd and 4th day after the 1st seeding. Dermal equivalents were allowed to mature for 3 weeks 
with an exchange of FDM medium (within deep-well plate and insert) every 2nd or 3rd day. Prior 
seeding of keratinocytes (NHEK, HaCaT or HaCaT-RAS A-5) medium was exchanged to rFAD medium 
(Table 4.1). 0.25 Mio singularized (cell strainer 70 µm) keratinocytes within 0.5 ml rFAD medium 
were seeded dropwise on top of the dermal equivalents. After 4-5 days of submersed cultivation the 
medium on top of the OTCs was removed to allow air-exposed growth and regeneration of the 
epidermis. Harvest and processing of OTCs is described in the section of the corresponding analysis 
methods. 
4.1.4. Stimulation of cultured keratinocytes and OTCs 
CsA (239835, Calbiochem) was dissolved in sterile DMSO at a stock concentration of 25 mg ml-1. 
Aliquots were prepared at room temperature and stored at -20°C. Thawed aliquots were used once 
and then discarded. Recombinant human CXCL14 (TP723048, OriGene) was dissolved in 20mM 
phosphate buffer, 100 mM NaCl, pH 7.2. Aliquots were stored at -20°C. Recombinant human DEFB4A 
(TP723032, OriGene) was dissolved in 20mM phosphate buffer, 100 mM NaCl, pH 7.2. Aliquots were 
stored at -20°C. Recombinant human IGFL1 (TP315281, Origene) was dissolved in 25mM Tris.HCL, pH 
7.3, 100mM glycine, 10% glycerol. Aliquots were stored at -20°C. 
Cells were stimulated with the stimulant or the corresponding amount of solvent. Stimulants and 
solvents were added to fresh culture medium and added to the cells (2D cultured cells) or to the well 
underneath the insert (OTCs). For long-term stimulation supplements were added with every culture 
medium exchange 3 times per week (Monday, Wednesday and Friday). As a standard treatment 10 
µg ml-1 CsA or as control 0.04% DMSO was used, if not stated differently. In case of OTCs, stimulation 
was started 1 week after the epithelial seeding. 
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4.1.5. UV irradiation of OTCs 
OTCs were irradiated prior to culture medium exchange 3 times per week (Monday, Wednesday and 
Friday). Old culture medium was removed and replaced by sterile PBS to prevent desiccation. OTCs 
were irradiated without cell culture lid for 3 min and 30 sec, corresponding to 5 J/cm2 UVA and 10 
mJ/cm2 UVB. Meanwhile control plates were kept in PBS outside the incubator. Afterwards PBS was 
removed and replaced by fresh culture medium containing respective stimulants. UV irradiation 
started together with the CsA treatment 1 week after epithelial seeding. The light source was a 
tanning lamp (HB 404, Philipps) with UV emission between 296nm and 380nm with a maximum at 
374nm. 
4.2. 2D cell culture analyses 
4.2.1. CellTiter-Blue® assay with cultured cells 
HaCaT keratinocytes were treated with CsA in conventional cultures (2D) and analyzed using the 
CellTiter-Blue® assay (Promega), which measures the metabolic activity of cells. HaCaT keratinocytes 
(35,000 per 100 µl per well, n=8) were seeded in flat-bottomed 96-well plates. Treatment started the 
next day. Cells were treated with increasing amounts of CsA (50 ng ml-1 - 100 µg ml-1) or the 
corresponding amount of its solvent DMSO for 72h. 20 µl resazurin (Promega) were added to the 
conditioned medium (100 µl) in each well and fluorescence resulting from resazurin metabolized into 
resorufin was measured after 1h in a standard cell culture incubator. Fluorescence was acquired 
using the fluorescence microplate reader infinite F200 PRO (Tecan). The fluorescence signal was 
detected by the following filter set (Ex = 550 nm, Em = 610nm) at 5 positions within each well. 
Results are presented as mean and the standard error of the mean. Data points were normalized to 
the mean of the lowest DMSO or CsA concentration, respectively. 
4.2.2. FACS-assisted apoptosis assay 
Cultured and stimulated cells were trypsinized and washed once with PBS (4°C) before transferal to 
the binding buffer (1 Mio cells per ml). Subsequent steps were performed according to 
manufacturer’s protocol (FITC Annexin V Apoptosis Detection Kit I, BD Pharmingen). Samples were 
acquired using the flow cytometer FACSCanto TT (BD). Compensation was performed with the BD 
FACSDiva Software and the data was analyzed using the software FlowJo. Data was presented as 
mean percentage of positive cells per total cell number. Per sample 3800 – 6000 single cells were 
analysed. 
4.2.3. Multiplex fluorescent in situ hybridization (M-FISH) 
M-FISH analyses were performed by Brigitte Schoell from Professor Anna Jauch’s group (Human 
Genetics, Heidelberg University Hospital). Highly proliferating cultured HaCaT cells were arrested 
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using colcemid (0.27 µg ml-1) for 4h at 37°C. Metaphase spreads were prepared and labeled 
according to (Speicher et al. 1996; Geigl et al. 2006). 30 metaphases were imaged and analyzed per 
treatment group. New chromosomal aberrations (translocations, deletions or insertions), which 
occurred only once and were not present in the control (DMSO-treated) cells, were counted. 
4.2.4. SYBR Green assay 
Cells (10,000 per well, n=4) were seeded in 24-well plates. Treatment with 0.25, 2.5 or 10 µg ml-1 CsA 
or the solvent DMSO (0.04%) was performed starting the following day. After 24h, 48h or 72h the 
medium was removed and sealed plates were stored at -20°C. Thawed plates were incubated with 
SYBR Green (1:2500 in 0.1% Triton/PBS) for 1h at room temperature protected from light. The 
readout was performed using a Fluoroskan Ascent (Thermo Fisher Scientific) at 485 nm. Cell numbers 
were determined with the help of a standard plate with defined numbers of cells, which was 
measured in parallel. Results are presented as mean and the standard error of the mean. Values from 
each CsA concentration or DMSO were normalized to the mean of the 24h value of CsA or of the 
corresponding DMSO concentration, respectively. 
4.3. 3D OTC analyses 
4.3.1. CsA quantification within OTCs 
OTCs were harvested 24h after the last treatment. OTCs were removed from the filter and washed 
with PBS to remove excess medium. The OTC was cut and one quarter was immersed in Dispase II (1 
mg ml-1 in PBS) for 1h at 37°C. Afterwards the dermal and epidermal parts were separated and 
separately frozen in liquid nitrogen. Prior to measurements samples were weighed and submersed in 
cell lysis solution (Promega). For lysis the samples were agitated (85 rpm) at 30°C for several hours 
and sonicated (2x 15 sec, 50% amplitude). Measurements were performed by Evelyn Jäger from 
Professor Peter Findeisen’s group (Institute for clinical chemistry, Mannheim). Samples were 
separated by high performance liquid chromatography (UltiMate3000, HPG-3200 RS, Dionex, Thermo 
Scientific) and analyzed by mass spectrometry using a ion trap (amaZonSpeed, Bruker). 
Quantification was done with the help of serial dilutions of CsA as a calibrator. Results were 
determined as µg per mg of tissue. Conversion into µg ml-1 was calculated according to Fisher et al. 
(Fisher et al. 1988). 
4.3.2. CellTiter-Blue® assay 
For the measurement of the metabolic activity of OTCs the CellTiter-Blue® (Promega) assay was used. 
Inserts containing the OTCs or OTCs removed from the insert and cut in halve were transferred to 
standard multi-well plates containing 840 µl conditioned medium and 160 µl resazurin (Promega). 
Fluorescence resulting from resazurin metabolized into resorufin was measured after 1h in a 
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standard cell culture incubator. For fluorescence measurements 100 µl of conditioned medium was 
transferred to a flat-bottomed 96-well plate. Fluorescence was acquired using the fluorescence 
microplate reader infinite F200 PRO (Tecan). The fluorescence signal was detected by the following 
filter set (Ex = 550 nm, Em = 610nm) at 5 positions within each well. Results are presented as mean 
and the standard error of the mean. Data points were normalized to the mean of the DMSO values 
from each time point. OTCs or parts of OTCs which were used for the CellTiter-Blue® assay were not 
used for subsequent RNA analysis. If further used for paraffin embedding, OTCs were washed in PBS 
for 1h. 
4.3.3. Measurement of transepithelial electrical resistance (TEER) 
TEER measurements were performed prior to harvest at non-sterile conditions. Inserts containing 
OTCs were shortly dipped in sterile PBS to remove excess medium and transferred to an Endohm 
chamber (World Precision Instruments, Sarasota, United States), filled with 4 ml sterile PBS. Care was 
taken that no air bubbles developed underneath the insert and the electrode in the bottom panel of 
the chamber. A sterile Teflon ring was put onto the middle of the OTC and sealed with sterile 
Vaseline. 200 µl sterile PBS was filled into the ring and the Endohm chamber lid was attached in a 
way that the top electrode within the lid contacted the PBS within the Teflon ring. The electrodes 
were then attached to an epithelial Voltohmmeter (Millicell ERS-2, Merck Millipore, Germany), which 
was set to Ohms. Power was applied and resistance was read off after 120 sec of measurement, to 
avoid early oscillation. The measurements were performed in collaboration with Dr Sabine 
Rosenberger (DKFZ). 
4.3.4. ELISA 
Conditioned media from DMSO- and CsA-treated OTCs was removed 24h after the last treatment and 
directly stored at -20°C until further usage. Samples were thawed on ice before ELISA measurements 
and then centrifuged (1 min, 3200 rpm) to remove particles. ELISAs were performed according to 
manufacturer’s protocol. Media was measured from three biological replicates in technical 
duplicates. Following ELISA kits (R&D Systems, Germany) were used: GM-CSF (DGM00), IL-1α 
(DLA50), pro-MMP1 (DMP100), MMP3 (DMP300) and pro-MMP10 (DM1000). Readouts were 
performed using the Multiskan FC Microplate Photometer (Thermo-Scientific) at 450 nm with 
background subtraction at 620 nm. Statistical significance was calculated by an unpaired, two-sided 
t-test. 
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4.3.5. H&E histological staining 
Sampling: OTCs were removed from the inserts, cut in halve or in one-third and transferred to 
stabilized formaldehyde-containing fixative (12004, Morphisto). Samples were kept in fixative for at 
least 24h. 
All succeeding steps were performed by Angelika Krischke (DKFZ) or Iris Martin (DKFZ): Samples were 
dehydrated by increasing ethanol solutions and transferred to xylene before paraffin embedding. 
Sections (7 µm) were cut with a microtome, placed onto microscope slides and dried for 48 h at 37°C. 
Slides were passed through deparaffinization, rehydration, H&E staining solution and dehydration 
steps according to manufacturer’s protocol (H&E kit, 12156, Morphisto). Ensuing sections were 
mounted in Eukitt (Sigma-Aldrich). 
4.3.6. Indirect immunofluorescent staining 
Sampling: OTCs were removed from the inserts, cut in halve or in one-third, mounted in Tissue Tek 
(Sakura Finetek) within a cryomold (Sakura Finetek), frozen at the gas phase of liquid nitrogen and 
stored at -80°C. Embedded samples were cut (6 µm) with a cryotome at -25°C (+/-1°C). Sections on 
microscope slides (Histobond, Marienfeld) were dried for 15 min at room temperature before storing 
at -80°C until further usage. Prior to IIF sections were fixed in methanol (5 min, 4°C) and consecutive 
acetone treatment (2 min, -20°C). Subsequently slides were immersed in 1% Triton/PBS+ (Serva 
Electrophoresis), followed by immersion in PBS+ and ddH2O and then slides were dried. Blocking of 
unspecific binding sites was done with 5% BSA/PBS+ for 30 min at room temperature. Primary 
antibodies (Table 4.3) were incubated in blocking solution overnight at 4°C. Before and after 
secondary antibody incubation, 1h at room temperature in blocking solution containing 2 µg ml-1 
DAPI (Sigma-Aldrich), slides were washed in 1% Triton/PBS+ (1x 5 min) and PBS+ (2x 5 min) and 
immersed in ddH2O. Sections were embedded in fluorescent mounting medium (DAKO). 
Modification from standard protocol: For LCE2 and LCE3 IIF stainings paraffin-embedded sections (6 
µm) on microscope slides (Histobond, Marienfeld) were used. After 24 h of drying at 37°C sections 
were deparaffinized (2x 3 min xylene, 3 min each 90%, 70% and 60% EtOH), rehydrated in ddH2O and 
then dried. All succeeding staining steps were performed as described in the previous passage 
starting with immersion into 1% Triton/PBS+. 
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Table 4.3 Primary antibodies 
Specificity Species Dilution Cat.-No. 
ColIV rabbit  1:100 10760 (Progen)
1
 
ColIV (1042.0) mouse  1:100 10710 (Progen)
1
 
ColVII (C805) mouse 1:500 077K4780 (Sigma-Aldrich)
2
 
FLG (FLG01) mouse 1:100 AM00245P (Acris)
3
 
ITGA6 (4F10) mouse 1:100 CBL458 (Merck Millipore)
4
 
ITGB1 (P4G11) mouse 1:100 MAB1951Z (Merck Millipore)
4
 
Ki67 rabbit 1:100 15580 (Abcam)
5
 
KRT10 (DE-K10) mouse 1:30 11414 (Progen)
1
 
LCE2 rabbit 1:1000 (Bergboer et al. 2011) 
LCE3 mouse 1:5000 (Niehues et al. 2015) 
PanKRT guinea pig 1:100 GP14 (Progen)
1
 
SPRR2 rabbit 1:100 AG-25B-0002 (AdipoGen)
6
 
1
Heidelberg, Germany; 
2
Steinheim, Germany; 
3
Herford, Germany; 
4
Darmstadt, Germany; 
5
Cambridge, United Kingdom; 
6
Liestal, Switzerland 
Table 4.4 Secondary antibodies 
Specificity Fluorophore Species Dilution Cat.-No. 
guinea pig IgG  Cy2 donkey 1:200 706-225-148 (Dianova)
1
 
mouse IgG  Cy3 donkey 1:200 715-166-151 (Dianova)
1
 
rabbit IgG Alexa488 donkey 1:200 711-546-152 (Dianova)
1
 
rabbit IgG Cy3 donkey 1:200 711-166-152 (Dianova)
1
 
1 
Hamburg, Germany    
4.3.7. Determination of the proliferation (Ki67) index 
For the proliferation index 2-3 sections from 2-3 OTC each were stained for Ki67 and ColIV as 
described in 4.3.6. Sections from one OTC were at least 70 µm apart. Pictures covering the full length 
were taken and merged using the ZEN2012 software (Zeiss). Ki67 positive cells throughout the 
epidermis were automatically counted using a macro in ImageJ (Table 4.5 ). The length of the 
basement membrane was as well measured in ImageJ according to the ColIV staining. Results are 
presented as Ki67+ cells per basement length. Significance was calculated with a two-sided, unpaired 
t-test. 
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Table 4.5 ImageJ macro for proliferation index 
roiManager ("Reset"); 
waitForUser ("Please select, when you finish click OK"); 
run ("Select None"); 
run ("Set Scale...", "distance=0 known=0 pixel=1 unit=pixel global"); 
setSlice (1); 
run ("Gaussian Blur...", "sigma=2 slice"); 
roiManager ("Deselect"); 
roiManager ("Combine"); 
roiManager ("Reset"); 
roiManager ("Add"); 
setAutoThreshold ("Triangle dark"); 
run ("Threshold..."); 
waitForUser ("Please check the Thresh. and Process - Find Max, when you finish 
click OK"); 
run ("Find Maxima...", "noise=(fill in) output=[Segmented Particles] above"); 
roiManager ("Select", 0); 
run ("Analyze Particles...", "size=50-Infinity summarize add"); 
close (); 
resetThreshold (); 
roiManager ("Show None"); 
roiManager ("Show All"); 
4.3.8. Gelatinase assay 
Unfixed cryo sections (6 µm, stored at -80°C) were incubated with the gelatinase buffer (50 µg ml-1 
DG-gelatin and 2 µg ml-1 DAPI) for 1h at room temperature protected from light. The buffer was 
prepared as described in the manufacturer’s protocol (EnzChek Gelatinase/Collagenase Assay Kit, Life 
Technologies). Afterwards, sections (not washed, nor fixed) were covered with a standard 
microscope cover slip and directly examined. For control and CsA-treated sections equal exposure 
times were set at the microscope. 
4.4. Gene expression analyses 
4.4.1. RNA Isolation 
For RNA isolation, OTCs were harvested 24h after the last medium exchange including DMSO or CsA 
treatment. 12 OTCs were harvested in one run. During harvesting OTCs remained in conditioned 
medium outside the incubator. OTCs were removed from the insert and cut into halve, one-third or 
one-quarter; edges were as well removed (Figure 4.1). 
 
Figure 4.1 OTC cut template for RNA isolation. 
Top view of an OTC, which was cut into halve (1/2), one-third (1/3) or one-quarter (1/4). Black lines: cutting 
edge. 
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The cut OTC sample was put back into conditioned medium until all OTCs were cut into appropriate 
samples. Afterwards all samples were transferred to 1 mg ml-1 Dispase II (Roche) in conditioned 
medium. After 1h at 37°C samples were all transferred back to conditioned medium without Dispase 
II. One after the other sample was separated into the dermal and epidermal compartment and 
transferred to 1 ml TRIzol Reagent (Life Technologies), frozen in liquid nitrogen and stored at -80°C. 
Alternatively samples were frozen without TRIzol reagent. TRIzol was then added to the sample after 
thawing prior to subsequent steps. In case separation of dermal and epidermal compartment was 
not necessary, samples were directly transferred to TRIzol without Dispase II treatment. 
Samples in TRIzol were homogenized with the help of the FastPrep (MP Biomedicals) and the 
addition of ceramic beads (1.4/2.8 mm, Precellys). Samples were mixed twice (30 sec at speed 6.0) 
and kept on ice in between. Afterwards samples were kept at room temperature and 0.2 ml 
chloroform were added and shaken vigorously for 15 sec by hand. Samples were then left standing at 
room temperature for 3 min. Samples were spun for 15 min (11,500 rpm) at 4°C. After centrifugation 
3 phases were visible. The upper aqueous phase was transferred to a fresh tube and 500 µl of 
isopropyl alcohol were added per 600 µl aqueous phase for RNA precipitation. Samples were mixed 
and incubated for 10 min at room temperature. Afterwards samples were spun for 10 min (11,500 
rpm) at 4°C, the supernatant was removed and the pellet was washed with 1ml 75% ethanol. After 
one more centrifugation (10 min, 9,200 rpm, 4°C) the ethanol was removed and the pellet dried for 
10 min at room temperature. The dried pellet was dissolved in RNase-free H2O and the concentration 
was measured with a NanoDrop (Thermo Scientific). 
4.4.2. Reverse transcription 
RNA was transcribed to cDNA using the RevertAid H Minus First Strand cDNA Synthesis Kit (Thermo 
Scientific) according to the manufacturers protocol; oligo (dt)18 primers were used. cDNA was directly 
used or stored at 4°C for short time storage. 
4.4.3. Quantitative RT-PCR 
Quantification of RNA was done using the Universal Probe Library system from Roche. 
Measurements were done in technical duplicates in 96-well plates with the LightCycler480 
Instrument II (Roche). Reactions were mixed according to the manufacturer’s protocol (0.4 µM 
forward and reverse primer, 0.1 µM UPL probe, the LightCycler 480 MasterMix and 50 ng cDNA). The 
primers (Table 4.6) were designed using the ‘Universal ProbeLibrary Assay Design Center’ (Roche) 
with the standard settings, including the parameter ‘intron spanning’. Following settings were used 
for amplification: Pre-incubation (10 min, 95°C), 45 cycles (10 sec 95°C [ramp rate 4.4°C/sec], 30 sec 
60°C [ramp rate 2.2°C/sec] and 1 sec 72°C [ramp rate 4.4°C/sec]). Fluorescence measurements were 
MATERIALS AND METHODS 
 
87 
 
done after each cycle. The crossing point (CP) was obtained by the ‘Second Derivative Maximum 
Method’ (LightCylcer 480 Software, Roche). 
Fold changes from one experiment were calculated according to (Pfaffl 2001) considering the 
efficiencies of the primers (Table 4.6). RNA samples from one experiment were compared to the 
mean CP value of all control (solvent) replicates from that experiment (Figure 4.2). Fold changes 
were calculated for all control samples (controlmean vs. controlindividual) and stimulant samples 
(controlmean vs. stimulantindividual). Calculations were done with samples from one cell culture 
experiment. Nevertheless, results from different cell culture experiments are presented together in 
one graph if stated in the legend. Data is presented as mean and the standard error of the mean. 
E (gene of interest)[meanCP (control)−CP (sample of interest)]
E (GAPDH)[meanCP (control)−CP (sample of interest)]
 
Figure 4.2 Equation for fold change calculations from qRT-PCR. 
E: Efficiency. CP: crossing point. Control: OTC treated with respective solvent. Sample of interest: RNA samples 
from OTCs treated with DMSO, PBS, CsA, UV, UV+CsA, CXCL14, DEFB4B or IGFL1. 
Table 4.6 qRT-PCR primer 
Gene name Forward primer Reverse primer Probe  Efficiencies 
ATF3 cgtgagtcctcggtgctc gcctgggtgttgaagcat #1 1.985 
ATF4 ccagcgacaaggctaagg tctccaacatccaatctgtcc #76 1.912 
ATF5 gctcccaccttctttcttcag caaggcgaaagtggaagact #70 2 
CRNN caactgcacagcgctcac tccacagttgctggatcgt #24 1.949 
CSF2 tctcagaaatgtttgacctcca gcccttgagcttggtgag #1 2 
CXCL14 acgtgaagaagctggaaatga tgacctcggtacctggacac #9 2 
DEFB4A tcagccatgagggtcttgta ggatcgcctataccaccaaa #35 1.948 
EGF catccattggcaaaaccag aacaccaagcagttccaagc #75 2 
ELF3 ttggtactgaccctgagcaa ttggtagctgatccagtccag #45 1.915 
FGF7 aagggacccaagagatgaaga cctttgattgccacaattcc #59 1.93 
FLG ggactctgagaggcgatctg tgctcccgagaagatccat #38 1.958 
GAPDH agccacatcgctcagacac gcccaatacgaccaaatcc #60 1.948 
HGF cagcatgtcctcctgcatc tcttttcctttgtccctctgc #15 1.87 
IGFL1 ggctgcatcgtagctgtctt gcacagcatcaggtaaggagt #80 1.944 
KRT10 atgagctgaccctgaccaag cagtggacacatttcgaagg #80 1.923 
LCE1B ctgctgtggaggagggagt tttggccatttgtgttcttct #75 2 
LCE2A ggagaaacttgcaaccagga tgtgtcagcccaaggaaag #2 2 
LCE3A cagcagaaccagcagcagt ggaagctggaggcagacac #75 2 
MMP1 gctaacctttgatgctataactacga tttgtgcgcatgtagaatctg #7 1.62 
MMP3 cagtttgctcagcctatcca tcacatctttttcgaggtcgt #58 1.9 
MMP10 gtgctgttgtgtctgccagt tcacatccttttcgaggttgta #13 2 
SPRR2B tgctgcccaactcctaaact tgcactgctgctgttgataa #67 2 
4.4.4. Whole genome RNA expression profiles 
Whole genome RNA expression profiling was done from three samples per condition. In order to get 
very pure samples, RNA isolated by TRIzol was additional processed using the RNeasy Mini kit 
(Qiagen) according to the manufacturer’s protocol ‘RNA Cleanup’ including the DNase steps. 
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Subsequent cDNA synthesis, labeling, hybridization and image acquisition was performed by the 
DKFZ Genomics and Proteomics Core Facility. The following Chip was used: Illumina HumanHT-12 v 
4.0 Expression BeadChip. 
4.4.5. Analysis of whole genome RNA expression profiles 
4.4.5.1. Chipster 
Raw gene expression data was analyzed with the open source software Chipster 3.8.1 
(http://chipster.csc.fi/). If not stated otherwise, standard settings were applied. For normalization 
the Illumina function was used with the following settings: normalization method (quantile), Illumina 
software version (GenomeStudio or BeadStudio 3), Chip type (Human-HT12v4), Identifier type 
(ProbeID). Subsequently, the data was preprocessed by ‘Remove missing values’. Finally, differential 
gene expression was determined by ‘Two groups tests’ with the following settings: Test (empirical 
Bayes), p-value adjustment method (BH), p-value threshold (0.01). 
Non-metric multidimensional scaling (NMDS) and visualization of hierarchical clustering (dendrogram 
based on Pearson correlation and average linking method) were performed from normalized data. 
4.4.5.2. Ingenuity® Pathway Analysis (IPA) 
If not stated otherwise, standard settings were applied. Data sets with differentially expressed genes 
created with Chipster were imported into IPA®. Data sets were analyzed using the ‘Core Analysis’ 
using ‘HumanHT-12 v 4.0’ as reference gene set. With the function ‘Comparison Analysis’ different 
data sets were compared to each other. 
4.4.5.3. Heat maps of ‘epidermal development’ genes 
Data sets of differentially expressed genes were filtered by the GO-term (GO-0008544) ‘epidermal 
development’ using Chipster. These filtered data sets were imported to IPA. Using the function 
’Compare’ the gene sets were aligned and sorted. Afterwards the data sets were exported to Excel. 
The heat maps were created by Lars-Lennart Oettl (ZI Mannheim) using MATLAB (The MAthWorks). 
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6. ABBREVIATIONS 
  
µm Micrometre 
ATF3 Activating transcription factor 3 
ATF4 Activating transcription factor 4 
ATF5 Activating transcription factor 5 
BCC Basal cell carcinoma 
BSA Bovine serum albumin 
CDKN2A Cyclin dependent kinase inhibitor 2A 
cm Centimetre 
CO2 Carbon dioxide 
ColIV Collagen type IV 
ColVII Collagen type VII 
CRNN Cornulin 
CsA Cyclosporine A 
cSCC Cutaneous squamous cell carcinoma 
CSF2 Colony stimulating factor 2 
CXCL14 C-X-C motif chemokine ligand 14 
ddH2O Double distilled water 
DEFB4A Defensin, beta 4A 
DMEM  Dulbecco's modified eagle's medium 
EGF Epidermal growth factor 
ELF3 E74 like ETS transcription factor 3 
EtOH Ethanol 
FAT1 FAT atypical cadherin 1 
FGF7 Fibroblast growth factor 7  
FLG Filaggrin 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GM-CSF Granulocyte-macrophage colony-stimulating factor  
HaCaT Human adult Calcium Temperature 
H&E Haematoxylin & eosin 
HGF Hepatocyte growth factor 
HRAS Hras proto-oncogene, GTpase 
IGFL1 IGF-like family member 1 
IL-1α Interleukin-1α 
IPA Ingenuity pathway analysis 
ITGA6 Integrin subunit alpha 6 
ITGB1 Integrin subunit beta 3 
KGF Keratinocyte growth factor 
KRT10 Keratin 10 
LCE1B Late cornified envelope 1B 
LCE2 Late cornified envelope 2 
LCE2A Late cornified envelope 2A 
LCE3 Late cornified envelope 3 
LCE3A Late cornified envelope 3A 
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LCE3E Late cornified envelope 3E 
min Minutes 
Mio Million 
ml Millilitre 
MMP1 Matrix metallopeptidase 1 
MMP3 Matrix metallopeptidase 3 
MMP10 Matrix metallopeptidase 10 
MYC V-myc avian myelocytomatosis viral oncogene 
homolog 
N2 Nitrogen 
NHDF Normal human dermal fibroblasts 
NHEK Normal human epidermal keratinocytes  
NMDS Non-metric multidimensional scaling  
O2 Oxygen 
OTC Organotypic culture 
OTK Organotypische Kultur 
OTR Organ transplant recipient 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
qRT-PCR Quantitative reverse transcription PCR 
RCAN1 Regulator of calcineurin 1 
RNA Ribonucleic acid 
SPRR2B Small proline-rich protein 2B 
TEER Transepithelial electrical resistance 
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7. APPENDIX 
Table 7.1 List of 20 TOP up- and down-regulated genes from a genome wide RNA expression profile from 
HaCaT epithelia (DMSO vs. CsA)
1
 
TOP 20 Up-regulated Genes TOP 20 Down-regulated Genes 
Symbol Gene Name p-value2 Fold 
Change3 
Symbol Gene Name p-value2 Fold 
Change
3 
LCE3A late cornified 
envelope 3A 
0 3.0 CRNN cornulin 0 -4.8 
DEFB4A defensin, beta 4A 0 2.8 KRT13 keratin 13 1.0E-06 -3.6 
LCE3E late cornified 
envelope 3E 
0 2.6 RCAN1 regulator of 
calcineurin 1 
0 -3.5 
CDSN corneodesmosin 5.0E-06 2.3 NR4A2 nuclear receptor 
subfamily 4, 
group A, 
member 2 
0 -3.4 
CPA4 carboxypeptidase 
A4 
0 2.2 CCL2 chemokine (C-C 
motif) ligand 2 
3.0E-06 -2.9 
EMP3 epithelial 
membrane 
protein 3 
0 2.1 NR4A2 nuclear receptor 
subfamily 4, 
group A, 
member 2 
0 -2.9 
IGFL1 IGF-like family 
member 1 
0 2.1 STC1 stanniocalcin 1 0 -2.8 
LCE3D late cornified 
envelope 3D 
2.0E-06 2.1 SLC2A3 solute carrier 
family 2 
(facilitated 
glucose 
transporter), 
member 3 
0 -2.7 
LY6D lymphocyte 
antigen 6 
complex, locus D 
0 2.1 OLFM4 olfactomedin 4 0 -2.6 
SPRR2B small proline-rich 
protein 2B 
0 2.0 CES1 carboxylesterase 
1 
0 -2.5 
FADS1 fatty acid 
desaturase 1 
0 1.9 TMPRSS11
D 
transmembrane 
protease, serine 
11D 
0 -2.5 
GPSM1 G-protein 
signaling 
modulator 1 
2.0E-05 1.9 MAL mal, T-cell 
differentiation 
protein 
2.0E-06 -2.5 
IL36G interleukin 36, 
gamma 
5.0E-06 1.9 PLIN2 perilipin 2 0 -2.3 
PRODH proline 
dehydrogenase 
(oxidase) 1 
0 1.8 DIO2 deiodinase, 
iodothyronine, 
type II 
1.0E-06 -2.1 
MYAD
M 
myeloid-
associated 
differentiation 
marker 
3.3E-05 1.8 HES1 hairy and 
enhancer of split 
1, (Drosophila) 
1.0E-06 -2.0 
GRHL3 grainyhead-like 3 1.0E-06 1.8 UBE2C ubiquitin- 6.0E-06 -2.0 
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(Drosophila) conjugating 
enzyme E2C 
CRCT1 cysteine-rich C-
terminal 1 
1.0E-06 1.7 SFTPD surfactant 
protein D 
4.0E-06 -2.0 
GSDMA gasdermin A 7.8E-04 1.7 KRT4 keratin 4 2.0E-06 -1.9 
EDN1 endothelin 1 2.1E-04 1.7 IFI27 interferon, 
alpha-inducible 
protein 27 
3.0E-05 -1.9 
PTGS2 prostaglandin-
endoperoxide 
synthase 2 
(prostaglandin 
G/H synthase and 
cyclooxygenase) 
4.1E-05 1.7 CD70 CD70 molecule 0 -1.9 
1OTCs were treated for 2 weeks 
2 0 = p-value ≤ 0.000001  
3 fold changes were calculated with Chipster. The table shows numbers recalculated from log2. Values below 1 (negative fold changes) 
were converted by the following formula: fold change= –(1/x).  
Underlined gene symbols: part of the GO-term: GO-0008544 (‘epidermal development’). 
APPENDIX 
 
105 
 
Table 7.2 List of 20 TOP up- and down-regulated genes from a genome wide RNA expression profile from 
HaCaT-RAS A-5 epithelia (DMSO vs. CsA)
1
 
TOP 20 Up-regulated Genes TOP 20 Down-regulated Genes 
Symbol Gene Name p-value2 Fold 
Change3 
Symbol Gene Name p-value2 Fold 
Change
3 
SPRR2G small proline-rich 
protein 2G 
1.4E-04 8.5 SCGB1A1 secretoglobin, 
family 1A, 
member 1 
(uteroglobin) 
0 -17.9 
LCE3D late cornified 
envelope 3D 
9.8E-05 6.2 RARRES3 retinoic acid 
receptor 
responder 
(tazarotene 
induced) 3 
2.0E-06 -5.1 
AADACL2 arylacetamide 
deacetylase-like 
2 
9.0E-06 5.8 CEACAM
1 
carcinoembryoni
c antigen-related 
cell adhesion 
molecule 1 
(biliary 
glycoprotein) 
2.0E-06 -4.5 
LCE2B late cornified 
envelope 2B 
3.9E-05 5.6 KRT24 keratin 24 1.0E-06 -4.3 
LCE2D late cornified 
envelope 2D 
5.2E-05 5.6 CEACAM
5 
carcinoembryoni
c antigen-related 
cell adhesion 
molecule 5 
8.0E-06 -4.1 
SPRR2B small proline-rich 
protein 2B 
6.7E-04 5.6 MAL mal, T-cell 
differentiation 
protein 
2.9E-03 -4.1 
SBSN suprabasin 1.7E-05 5.4 MUC4 mucin 4, cell 
surface 
associated 
0 -4.1 
SPRR2C small proline-rich 
protein 2C 
(pseudogene) 
3.2E-04 5.3 GABRP gamma-
aminobutyric 
acid (GABA) A 
receptor, pi 
1.0E-06 -4.1 
ASPRV1 aspartic 
peptidase, 
retroviral-like 1 
5.4E-05 5.2 MUC20 mucin 20, cell 
surface 
associated 
6.0E-06 -4.0 
DSG1 desmoglein 1 1.7E-05 4.9 CAPN13 calpain 13 0 -3.9 
LCE2A late cornified 
envelope 2A 
1.3E-04 4.4 IGFBP3 insulin-like 
growth factor 
binding protein 3 
0 -3.7 
KPRP keratinocyte 
proline-rich 
protein 
2.8E-04 4.4 KYNU kynureninase 0 -3.7 
SERPINA1
2 
serpin peptidase 
inhibitor, clade A 
(alpha-1 
antiproteinase, 
antitrypsin), 
member 12 
1.5E-04 4.2 FOXA1 forkhead box A1 3.4E-05 -3.7 
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CDSN corneodesmosin 4.8E-04 4.2 ELF3 E74-like factor 3 
(ets domain 
transcription 
factor, epithelial-
specific ) 
0 -3.6 
SPRR2E small proline-rich 
protein 2E 
5.2E-05 4.1 IGFBP3 insulin-like 
growth factor 
binding protein 3 
0 -3.5 
LCE1B late cornified 
envelope 1B 
4.3E-05 4.1 MDK midkine (neurite 
growth-
promoting factor 
2) 
6.0E-06 -3.5 
LCE6A late cornified 
envelope 6A 
1.8E-04 3.9 ALOX5 arachidonate 5-
lipoxygenase 
1.0E-06 -3.4 
FLG filaggrin 2.5E-04 3.8 MAL mal, T-cell 
differentiation 
protein 
7.0E-04 -3.4 
ALOX12B arachidonate 12-
lipoxygenase, 
12R type 
1.3E-04 3.8 ADIRF adipogenesis 
regulatory factor 
7.1E-05 -3.2 
LCE2C late cornified 
envelope 2C 
3.5E-04 3.7 STC1 stanniocalcin 1 0 -3.1 
1 OTCs were treated for 3 weeks 
2 0 = p-value ≤ 0.000001  
3 fold changes were calculated with Chipster. The table shows numbers recalculated from log2. Values below 1 (negative fold changes) 
were converted by the following formula: fold change= –(1/x). 
Underlined gene symbols: part of the GO-term: GO-0008544 (‘epidermal development’). 
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Table 7.3 Genes differentially expressed in HaCaT and HaCaT-RAS A-5 epithelia [taken from genome wide 
RNA expression profiles (DMSO vs. CsA)]
1
 
  HaCaT HaCaT-RAS A-5   
        
Symbol Entrez Gene Name p-value
2
 Fold 
change 
(log2) 
 
p-value
2
 Fold 
change 
(log2) 
Location Type(s) 
DEFB4A/DEFB4B3 defensin beta 4A 0 1.48 0.016 1.207 Extracellular 
Space 
other 
XK X-linked Kx blood group 0 1.47 0 -2.717 Plasma 
Membrane 
transporter 
LCE3E late cornified envelope 3E 0 1.397 0.002 1.533 Other other 
CDSN corneodesmosin 0 1.213 0 2.063 Plasma 
Membrane 
other 
CPA4 carboxypeptidase A4 0 1.157 0 1.613 Extracellular 
Space 
peptidase 
IGFL13 IGF like family member 1 0 1.093 0 1.29 Extracellular 
Space 
other 
LCE3D late cornified envelope 3D 0 1.093 0 2.627 Other other 
SPRR2B small proline rich protein 
2B 
0 0.987 0.001 2.48 Cytoplasm other 
GPSM1 G-protein signaling 
modulator 1 
0 0.927 0.016 0.707 Cytoplasm other 
LOC102724788/PROD
H 
proline dehydrogenase 1 0 0.87 0 0.667 Cytoplasm enzyme 
CRCT1 cysteine rich C-terminal 1 0 0.787 0 1.703 Other other 
GSDMA gasdermin A 0.001 0.777 0.003 0.917 Cytoplasm other 
CXCL143 C-X-C motif chemokine 
ligand 14 
0 0.747 0 1.783 Extracellular 
Space 
cytokine 
SPRR2C small proline rich protein 
2C (pseudogene) 
0 0.73 0 2.397 Cytoplasm other 
CST6 cystatin E/M 0 0.713 0 1.207 Extracellular 
Space 
other 
SLC5A1 solute carrier family 5 
member 1 
0 0.707 0.005 0.757 Plasma 
Membrane 
transporter 
ELOVL4 ELOVL fatty acid elongase 4 0 0.7 0 1.733 Cytoplasm enzyme 
CDH16 cadherin 16 0 0.687 0 1.27 Plasma 
Membrane 
enzyme 
LCE2C/LCE2D late cornified envelope 2D 0 0.677 0 2.483 Other other 
CLCF1 cardiotrophin-like cytokine 
factor 1 
0 0.633 0.003 0.85 Extracellular 
Space 
cytokine 
LCE2B late cornified envelope 2B 0.001 0.613 0 2.497 Other other 
LCE6A late cornified envelope 6A 0.004 0.607 0 1.947 Other other 
KPRP keratinocyte proline rich 
protein 
0.001 0.603 0 2.137 Cytoplasm other 
PSORS1C2 psoriasis susceptibility 1 
candidate 2 
0.002 0.603 0 1.327 Extracellular 
Space 
other 
IGFL2 IGF like family member 2 0 -0.623 0 1.507 Other other 
C17orf53 chromosome 17 open 
reading frame 53 
0 -0.637 0.007 -0.63 Other other 
PHLDA1 pleckstrin homology like 
domain family A member 1 
0 -0.64 0 -1.093 Cytoplasm other 
ELF3 E74 like ETS transcription 
factor 3 
0.001 -0.64 0 -1.843 Nucleus transcriptio
n regulator 
SLC16A3 solute carrier family 16 
member 3 
0 -0.647 0 -0.887 Plasma 
Membrane 
transporter 
FGG fibrinogen gamma chain 0 -0.65 0 1.17 Extracellular 
Space 
other 
PRC1 protein regulator of 
cytokinesis 1 
0 -0.66 0 -0.663 Nucleus other 
TSPAN6 tetraspanin 6 0 -0.687 0.006 -0.837 Plasma 
Membrane 
other 
CEACAM5 carcinoembryonic antigen 
related cell adhesion 
molecule 5 
0 -0.693 0 -2.04 Plasma 
Membrane 
other 
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CEACAM1 carcinoembryonic antigen 
related cell adhesion 
molecule 1 
0 -0.703 0 -2.16 Plasma 
Membrane 
other 
PHGR1 proline/histidine/glycine-
rich 1 
0 -0.74 0 -0.96 Other other 
PPP1R1B protein phosphatase 1 
regulatory inhibitor subunit 
1B 
0 -0.743 0.001 -0.737 Cytoplasm phosphatas
e 
TOP2A topoisomerase (DNA) II 
alpha 
0 -0.75 0 -0.977 Nucleus enzyme 
CAPN5 calpain 5 0 -0.763 0 -1.27 Cytoplasm peptidase 
CXCL2 C-X-C motif chemokine 
ligand 2 
0.001 -0.793 0.007 0.647 Extracellular 
Space 
cytokine 
AOC1 amine oxidase. copper 
containing 1 
0 -0.8 0.004 -1.367 Extracellular 
Space 
enzyme 
MDK midkine (neurite growth-
promoting factor 2) 
0 -0.843 0 -1.8 Extracellular 
Space 
growth 
factor 
HILPDA hypoxia inducible lipid 
droplet associated 
0 -0.85 0 -1.157 Cytoplasm other 
CDCA5 cell division cycle 
associated 5 
0 -0.86 0 -0.717 Cytoplasm other 
SPRR3 small proline rich protein 3 0 -0.867 0.047 -0.923 Cytoplasm other 
CCNB2 cyclin B2 0 -0.883 0.001 -0.703 Cytoplasm other 
HIST1H4C histone cluster 1. H4c 0 -0.907 0 -0.64 Nucleus other 
FOXQ1 forkhead box Q1 0 -0.93 0.002 -1.187 Nucleus transcriptio
n regulator 
IFI27 interferon alpha inducible 
protein 27 
0 -0.96 0 -1.55 Cytoplasm other 
KRT4 keratin 4 0 -0.963 0.001 -1.347 Cytoplasm other 
UBE2C ubiquitin conjugating 
enzyme E2 C 
0 -0.987 0.001 -0.81 Cytoplasm enzyme 
PLIN2 perilipin 2 0 -1.197 0 -0.687 Plasma 
Membrane 
other 
MAL mal T-cell differentiation 
protein 
0 -1.307 0.003 -2.04 Plasma 
Membrane 
transporter 
OLFM4 olfactomedin 4 0 -1.38 0 -0.793 Extracellular 
Space 
other 
STC1 stanniocalcin 1 0 -1.487 0 -1.623 Extracellular 
Space 
kinase 
CCL2 C-C motif chemokine ligand 
2 
0 -1.557 0 1.043 Extracellular 
Space 
cytokine 
KRT13 keratin 13 0 -1.847 0.022 -0.873 Cytoplasm other 
CRNN cornulin 0 -2.273 0.015 -1.01 Cytoplasm other 
1 the rows of the table are sorted by the fold change of HaCaT 
2 0 = p-value ≤ 0.000001  
3 candidate genes for validation and stimulation experiments 
 
    
APPENDIX 
 
109 
 
Table 7.4 List of 20 TOP up- and down-regulated genes from a genome wide RNA expression profile from 
HaCaT-OLD epithelia (DMSO vs. CsA treatment)
1
 
TOP 20 Up-regulated Genes TOP 20 Down-regulated Genes 
Symbol Gene Name p-value
2
 Fold 
Change
3
 
Symbol Gene Name p-value
2
 Fold 
Change
3
 
DHRS9 dehydrogenase/reductase 
(SDR family) member 9 
0 2.8 IFI27 interferon, alpha-
inducible protein 27 
0 -3.2 
PTGS2 prostaglandin-
endoperoxide synthase 2 
(prostaglandin G/H 
synthase and 
cyclooxygenase) 
0 2.5 TCN1 transcobalamin I 
(vitamin B12 binding 
protein, R binder 
family) 
1.0E-06 -2.9 
DHRS9 dehydrogenase/reductase 
(SDR family) member 9 
0 2.4 ALDH3A1 aldehyde 
dehydrogenase 3 
family, member A1 
0 -2.8 
IL1RL1 interleukin 1 receptor-like 
1 
0 2.3 KRT2 keratin 2 0 -2.8 
EMP3 epithelial membrane 
protein 3 
0 2.2 SPRR3 small proline-rich 
protein 3 
0 -2.6 
THBS1 thrombospondin 1 0 2.1 S100A7A S100 calcium binding 
protein A7A 
0 -2.5 
LEPREL1 leprecan-like 1 0 2.0 HTR3A 5-hydroxytryptamine 
(serotonin) receptor 
3A, ionotropic 
0 -2.5 
MYADM myeloid-associated 
differentiation marker 
3.0E-06 2.0 S100P S100 calcium binding 
protein P 
0 -2.4 
TNC tenascin C 2.0E-06 2.0 HRNR hornerin 2.4E-03 -2.4 
RGCC regulator of cell cycle 0 1.9 DEFB1 defensin, beta 1 1.0E-06 -2.3 
CLCF1 cardiotrophin-like 
cytokine factor 1 
0 1.9 CD36 CD36 molecule 
(thrombospondin 
receptor) 
4.0E-06 -2.3 
PTGS2 prostaglandin-
endoperoxide synthase 2 
(prostaglandin G/H 
synthase and 
cyclooxygenase) 
2.3E-05 1.9 GCNT3 glucosaminyl (N-acetyl) 
transferase 3, mucin 
type 
0 -2.2 
CREB3L2 cAMP responsive element 
binding protein 3-like 2 
0 1.9 SERPINB4 serpin peptidase 
inhibitor, clade B 
(ovalbumin), member 4 
0 -2.1 
FBN2 fibrillin 2 5.0E-06 1.8 TMPRSS11
D 
transmembrane 
protease, serine 11D 
0 -2.1 
EDN1 endothelin 1 2.1E-05 1.8 IFIT2 interferon-induced 
protein with 
tetratricopeptide 
repeats 2 
0 -2.1 
GPSM1 G-protein signaling 
modulator 1 
1.0E-06 1.8 AKR1B10 aldo-keto reductase 
family 1, member B10 
(aldose reductase) 
0 -2.1 
FOS FBJ murine osteosarcoma 
viral oncogene homolog 
0 1.8 LOR loricrin 1.6E-05 -2.0 
PHACTR3 phosphatase and actin 
regulator 3 
3.0E-06 1.8 GBP2 guanylate binding 
protein 2, interferon-
inducible 
0 -2.0 
LCE3E late cornified envelope 3E 1.3E-05 1.8 GPNMB glycoprotein 
(transmembrane) nmb 
0 -2.0 
MYADM myeloid-associated 
differentiation marker 
1.0E-06 1.8 CRNN cornulin 0 -2.0 
1 OTCs were treated for 4 weeks 
2 0 = p-value ≤ 0.000001  
3 fold changes were calculated with Chipster. The table shows numbers recalculated from log2. Values below 1 (negative fold changes) 
were converted by the following formula: fold change= –(1/x). Underlined gene symbols: part of the GO-term: GO-0008544. 
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Table 7.5 List of 20 TOP up- and down-regulated genes from a genome wide RNA expression profile from 
HaCaT epithelia (DMSO vs. UV+CsA)
1
 
TOP 20 Up-regulated Genes TOP 20 Down-regulated Genes 
Symbol Gene Name p-
value
2
 
Fold 
Change
3
 
Symbol Gene Name p-value
2
 Fold 
Change
3
 
MYADM myeloid-associated 
differentiation marker 
0 3.2 KRT13 keratin 13 0 -10.3 
DEFB4A defensin, beta 4A 0 2.6 CRNN cornulin 0 -7.4 
CDSN corneodesmosin 1.0E-06 2.4 MAL mal, T-cell 
differentiation protein 
0 -6.4 
DSC1 desmocollin 1 4.0E-05 2.4 CCL2 chemokine (C-C motif) 
ligand 2 
0 -6.3 
CXCL14 chemokine (C-X-C motif) ligand 
14 
3.0E-06 2.4 OLFM4 olfactomedin 4 0 -5.7 
SPRR2B small proline-rich protein 2B 0 2.3 STC1 stanniocalcin 1 0 -5.6 
LCE3E late cornified envelope 3E 0 2.3 KRT4 keratin 4 0 -5.6 
TYMP thymidine phosphorylase 0 2.1 CES1 carboxylesterase 1 0 -5.0 
COL17A1 collagen, type XVII, alpha 1 5.0E-06 2.1 HTR3A 5-hydroxytryptamine 
(serotonin) receptor 3A, 
ionotropic 
0 -4.7 
EMP3 epithelial membrane protein 3 0 2.1 SPINK7 serine peptidase 
inhibitor, Kazal type 7 
(putative) 
0 -3.9 
IL36G interleukin 36, gamma 0 2.1 NR4A2 nuclear receptor 
subfamily 4, group A, 
member 2 
0 -3.9 
GPSM1 G-protein signaling modulator 
1 
1.0E-06 2.1 MAL mal, T-cell 
differentiation protein 
0 -3.8 
CPA4 carboxypeptidase A4 0 2.0 TMPRSS11
D 
transmembrane 
protease, serine 11D 
0 -3.8 
PFKFB4 6-phosphofructo-2-
kinase/fructose-2,6-
biphosphatase 4 
1.0E-06 2.0 CD36 CD36 molecule 
(thrombospondin 
receptor) 
0 -3.7 
PTGS2 prostaglandin-endoperoxide 
synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase) 
0 2.0 DIO2 deiodinase, 
iodothyronine, type II 
0 -3.6 
IGFL1 IGF-like family member 1 1.0E-06 2.0 ID1 inhibitor of DNA binding 
1, dominant negative 
helix-loop-helix protein 
0 -3.3 
DSC1 desmocollin 1 2.8E-04 2.0 SFTPD surfactant protein D 0 -3.2 
RGS20 regulator of G-protein signaling 
20 
0 2.0 GCNT3 glucosaminyl (N-acetyl) 
transferase 3, mucin 
type 
0 -3.1 
LAMC2 laminin, gamma 2 0 1.9 SLC2A3 solute carrier family 2 
(facilitated glucose 
transporter), member 3 
1.0E-06 -3.1 
LCE3A late cornified envelope 3A 3.1E-05 1.9 VS.IG8 V-set and 
immunoglobulin 
domain containing 8 
0 -3.0 
1 OTCs were treated for 2 weeks 
2 0 = p-value ≤ 0.000001  
3 fold changes were calculated with Chipster. The table shows numbers recalculated from log2. Values below 1 (negative fold changes) 
were converted by the following formula: fold change= –(1/x). 
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Table 7.6 List of 20 TOP up- and down-regulated genes from a genome wide RNA expression profile from 
HaCaT-RAS A-5 epithelia (DMSO vs. UV+CsA)
1
 
TOP 20 Up-regulated Genes TOP 20 Down-regulated Genes 
Symbol Gene Name p-value
2
 Fold 
Change
3
 
Symbol Gene Name p-value
2
 Fold 
Change
3
 
DSC1 desmocollin 1 0 26.2 KRT13 keratin 13 0 -82.9 
DEFB4A defensin, beta 4A 0 20.3 MAL mal, T-cell 
differentiation protein 
0 -40.9 
SPRR2B small proline-rich protein 2B 0 18.9 SCGB1A1 secretoglobin, family 
1A, member 1 
(uteroglobin) 
0 -33.8 
SPRR2G small proline-rich protein 2G 0 16.0 NA NA 0 -30.0 
SPRR2C small proline-rich protein 2C 
(pseudogene) 
0 15.3 KRT4 keratin 4 0 -21.7 
KRT2 keratin 2 0 15.0 SPRR3 small proline-rich 
protein 3 
0 -15.8 
SERPINA12 serpin peptidase inhibitor, 
clade A (alpha-1 
antiproteinase, antitrypsin), 
member 12 
0 14.4 ADIRF adipogenesis regulatory 
factor 
0 -15.2 
DSG1 desmoglein 1 0 13.3 AOC1 amine oxidase, copper 
containing 1 
0 -11.5 
AADACL2 arylacetamide deacetylase-
like 2 
0 12.2 CLDN8 claudin 8 0 -11.4 
CDSN corneodesmosin 0 11.5 CEACAM1 carcinoembryonic 
antigen-related cell 
adhesion molecule 1 
(biliary glycoprotein) 
0 -10.5 
LCE3D late cornified envelope 3D 0 8.0 ELF3 E74-like factor 3 (ets 
domain transcription 
factor, epithelial-
specific ) 
0 -10.4 
SBSN suprabasin 0 7.9 MAL mal, T-cell 
differentiation protein 
0 -10.0 
KRT3 keratin 3 0 7.9 HIST1H4C histone cluster 1, H4c 0 -9.9 
ELOVL4 ELOVL fatty acid elongase 4 0 6.2 KRT15 keratin 15 0 -9.3 
ALOX12B arachidonate 12-
lipoxygenase, 12R type 
0 6.1 S100A4 S100 calcium binding 
protein A4 
0 -9.3 
HRNR hornerin 0 6.0 S100P S100 calcium binding 
protein P 
0 -9.2 
SPRR2E small proline-rich protein 2E 0 6.0 CLDN8 claudin 8 0 -9.1 
TMEM45A transmembrane protein 45A 0 5.6 CRNN cornulin 0 -9.1 
FLG filaggrin 0 5.6 FOXA1 forkhead box A1 0 -8.3 
SPRR2E small proline-rich protein 2E 0 5.5 CEACAM1 carcinoembryonic 
antigen-related cell 
adhesion molecule 1 
(biliary glycoprotein) 
0 -8.1 
1 OTCs were treated for 3 weeks 
2 0 = p-value ≤ 0.000001  
3 fold changes were calculated with Chipster. The table shows numbers recalculated from log2. Values below 1 (negative fold changes) 
were converted by the following formula: fold change= –(1/x). 
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Table 7.7 List of 20 TOP up- and down-regulated genes from a genome wide RNA expression profile from 
HaCaT epithelia (DMSO vs. UV)
1
 
TOP 20 Up-regulated Genes TOP 20 Down-regulated Genes 
Symbol Gene Name p-value
2
 Fold 
Change
3
 
Symbol Gene Name p-
value
2
 
Fold 
Change
3
 
DSC1 desmocollin 1 3.0E-06 3.1 MAL mal, T-cell differentiation 
protein 
0 -5.6 
SERPINA12 serpin peptidase inhibitor, 
clade A (alpha-1 
antiproteinase, antitrypsin), 
member 12 
4.7E-05 2.7 KRT13 keratin 13 0 -5.3 
CDSN corneodesmosin 6.5E-05 2.0 CCL2 chemokine (C-C motif) 
ligand 2 
0 -4.2 
ARG1 arginase 1 3.7E-05 1.9 KRT4 keratin 4 0 -3.3 
SPRR2B small proline-rich protein 
2B 
7.0E-06 1.9 DCN decorin 0 -3.0 
ADAP2 ArfGAP with dual PH 
domains 2 
8.0E-05 1.8 KLK12 kallikrein-related 
peptidase 12 
0 -2.9 
FLG filaggrin 1.1E-04 1.8 HTR3A 5-hydroxytryptamine 
(serotonin) receptor 3A, 
ionotropic 
0 -2.8 
DEFB4A defensin, beta 4A 2.1E-05 1.8 TMPRSS11
D 
transmembrane 
protease, serine 11D 
0 -2.7 
COL17A1 collagen, type XVII, alpha 1 6.6E-05 1.7 SPINK7 serine peptidase 
inhibitor, Kazal type 7 
(putative) 
0 -2.6 
PSAT1 phosphoserine 
aminotransferase 1 
1.4E-04 1.7 CES1 carboxylesterase 1 0 -2.6 
ASNS asparagine synthetase 
(glutamine-hydrolyzing) 
5.4E-05 1.7 ELF3 E74-like factor 3 (ets 
domain transcription 
factor, epithelial-specific 
) 
0 -2.5 
HRNR hornerin 2.6E-03 1.7 HTR3A 5-hydroxytryptamine 
(serotonin) receptor 3A, 
ionotropic 
0 -2.5 
TRIB3 tribbles homolog 3 
(Drosophila) 
1.3E-05 1.7 KLK13 kallikrein-related 
peptidase 13 
0 -2.5 
MAP2 microtubule-associated 
protein 2 
6.1E-05 1.7 CD70 CD70 molecule 0 -2.3 
SH3KBP1 SH3-domain kinase binding 
protein 1 
2.9E-05 1.6 OLFM4 olfactomedin 4 0 -2.3 
RCAN1 regulator of calcineurin 1 6.6E-05 1.6 C6orf15 chromosome 6 open 
reading frame 15 
0 -2.1 
SPRR2C small proline-rich protein 
2C (pseudogene) 
1.3E-05 1.6 STC1 stanniocalcin 1 0 -2.1 
COL17A1 collagen, type XVII, alpha 1 6.0E-06 1.6 ID1 inhibitor of DNA binding 
1, dominant negative 
helix-loop-helix protein 
0 -2.1 
SLPI secretory leukocyte 
peptidase inhibitor 
7.0E-06 1.6 GBP6 guanylate binding 
protein family, member 
6 
0 -2.1 
TNFRSF21 tumor necrosis factor 
receptor superfamily, 
member 21 
1.1E-05 1.6 DHRS9 dehydrogenase/reductas
e (SDR family) member 9 
1.0E-06 -2.1 
1 OTCs were treated for 2 weeks 
2 0 = p-value ≤ 0.000001  
3 fold changes were calculated with Chipster. The table shows numbers recalculated from log2. Values below 1 (negative fold 
changes) were converted by the following formula: fold change= –(1/x) 
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Table 7.8 List of 20 TOP up- and down-regulated genes from a genome wide RNA expression profile from 
HaCaT-RAS A-5 epithelia (DMSO vs. UV)
1
 
TOP 20 Up-regulated Genes TOP 20 Down-regulated Genes 
Symbol Gene Name p-value
2
 Fold 
Change
3
 
Symbol Gene Name p-value
2
 Fold 
Change
3
 
KRT2 keratin 2 0 26.5 KRT13 keratin 13 0 -46.6 
DSC1 desmocollin 1 0 23.2 MAL mal, T-cell differentiation 
protein 
0 -38.1 
DEFB4A defensin, beta 4A 0 20.4 SCGB1A1 secretoglobin, family 1A, 
member 1 (uteroglobin) 
0 -32.2 
SPRR2B small proline-rich protein 
2B 
0 19.8 KRT4 keratin 4 0 -21.3 
SERPINA12 serpin peptidase inhibitor, 
clade A (alpha-1 
antiproteinase, 
antitrypsin), member 12 
0 17.6 CLDN8 claudin 8 0 -14.2 
SPRR2G small proline-rich protein 
2G 
1.0E-06 17.3 ADIRF adipogenesis regulatory 
factor 
1.0E-06 -9.3 
SPRR2C small proline-rich protein 
2C (pseudogene) 
0 16.0 SPRR3 small proline-rich protein 
3 
0 -8.3 
LCE3D late cornified envelope 3D 0 11.0 KRT15 keratin 15 0 -8.2 
HRNR hornerin 0 10.6 CEACAM1 carcinoembryonic 
antigen-related cell 
adhesion molecule 1 
(biliary glycoprotein) 
0 -7.9 
AADACL2 arylacetamide 
deacetylase-like 2 
0 10.2 FOXA1 forkhead box A1 0 -7.8 
CDSN corneodesmosin 0 9.2 GCNT3 glucosaminyl (N-acetyl) 
transferase 3, mucin 
type 
0 -7.4 
DSG1 desmoglein 1 0 9.0 ELF3 E74-like factor 3 (ets 
domain transcription 
factor, epithelial-specific 
) 
0 -7.2 
LCE2B late cornified envelope 2B 1.0E-06 7.9 RARRES3 retinoic acid receptor 
responder (tazarotene 
induced) 3 
0 -7.1 
LCE2D late cornified envelope 2D 1.0E-06 7.9 CEACAM5 carcinoembryonic 
antigen-related cell 
adhesion molecule 5 
0 -6.9 
KRT3 keratin 3 0 7.3 CEACAM1 carcinoembryonic 
antigen-related cell 
adhesion molecule 1 
(biliary glycoprotein) 
0 -6.8 
SBSN suprabasin 0 6.9 AOC1 amine oxidase, copper 
containing 1 
0 -6.7 
SPRR2E small proline-rich protein 
2E 
0 6.8 DHRS9 dehydrogenase/reductas
e (SDR family) member 9 
0 -6.6 
LCE2A late cornified envelope 2A 0 6.7 KRT19 keratin 19 0 -6.5 
ALOX12B arachidonate 12-
lipoxygenase, 12R type 
0 6.5 MUC20 mucin 20, cell surface 
associated 
0 -5.9 
FGG fibrinogen gamma chain 0 6.4 S100A4 S100 calcium binding 
protein A4 
4.0E-06 -5.8 
1 OTCs were treated for 3 weeks 
2 0 = p-value ≤ 0.000001  
3 fold changes were calculated with Chipster. The table shows numbers recalculated from log2. Values below 1 (negative fold changes) 
were converted by the following formula: fold change= –(1/x) 
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Table 7.9 Genes differentially expressed in HaCaT and HaCaT-RAS A-5 epithelia treated with CsA or UV or 
UV+CsA 
  Fold Change (log2)  
  HaCaT HaCaT-RAS A-5  
Symbol Gene Name CsA UV UV+Cs
A 
CsA UV UV+Cs
A 
Protein type 
ANGPTL4 angiopoietin like 4 -0.42 -0.46 -0.68 -1.42 -1.01 -1.81 other 
AOC1 amine oxidase, copper containing 
1 
-0.80 -0.65 -0.88 -1.37 -2.74 -3.52 enzyme 
ARRDC4 arrestin domain containing 4 0.44 0.49 0.52 0.50 0.76 1.31 other 
BPIFC BPI fold containing family C 0.42 0.42 0.56 0.62 0.72 0.72 transporter 
CAPN5 calpain 5 -0.76 -0.99 -1.27 -1.27 -1.68 -2.07 peptidase 
CD14 CD14 molecule -0.37 -0.54 -0.59 -0.69 -1.86 -2.24 transmembrane 
receptor 
CD36 CD36 molecule -0.73 -0.93 -1.90 0.51 0.47 -0.70 transmembrane 
receptor 
CDH16 cadherin 16 0.69 0.42 0.83 1.27 0.86 1.42 enzyme 
CDSN corneodesmosin 1.21 0.99 1.29 2.06 3.20 3.53 other 
CEACAM1 carcinoembryonic antigen related 
cell adhesion molecule 1 
-0.70 -0.91 -0.91 -2.16 -2.99 -3.40 transporter 
CEACAM5 carcinoembryonic antigen related 
cell adhesion molecule 5 
-0.69 -0.95 -1.39 -2.04 -2.78 -3.00 other 
CLDN7 claudin 7 -0.33 -0.48 -0.63 -1.13 -1.88 -2.06 other 
CPA4 carboxypeptidase A4 1.16 0.45 1.03 1.61 1.53 1.36 peptidase 
CTSV cathepsin V 0.40 0.65 0.65 1.31 1.39 1.26 peptidase 
ELF3 E74 like ETS transcription factor 3 -0.64 -1.35 -1.30 -1.84 -2.85 -3.38 transcription 
regulator 
ELOVL4 ELOVL fatty acid elongase 4 0.70 0.54 0.91 1.73 2.35 2.62 enzyme 
FAM3D family with sequence similarity 3 
member D 
-0.40 -0.53 -0.75 -0.66 -0.77 -1.15 cytokine 
FGG fibrinogen gamma chain -0.65 -0.63 -0.84 1.17 2.68 1.06 other 
FOXC1 forkhead box C1 -0.40 -0.37 -0.46 -1.00 -1.12 -1.27 transcription 
regulator 
GCHFR GTP cyclohydrolase I feedback 
regulator 
-0.58 -0.44 -0.77 -1.01 -1.52 -1.73 other 
GCNT3 glucosaminyl (N-acetyl) 
transferase 3, mucin type 
-0.53 -1.04 -1.64 -1.35 -2.89 -2.99 enzyme 
GLDC glycine decarboxylase -0.35 -0.37 -0.45 -1.27 -1.24 -2.17 enzyme 
GSTA2 glutathione S-transferase alpha 2 -0.54 -0.51 -0.50 -0.45 -0.39 -0.96 enzyme 
HP haptoglobin -0.50 -0.39 -0.50 -0.88 -0.71 -1.40 peptidase 
IGFBP3 insulin like growth factor binding 
protein 3 
-0.52 -0.45 -0.54 -1.89 -1.64 -1.02 other 
ISG15 ISG15 ubiquitin-like modifier -0.52 -0.49 -0.62 -1.28 -1.71 -1.93 other 
KRT4 keratin 4 -0.96 -1.72 -2.47 -1.35 -4.41 -4.44 other 
KRT7 keratin 7 -0.43 -0.35 -0.44 -0.98 -1.64 -1.57 other 
LAMA3 laminin subunit alpha 3 0.45 0.55 0.77 0.70 0.79 1.19 other 
LCN2 lipocalin 2 -0.35 -0.64 -1.24 -1.17 -2.03 -2.56 transporter 
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LYPD2 LY6/PLAUR domain containing 2 0.36 -0.76 -0.76 -0.75 -1.54 -2.35 other 
MAL mal, T-cell differentiation protein -1.31 -2.49 -2.67 -2.04 -5.25 -5.35 transporter 
MDK midkine (neurite growth-
promoting factor 2) 
-0.84 -0.55 -0.89 -1.80 -2.02 -2.30 growth factor 
MUC4 mucin 4, cell surface associated -0.55 -0.68 -0.71 -2.02 -2.40 -2.52 other 
PHGR1 proline, histidine and glycine rich 1 -0.74 -0.62 -0.96 -0.96 -1.29 -1.53 other 
PITX1 paired like homeodomain 1 -0.56 -0.58 -0.75 -0.79 -0.94 -1.30 transcription 
regulator 
PPP1R1B protein phosphatase 1 regulatory 
inhibitor subunit 1B 
-0.74 -0.98 -1.39 -0.74 -1.11 -1.39 phosphatase 
S100P S100 calcium binding protein P -0.55 -0.77 -1.38 -0.96 -2.15 -3.20 other 
SBSN suprabasin 0.39 0.43 0.52 2.43 2.80 2.98 other 
SLC16A3 solute carrier family 16 member 3 -0.65 -0.39 -0.54 -0.89 -0.74 -1.18 transporter 
SLC5A1 solute carrier family 5 member 1 0.71 0.50 0.92 0.76 1.51 2.05 transporter 
SOX7 SRY-box 7 -0.69 -0.48 -1.17 -0.51 -0.47 -0.98 transcription 
regulator 
SPRR2B small proline rich protein 2B 0.99 0.90 1.23 2.48 4.31 4.24 other 
SPRR2C small proline rich protein 2C 
(pseudogene) 
0.73 0.69 0.78 2.40 4.00 3.94 other 
SPRR2G small proline rich protein 2G 0.40 0.39 0.40 3.08 4.11 4.00 other 
SRPX2 sushi repeat containing protein, X-
linked 2 
-0.50 -0.78 -0.74 -1.52 -1.75 -1.95 other 
STC1 stanniocalcin 1 -1.49 -1.07 -2.48 -1.62 -1.35 -2.37 kinase 
TMPRSS11
D 
transmembrane protease, serine 
11D 
-1.31 -1.44 -1.91 -0.56 -0.93 -1.31 peptidase 
TSPAN6 tetraspanin 6 -0.69 -0.72 -0.98 -0.84 -1.23 -1.36 other 
TYMP thymidine phosphorylase 0.69 0.65 1.10 -0.58 -0.52 -0.49 growth factor 
XK X-linked Kx blood group 1.47 -1.22 -1.79 -2.72 -5.14 -4.91 transporter 
XKRX XK related, X-linked 0.58 0.54 0.62 0.77 1.21 1.24 other 
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Table 7.10 List of 20 TOP up- and down-regulated genes from genome wide RNA expression profile from 
HaCaT-GOLD epithelia (DMSO vs. CsA)
1
 
TOP 20 Up-regulated Genes TOP 20 Down-regulated Genes 
Symbol Gene Name p-value
2
 Fold 
Change
3
 
Symbol Gene Name p-value
2
 Fold 
Change
3
 
DEFB103B defensin, beta 103B 0 8.1 KRT2 keratin 2 0 -19.6 
CRCT1 cysteine-rich C-terminal 1 0 7.5 OLFM4 olfactomedin 4 0 -12.3 
UPP1 uridine phosphorylase 1 0 6.6 DAPL1 death associated 
protein-like 1 
0 -11.2 
FAM25A family with sequence 
similarity 25, member A 
0 6.0 DSC1 desmocollin 1 0 -8.9 
SERPINE2 serpin peptidase inhibitor, 
clade E (nexin, plasminogen 
activator inhibitor type 1), 
member 2 
0 5.8 KRT13 keratin 13 0 -7.0 
IL1A interleukin 1, alpha 0 5.4 HRNR hornerin 0 -6.7 
IL1B interleukin 1, beta 0 5.3 SPRR3 small proline-rich 
protein 3 
0 -6.6 
LCE3D late cornified envelope 3D 0 5.2 CD36 CD36 molecule 
(thrombospondin 
receptor) 
0 -6.5 
TM4SF19 transmembrane 4 L six 
family member 19 
0 5.1 ALDH3A1 aldehyde 
dehydrogenase 3 
family, member A1 
0 -6.3 
LAMC2 laminin, gamma 2 0 4.5 LOR loricrin 0 -6.1 
LCE3E late cornified envelope 3E 0 4.5 AADACL2 arylacetamide 
deacetylase-like 2 
0 -5.4 
RNASE7 ribonuclease, RNase A 
family, 7 
0 4.1 KRT3 keratin 3 1.0E-06 -5.1 
LAMC2 laminin, gamma 2 0 4.1 TMEM45A transmembrane protein 
45A 
0 -4.8 
PTGS2 prostaglandin-endoperoxide 
synthase 2 (prostaglandin 
G/H synthase and 
cyclooxygenase) 
0 4.1 CRNN cornulin 0 -4.7 
TGFBI transforming growth factor, 
beta-induced, 68kDa 
0 4.0 FLG filaggrin 0 -4.3 
PTGS2 prostaglandin-endoperoxide 
synthase 2 (prostaglandin 
G/H synthase and 
cyclooxygenase) 
0 3.9 TMEM45A transmembrane protein 
45A 
0 -4.2 
GPSM1 G-protein signaling 
modulator 1 
0 3.9 VIPR1 vasoactive intestinal 
peptide receptor 1 
0 -4.2 
SERPINE1 serpin peptidase inhibitor, 
clade E (nexin, plasminogen 
activator inhibitor type 1), 
member 1 
0 3.7 FLG filaggrin 0 -4.2 
ACKR3 atypical chemokine receptor 
3 
0 3.6 LOC645638 WDNM1-like 
pseudogene 
0 -4.0 
SERPINB1 serpin peptidase inhibitor, 
clade B (ovalbumin), 
member 1 
0 3.6 RPTN repetin 0 -4.0 
1 OTCs were treated for 2 weeks 
2 0 = p-value ≤ 0.000001  
3 fold changes were calculated with Chipster. The table shows numbers recalculated from log2. Values below 1 (negative fold changes) 
were converted by the following formula: fold change= –(1)/x 
 
